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Head and neck squamous cell carcinoma (HNSCC) is the sixth most common cancer 
worldwide and as only approximately 50% of patients survive five years after diagnosis, new 
treatment options are urgently needed.  A complex array of molecular and microenvironmental 
alterations are believed to play a role in HNSCC pathogenesis, including suppression of 
antitumor immunity by expression of the immune checkpoint signal Programmed Death Ligand 
1 (PDL1). The advancement of predictive and prognostic biomarkers, as well as rationally 
designed and personalized treatment regimens, will be especially crucial to improving outcomes 
across the spectrum of HNSCC subtypes.  In an effort to comprehensively understand disease 
heterogeneity and mechanisms regulating immune escape, we have profiled various genetic, 
transcriptomic, and immunologic features of HNSCC.   
The focus of this work was on the regulation of PDL1, a target for immunotherapy that 
has garnered significant attention in recent years.  We aimed to provide a more complete portrait 
of the molecular pathways contributing to immunosuppression in HNSCC, and to identify 
signals that could be exploited as biomarkers and therapeutic targets.  We utilized multiple 
genome wide screening techniques to select HNSCC cells with altered PDL1 expression and 
validated several hits nominated by these screens, most notably FGFR and TLR2 signaling.  We 
expect these findings to contribute to a broader understanding of PDL1 checkpoint regulation in 
models and tumors with diverse genetic and phenotypic characteristics, and that this knowledge 
will ultimately lead to novel biomarkers and therapeutic combinations to improve patient 





Chapter 1 Introduction 
 
1.1 Surveilling the Potential for Precision Medicine- Driven PD1/PDL1 Targeted 
Therapy in HNSCC1 
Abstract 
Immunotherapy is becoming an accepted treatment modality for many patients with cancer and 
is now approved for use in platinum-refractory recurrent or metastatic head and neck squamous 
cell carcinoma (HNSCC). Despite these successes, a minority of patients with HNSCC receiving 
immunotherapy respond to treatment, and few undergo a complete response. Thus, there is a 
critical need to identify mechanisms regulating immune checkpoints in HNSCC in the hopes of 
predicting responders, and so that novel combination strategies can be developed for non-
responders. Here, we review the immunotherapy and molecular genetics literature to describe 
what is known about immune checkpoints in common genetic subsets of HNSCC. We highlight 
several highly recurrent genetic lesions that may serve as biomarkers or targets for combination 
immunotherapy in HNSCC. 
Introduction 
Over the last decade, research in head and neck squamous cell carcinoma (HNSCC) has 
shown that suppression of the host immune system plays a key role in the development and 
 
1 This section was published in the Journal of Cancer in collaboration with the following authors: Rebecca Hoesli, 
Nicole Michmerhuizen, Samantha Devenport, Megan Ludwig, Taylor Vandenberg, Chloe Matovina, Nadine Jawad, 





progression of HNSCC. Many critical components of both the innate and adaptive immune 
systems are dysfunctional in patients with HNSCC, including the activity of natural killer cells, 
the function of antigen presenting machinery, and the maturation of dendritic cells 1-4. 
Additionally, in the composition of functioning cells such as T lymphocytes, there is a shift 
towards immunosuppression, with higher numbers of the immunosuppressive regulatory T cells 
and immunosuppressive cytokines, while the overall number of lymphocytes is decreased 5-9. 
Many of these defects feedback amongst themselves, resulting in the release of cytokines and 
recruitment of immunosuppressive cells, further promoting the immunosuppressive environment. 
Importantly, this immunosuppression appears to play pivotal roles in both HNSCCs driven by 
high risk human papilloma virus (HPV) and HPV negative disease. 
In addition to these defects, HNSCCs, like other immunosuppressive cancers, have co-
opted beneficial physiologic signaling pathways to aid in immune evasion. In the intact immune 
system, there is a necessary equilibrium between activation and suppression of the immune 
system. This balance prevents excessive activation of the immune system resulting in 
autoimmune diseases, as well as pathologic suppression resulting in opportunistic infections. 
Various co-stimulatory and co-inhibitory signaling pathways are involved in maintaining this 
equilibrium, including the CTLA-4 and programmed death-1 (PD-1):programmed death ligand-1 
(PDL1) pathways, which serve as checkpoints to mitigate excessive inflammation. Both of these 
pathways are thought to have been exploited by HNSCC in order to enhance the 
immunosuppressive environment, preventing immune surveillance and tumor destruction 10, 11. 
Therapies targeting the co-inhibitory receptor CTLA-4 were among the earliest immunotherapies 





pathway, were quickly advanced 10. This review will focus on the various genetic alterations and 
molecular pathways that may contribute to dysregulation of the PD-1:PDL1 pathway. 
Immune Checkpoints and PD1/PDL1 Signaling 
The PD-1/PDL1 pathway is an important co-inhibitory pathway involved in the 
regulation of the human immune response. This pathway serves as an immune checkpoint, 
providing protection against excessive tissue damage induced by inflammation 10, and is 
especially important in regulating antigen-specific effector T-cell activity in peripheral tissues. 
The PD-1 receptor is a transmembrane protein expressed by T cells, B cells, and many types of 
tumor-infiltrating lymphocytes (TILs). PD-1 can bind either of two ligands: PDL1 or PDL2, both 
of which are cell surface proteins of the B7 family 12, 13. Upon ligand binding, generation and 
activation of effector T cells, particularly CD8+ T cells, is dramatically suppressed 14. 
Expression of PDL1 can be stimulated by interferon-γ (IFN-γ), a cytokine produced primarily by 
effector lymphocytes 15. In general, interferons function as lines of communication between the 
innate and adaptive immune responses by activating immature dendritic cells and CD8+ T cells. 
IFN-γ is largely responsible for inducing inflammation, a critical component of the immune 
response. Cancer cells are thought to induce an immune response, and inflammation is common 
within the tumor microenvironment. However, it is hypothesized that cancer cells can develop an 
“adaptive immune resistance” to increased levels of inflammation by upregulating PDL1 in 
response to IFN-γ, thereby protecting themselves against immune attack by promoting T cell 
anergy and apoptosis 16, 17. An interesting connection has also emerged between HPV infection, 
now recognized as a common initiator of oropharyngeal cancer, and immunosuppression. Major 
sites of HPV infection, such as the tonsillar crypts, may be prone to harboring high levels of 





excessive inflammation also creates a permissive environment for both persistent HPV and 
associated tumors to flourish 18. It has also been postulated that immunosuppressive pathways 
initiated by HPV itself allow for malignant transformation at the site of infection 19. 
Although the PD-1/PDL1 pathway was discovered more than two decades ago, the 
therapeutic potential associated with targeting this pathway in cancer was not immediately 
recognized. As the immunosuppressive function of the PD-1/PDL1 interaction was revealed and 
PDL1 expression was observed in tumor cells, researchers hypothesized that blockade of this 
pathway could help facilitate eradication of tumors and impede tumor metastasis 20. This 
hypothesis was first tested in melanoma, in which treatment with monoclonal antibodies (mAbs) 
directed against PD-1 showed promising results. In a meta-analysis of 5 multi-center randomized 
control trials including 2,828 patients, patients treated with an anti- PD-1 mAb experienced 
superior progression free survival (PFS) ranging from 3.7 to 6.9 months as compared with 2.2 to 
4.2 months in the control group. Six-month PFS was significantly improved for patients treated 
with anti-PD-1 therapy, with a hazard ratio (HR) of 0.55 21. There was also a statistically 
significant improvement in overall response rate (ORR) with an odds ratio (OR) of 3.89 21. Two 
anti-PD-1 antibodies, pembrolizumab and nivolumab, have since been approved by the FDA for 
the treatment of advanced melanoma due to convincing data demonstrating increased ORR, as 
well as improved PFS and OS 11. 
Currently, five mAb therapies targeting the PD-1/PDL1 pathway are under investigation 
for use in HNSCC. Pembrolizumab and Nivolumab target PD-1, while MEDI4736, 
Atezolizumab, and Avelumab target PDL1. Pembrolizumab has shown considerable promise for 
use in patients with recurrent and/or metastatic HNSCC. An 18.2% ORR has been reported with 





for platinum-refractory recurrent or metastatic HNSCC patients 22. Interestingly, ORR was 
independent of HPV status and PDL1 status 23. A phase 3 trial is also currently underway for 
Nivolumab versus either Cetuximab, Docetaxel, or Methotrexate for recurrent/metastatic 
HNSCC (Clinical Trial: NCT02105636). Preliminary results show a doubling in the one year 
overall survival rate to 36% in Nivolumab treated patients. Median overall survival was 7.5 
months in the Nivolumab group as compared to 5.1 months in the standard treatment group. 
Interestingly, both HPV positive and HPV negative patients benefit with the median survival for 
HPV positive patients increasing from 4.4 to 9.1 months, and that of HPV negative patients 
increasing from 5.8 to 7.5 months 24. Due to its early success, additional trials evaluating the 
efficacy of Nivolumab in combination with chemotherapy and/or radiation for definitive therapy 
in locoregionally advanced HNSCC are currently underway (NCT02764593). 
Of the mAbs against PDL1, MEDI4736 or Durvalumab, is currently being evaluated in a 
phase 3 trial of Durvalumab alone versus Durvalumab plus an anti-CTLA-4 inhibitor 
(tremelimumab) versus standard treatment (NCT02369874) 25. Atezolizumab and Avelumab are 
currently in several Phase 1b/2 trials evaluating the safety and efficacy of these inhibitors in 
advanced solid tumor malignancies, as listed in Table1.1. Several ongoing trials are investigating 
their use alone and in combination with other targeted therapies. 
Given the enthusiasm for drugs targeting the PD1/PDL1 pathways in the management of 
recurrent HNSCC, it is reasonable to expect that new protocols will be developed expanding the 
application of immunotherapy in this context. An enhanced understanding of PD-1 and PDL1 
expression and modulation, in addition to other factors predicting response to PD-1/PDL1 





modulators of PDL1 expression, as well as important considerations associated with targeting 
PDL1 in HNSCC patients. 
PD-1 and PDL1 expression in HNSCC 
While several studies have evaluated expression of PDL1 in HNSCC by immunohistochemistry, 
results are highly variable. Thus, the clinical significance of PDL1 expression in tumor cells 
remains unclear. PDL1 staining may be membranous and/or diffuse, and often appears at the 
interface of tumor cells and T cells. PDL1 expression is reported in 51-87% of HNSCC tumors 
across several reports and criteria for PDL1 “positivity” are highly variable 18, 26-31. Small sample 
size, inconsistent representation of different disease sites, prior therapy, or the antibody used to 
detect PDL1 may contribute to discrepancies among these studies. Intratumoral heterogeneity 
and temporal changes in PDL1 expression may also lead to false negatives 32. HPV associated 
cancers are more likely to express PDL1, but PDL1 expression has not been directly correlated 
with survival despite the better prognosis observed among these cancers. However, tumor 
infiltration with high numbers of PD-1 expressing CD8+ T cells is associated with longer overall 
survival; the mechanism and implications thereof remain unclear 29, 33. 
Potential for intrinsic modulation of PDL1 by oncogenic pathways 
JAK2/STAT1 mediated induction of PDL1 expression on the surface of tumor cells has 
been demonstrated in response to IFN-γ, and, recently, epidermal growth factor (EGF) 34. The 
finding that EGF can promote PDL1 expression was especially interesting given that the EGF 
receptor (EGFR) is highly overexpressed in HNSCC. This observation highlights the possibility 
that other signals, including common oncogenic drivers, may contribute to immunosuppression 
by promoting PDL1 expression. Elucidating the molecular mechanisms governing PDL1 





immunotherapy with other agents targeting upstream regulators of the PDL1/PD-1 pathway. 
While mechanisms regulating PDL1 have been examined in other cancers, few studies have 
addressed intrinsic modulation of PDL1 in HNSCC, especially in the context of emerging 
precision medicine paradigms that match targeted therapies with specific genetic lesions 35-39. 
Interestingly, several potentially targetable pathways including EGFR, phosphatidylinositol 3-
kinase (PI3K)/Akt, MAPK, p53, STAT and HIF-1α are commonly deregulated in HNSCC and 
could potentially influence the expression of PDL1 (Figure 1.1).  There is potential to exploit 
newly discovered relationships between PDL1 regulation and other well-described drug targets, 
and rapidly translate these findings, as many of these pathways are already being targeted in 
clinical trials (Table 1.2). 
 
EGFR 
EGFR is overexpressed in >90% of HNSCCs by a variety of genetic mechanisms including 
amplification (~10% of cases) 40-43. It is therefore not surprising that targeting EGFR has become 
an important strategy in the management of HNSCC. Several small molecule inhibitors of EGFR 
signaling are currently being investigated, and clinical success has been achieved with biologics 
such as Cetuximab, a chimeric IgG1 mAb against EGFR 44. As both EGFR- and PD-1/PDL1- 
targeted therapies have advanced, evidence has emerged for a potential confluence of these two 
pathways. In NSCLC, where immune checkpoint inhibitors have been more extensively studied 
and exploited, an interesting relationship between EGFR and PDL1 has been noted. Specifically, 
tumors with activating genetic aberrations to EGFR were more likely to have PDL1 
overexpression than those without 45, 46, and treatment of these tumors with the small molecule 





mechanistic link between the two molecules 46. Surprisingly, refractory NSCLC tumors arising 
after gefitinib treatments also have elevated PDL1 expression 47, suggesting that immune escape 
is an important mechanism to overcoming EGFR inhibitor response. More recently, Concha-
Benavente et. al. noted a similar relationship in HNSCC models showing that Cetuximab-
mediated EGFR inhibition caused a reduction in adaptive PDL1 expression through modulation 
of the JAK2/STAT1 effectors 34. 
The postulate that EGFR activation can promote immune escape through regulation of 
PDL1 expression is especially interesting given the prevalence of Cetuximab-based therapies in 
HNSCC. The logical hypothesis addresses whether these two therapies can be combined, 
particularly given the poor observed response to Cetuximab as a single agent. It is unclear if 
combination Cetuximab + PD1/PDL1 checkpoint inhibitors would provide an incremental effect, 
as Cetuximab inhibits PDL1 expression thereby removing the immunotherapy target, perhaps 
suggesting the need for sequential use of the drugs. However, by activating T-cells to clear any 
tumor cells that are innately resistant to Cetuximab (or the EGFR-based modulation of PDL1), 
this combination may effectively clear heterogeneous tumor cell populations, although this 
remains to be proven in vivo. Clinical trials assessing these combinations in advanced HNSCC 
patients are currently being evaluated and sequential trials assessing PDL1 inhibition following 
Cetuximab failure are already ongoing (NCT02255097). An additional facet of mAb therapies is 
the potential for antibody-dependent cellular cytotoxicity (ADCC), a mechanism for the 
clearance of IgG1-coated target cells. ADCC is triggered by engagement of Fc receptors on 
immune effector cells with the Fc region of IgG1. Cetuximab induces ADCC in an EGFR-
dependent manner in cell culture and in murine models 48-51, and although the contribution of 





increased ADCC has been reported. In a study of 22 HNSCC and colorectal cancer patients, 
Bertino et al observed more pronounced increases in ADCC in patients who experienced clinical 
benefit from Cetuximab than in those who did not 52. ADCC may play a key role in the clinical 
efficacy of EGFR targeted mAbs, and could have important implications for combination 
immunotherapeutic strategies. For example, it is possible that the combined effects of relief from 
T-cell anergy, stimulation of natural killer cells, and inhibition of EGFR signaling in addicted 
cells may amplify the anti-tumor function of either strategy alone. EGFR-based therapies may 
therefore have important mechanistic consequences on PD1/PDL1-based therapies in HNSCC, 




The PI3K pathway, based on data from The Cancer Genome Atlas and other analyses, 
has been identified as the most frequently mutated of any oncogenic and targetable pathway in 
HNSCC 53-55. Activating mutations and/or amplification of PIK3CA, which encodes PI3K's 
catalytic subunit and alpha isoform, was the most frequent alteration observed in the PI3K 
pathway. Aberration of this gene was reported in 37% of the TCGA HNSCC cohort 53. As a 
whole, alterations in the PI3K pathway contribute to tumor progression and increased cell growth 
and viability; they are also more commonly observed in advanced stage disease 56, 57. 
Various interferons have been shown to activate the PI3K pathway as well as to induce 
the expression of PDL1. In response to interferon, PI3K signaling is required for phosphorylation 
of STAT1 at the serine 727 residue and for the associated increase in gene transcription 58, 59. 





63. Chen et al. showed that PDK2 signaling, which can be initiated by the PI3K-PKC pathway, is 
responsible for interferon-induced PDL1 expression in oral squamous cell carcinoma 15, and 
Kondo et al. demonstrated the dependence of interferon-induced PDL1 expression on NF-κB in 
myodysplastic syndrome blast cells 64. Additionally, in dermal fibroblasts, interferon treatment 
led to translocation of NF-κB to the nucleus and transient phosphorylation of ERK and AKT. 
This effect was abrogated upon treatment with PI3K and MEK but not PKC inhibitors 60. BRAF-
inhibitor resistant melanoma cells also display inducible PDL1 expression that is dependent on 
NF-κB. In contrast to observations in dermal fibroblasts, however, the PI3K and MAPK 
pathways were not significant mediators of this response 65. Ferris and colleagues reported that 
PI3K inhibitors wortmannin and BYL719 blocked AKT phosphorylation but failed to reverse the 
extrinsic interferon- or intrinsic EGFR-mediated increases in PDL1 expression in HNSCC cell 
lines 34. These data indicate that the role of PI3K, NF-κB, and PKC may be cell-type specific and 
therefore motivate further studies of the signaling mechanisms in HNSCCs. 
The PI3K pathway is also commonly activated in HNSCC via loss of PTEN, which 
functions as a “brake” on PI3K signaling. The PTEN tumor suppressor has been associated with 
PDL1 expression in other cancer types. Transgenic mouse models of lung SCC with loss of both 
PTEN and Lkb1, for example, developed tumors with elevated levels of PDL1 66. Parsa et al. 
showed that loss of PTEN in glioblastoma patients correlated with increased PDL1 expression 
and that PDL1 translation was S6K1-mediated 67. Furthermore, a negative correlation between 
PTEN and PDL1 expression has been identified in pancreatic and colorectal cancer samples 68, 69. 
miRNAs may also be an important component of this response as the upregulation of miRNAs, 
including miR-21, -20b, and 130b, in colorectal and esophageal cancers has been shown to 







In HNSCC, genetic alterations in MAPK family members are relatively rare. Only 5% of 
patients in the TCGA cohort displayed mutations or copy number changes in HRAS, with other 
alterations in this pathway (such as those affecting KRAS and MAPK1) occurring even less 
frequently 53. In spite of this, signaling of the Ras-MEK-ERK pathway is often aberrant in 
HNSCC due to overexpression of EGFR or activation of other RTKs 71. 
The signaling functions of the MAPK pathway, like those of the PI3K pathway, are 
important in interferon-induced changes in PDL1 expression. MAPK acts in coordination with 
the JAK/STAT pathway to regulate gene transcription, and inhibitors of MAPK pathway 
members (including MEK, ERK, and JNK) block these effects 72. Consistent with this, Liu et al. 
showed that PMA, a known MEK/ERK pathway activator, could increase PDL1 expression in 
multiple myeloma; similarly, blocking MEK/ERK via pharmacological methods or siRNA 
knockdown resulted in decreased interferon-induced PDL1 expression 73. Melanoma cells 
resistant to BRAF inhibition also displayed MAPK activation and increased PDL1 expression via 
c-Jun and STAT3, and this effect was reversed by MEK inhibitors 74. Similar evidence for the 
role of the MAPK pathway in inducing PDL1 expression was identified in bladder cancer, where 
inhibitors of ERK and JNK blocked the induction of PDL1 expression by LPS treatment 75. 
MAPK signaling also modulates PDL1 expression in anaplastic large cell lymphoma (via ALK) 
and in Hodgkin's lymphoma (via p38 MAPK and MEK1/2) 76. 
Recent studies of breast cancer cell lines and murine models, however, have indicated that MEK 
inhibitor trametinib might induce PDL1 expression and therefore be useful in priming patients 





KRAS-mutant NSCLC cells showed varying PDL1 transcript levels following trametinib 
treatment 78. Combination MAPK and PDL1 inhibitor treatments have been proposed and tested 
in vitro and in vivo, and combination therapies are currently being evaluated in clinical trials 
(such as NCT02027961 and NCT01988896 for BRAF-mutant melanoma and NSCLC patients, 
respectively) 79. 
While these dual therapies might be effective in HNSCC, further work regarding both the 
specific mechanism of MAPK pathway activation in PDL1 expression and the modulation of 
PDL1 levels by MAPK inhibitors are necessary. Initial studies by Ferris and colleagues suggest 
that MEK inhibitors do not significantly alter PDL1 expression in HNSCC cell lines, but that 
JAK2 and STAT1 might be critical mediators of immunogenicity 34. Additional research will aid 
in selecting patients who are the most likely to respond to combination MAPK-immunotherapy 




The TP53 gene, encoding the p53 tumor suppressor, is the most commonly mutated gene 
in HNSCC 80. Cortez et al recently reported that p53 can regulate PDL1 production via miR-34. 
p53 deficient or mutant tumors express significantly higher PDL1 levels than wild type p53 
tumors 81. In cell lines, p53 induced miR-34 repressed PDL1 expression. Interestingly, injection 
of miR-34 mimics, such as the drug MRX34, reduces PDL1 expression and increases immune 
response to tumorous growth. When MRX34 was paired with radiation therapy (XRT), a 
common anti-cancer treatment that induces the adaptive immune response to promote tumor 





Understanding the relationship between the p53 pathway and its effects on PDL1 expression may 
allow physicians to better tailor treatment of tumors with p53 mutations. 
 
STAT3 
The STAT signaling pathway is known to play an important role in many cellular 
processes, including division, apoptosis, and motility. Involvement of the transcriptional 
activator STAT3 has been reported in the development and growth of tumors 82, and recent 
studies aim to elucidate the role of STAT3 in PDL1 expression on tumor cells 83. STAT3 
inhibition reduces PDL1 expression in NSCLC 84. Similarly, in multiple types of lymphoma, 
PDL1 expression is enhanced by STAT3 and is decreased upon STAT3 inhibition 85, 86. As 
activated STAT3 was elevated in HNSCC tumors compared to normal epithelium 87, elucidating 
a role for STAT3 in regulating PDL1 in HNSCC may shed light on potential therapeutic targets 
or factors influencing the ability of these tumors to respond to PD-1 blockade. However, a recent 
study found no correlation between STAT3 and PDL1 expression in HPV positive HNSCC, and 
only a weak correlation in HPV negative HNSCC 34. 
 
HIF-1α 
Hypoxia inducible factors (HIFs) are transcriptional regulators integral to the response to 
hypoxia in solid tumors, and are believed to be critical to metastasis 88. Under hypoxic 
conditions, tumors utilize HIF-1α to upregulate glycolysis and to increase blood flow to the 
tumor by promoting angiogenesis. Recently, HIF-1α was suggested to play a role in PDL-1 
expression 89. Specifically, in myeloid derived stem cells (MDSCs), HIF-1α binds directly to the 





has also been shown to bind with HIF-1 in mammary cells 90. Hypoxia-induced PDL1 expression 
has been demonstrated in MDSCs, macrophages, dendritic cells, and tumor cells including breast 
and prostate cancer cell lines 89, 90, and this effect was HIF-1α dependent. While no direct link has 
been established between HIF-1 and PDL1 in HNSCC, given the reported overexpression of 
HIF-1α in HNSCC tissue vs adjacent normal tissue 91 and the poor prognosis associated with low 
intratumoral oxygen levels in HNSCC 92, a more detailed understanding of the potential for 




Finally, there are additional genomic mutations in head and neck squamous cell 
carcinomas noted in the data from The Cancer Genome Atlas HNSCC cohort that make 
attractive targets for investigation in the development of immunotherapies. In addition to those 
described above, defects of note include mutations affecting other components of the innate and 
adaptive immune response, including antigen processing machinery and HLA, as well as tumor 
necrosis factor (TNF) receptor-associated factor 3 (TRAF3). HLA molecules play a key role in 
tumor identification and antigen presentation in the functioning immune system. HLA associates 
with degraded tumor peptides and β2-microglobulins, and once properly folded, the HLA 
complex consisting of the HLA protein chains, β2-microglobulins, and tumor peptides is 
transported to the cell surface, where it is recognized by T cells 3. However, in one study of head 
and neck cancers, approximately 40% of primary tumors had at least selective loss of HLA class 





remains an attractive target for immunotherapies, as it could play an important role in activating 
T cells against tumor antigens. 
TRAF3 plays an important role in regulating the crossroads between the anti-viral, anti-
inflammatory, and cancer pathways by modulating toll-like receptors, TNF receptors, and 
producing interferons and anti-inflammatory cytokines 94. They have been implicated in multiple 
myeloma in humans, and in one study of transgenic mice, overexpression was associated with 
autoimmunity and a predisposition to developing squamous cell carcinoma 95. In the data from 
The Cancer Genome Atlas, TRAF3 mutation was a distinguishing mutation of HPV positive 
tumors 80. No current therapies have been developed, but like HLA mutations, it remains as 
attractive area for investigation. 
HPV and PDL1 
Human papillomavirus (HPV), a known risk factor for HNSCC, has been linked to PD-1 
pathway activation in several settings. In a 2013 study, Yang et. al described a correlation 
between PD-1 on T cells, persistent high risk (HR)-HPV infection, and the development of 
cervical intraepithelial neoplasia (CIN) 96. A positive correlation between PDL1 expression and 
CIN grade was also observed in HR-HPV positive patients, suggesting that the PD-1:PDL1 
pathway may play a role in permitting HR-HPV-related CIN progression 96. 
With rates of HPV associated oropharyngeal cancers rapidly rising, it has become clear 
that the distinct pathogenesis of these cancers may warrant the development of alternate 
treatment protocols 97. HPV associated HNSCCs generally have favorable clinical outcomes 
independently predicted by HPV status 98, 99. The oropharyngeal tumors that result from HPV 
infection grow in the tonsillar crypts and near the base of tongue, which are also the most 





normal and HNSCC patients 18. It is therefore plausible that a dampened effector T cell response 
within these crypts may yield an environment especially permissive to both initial HPV infection 
and SCC tumorigenesis. 
HPV positive HNSCCs are able to grow and evade anti-tumor immunity despite high 
levels of inflammation. In order to evaluate the relevance of PD-1:PDL1 pathway in the 
development of HPV associated HNSCC, Lyford-Pike et. al analyzed PD-1 expression on TILs 
and peripheral blood mononuclear cells (PBMCs) isolated from patients with HPV positive 
HNSCC versus those from patients with a nonmalignant tonsillar pathology (such as hypertrophy 
or tonsillitis), and identified a population of PD-1 expressing CD8+ TILs in HPV positive 
HNSCC tumors. Such a population was not observed in T-cells infiltrating nonmalignant 
inflamed tonsils. Furthermore, the PD-1 expressing CD8+ TILs exhibited diminished ability to 
produce IFN-γ in response to stimulation with PMA/ionomycin compared to TILs not expressing 
PD-1, indicating the functional suppression of affected T-lymphocytes. Lyford-Pike also showed 
PDL1 expression localized to the interface of the tumor and CD8+ TILs 18. This study implies 
that the PD-1:PDL1 pathway is likely important in both persistence of the initial HPV infection 
and suppression of anti-tumor immunity during tumorigenesis. Because high levels of 
membranous PDL1 expression were observed within tumors, HPV positive HNSCC patients are 
logical candidates for PD-1:PDL1-targeted therapy. Furthermore, a recent study in mice 
demonstrated improved anti-tumor activity in large HPV-induced tumors when immunization 
against HPV16 genes E6 and E7 was combined with an anti-PD-1 antibody 100. 
Taken together, these data support the idea that blocking PD-1:PDL1 interactions may be a 
potential therapeutic option for HPV-infected patients. Indeed, early reports from the 





Additionally, in the context of cervical lesions, HPV-induced malignant progression correlates 
with low or undetectable T cell response to HPV antigens 101. Anti-tumor vaccines currently in 
clinical trials aim to stimulate an immune response against HPV specific antigens, such as viral 
oncoproteins E6 and E7, which function in malignant transformation to inactivate p53 and pRb, 
respectively 
(NCT02865135, NCT02864147, NCT02002182, NCT02596243, NCT02163057) 102, 103.  It is 
possible that future immunotherapeutic protocols for the management of HPV positive HNSCC 
may achieve maximal benefit by combining vaccines to promote generation of tumor-specific 
effector T cells with anti-PD-1/PDL1 mAbs to relieve immunosuppression. 
Predicting response to PD-1 blockade 
PDL1 expression was initially considered a logical potential biomarker predicting 
response to anti-PD-1 therapy, but the many factors complicating its detection have limited its 
current utility, and no correlation between PDL1 expression and response to immunotherapy has 
been observed 29. Thus, new methods for predicting potential responders are needed. 
Immunotherapy trials for other cancers may yield insight into potential biomarkers for response 
to PD-1 blockade in HNSCC. As in HNSCC, a main risk factor for non-small cell lung cancer 
(NSCLC) is smoking, which is associated with higher nonsynonymous mutation burden 104. 
Recently, Rizvi et al reported improved objective response, durable clinical benefit, and 
progression free survival in Pembrolizumab-treated NSCLC patients with more non-synonymous 
mutations and a molecular smoking signature 105. Not surprisingly, mutational load positively 
correlated with higher neoantigen levels, which were also associated with improved treatment 
efficacy. A similar trend of high mutational load was observed in bladder cancer patients 





highly mutated tumors could potentially improve the ability of T-cells to recognize tumor cells 
following release from PDL1-mediated immunosuppression. Smoking status has not yet been 
reported for HNSCC patients treated with anti- PD-1 mAbs, and further investigation will be 
necessary to determine whether the correlations observed in NSCLC are recapitulated in the 
HNSCC setting. 
In advanced melanoma patients who responded to pembrolizumab, tumors had less 
diverse T cell populations at baseline, but the number of expanded clones after treatment was 10 
fold higher than in patients with disease progression 107. These data suggest that a pre-existing T-
cell repertoire poised to target tumor cells but negatively regulated by PD-1: PDL1 may predict 
response to PD-1 blockade. Again, this mechanism has yet to be investigated in HNSCC 
patients. 
Limitations 
Given the recent approval of anti-PD-1 therapy in the treatment of recurrent HNSCC, 
immunotherapy represents an exciting new avenue in the management of a disease with a limited 
armamentarium of systemic treatment options. It is also important, however, to consider the 
current limitations of immune checkpoint blockade. Improvements to OS, ORR, and PFS have 
been reported in patients treated with nivolumab and pembrolizumab, but many patients do not 
respond to immunotherapy, and no criteria currently exist to aid in selection of patients likely 
benefit from PD-1 blockade. Additionally, many patients, such as those with preexisting 
autoimmune disease, are not considered candidates for immunotherapy due to concern for 
unacceptable toxicity. 
If and when immunotherapy is extended beyond the metastatic/recurrent setting, 





HNSCC recurrence to patients who have already received XRT, which may sensitize tumors to 
immune attack. In murine models, XRT increases type I IFN levels in tumors, thereby promoting 
T-cell effector function. XRT also induced IFN- dependent up-regulation of the CXCR3 
chemokine, which enhanced the recruitment of T cells to tumors 108. It is also speculated that the 
high mutational load in XRT treated tumors leads to higher neoantigen levels, and therefore 
improved detection by T cells. If these mechanisms are found to be at play, the utility of PD-1 
blockade as a frontline monotherapy may be limited. However, further investigation of a role for 
RT in sensitizing cancers to anti-tumor immunity may provide rationale for protocols combining 
XRT with immune checkpoint blockade. Several studies in mice, as well as anecdotal evidence 
in humans, support the hypothesis that XRT and immunotherapy may synergize to promote 
tumor clearance by the immune system. Concurrent immune checkpoint therapy and XRT 
induced anti-tumor T-cell responses in mice, even outside the radiation field 109. Instances of 
abscopal effects of XRT have been observed in melanoma patients also treated with immune 
checkpoint inhibitors 110, 111. 
Conclusions 
The exploitation of anti-tumor immunity in the treatment of cancer is a promising and 
rapidly expanding field, but more research is needed to understand mechanisms mediating 
response to immunotherapy and expand the population of patients who will benefit from this 
strategy. While anti-PD-1/PDL1 therapy has improved outcomes in comparison to the standard 
of care for a subset of patients with HNSCC, the proportion of responding patients, as well as the 
degree of benefit, remains modest. The future of anti-PD-1/PDL1 therapy in the treatment of 
HNSCC relies upon a better understanding of the dysregulated pathways in HNSCC that may 





treatment of cancer, countless opportunities for modulation of PDL1 can be envisioned. Trials 
capitalizing on mechanistic discoveries by combining anti-PD-1 therapy with other precision-















Figure 1-1 Potential for PDL1 modulation in HNSCC. 
Members of the EGFR, STAT, PI3K, p53, and HIF-1α signaling pathways, all of which may be 
de-regulated in HNSCC, are shown. EGFR is aberrantly activated in HNSCC and may promote 
PDL1 transcription via JAK/STAT or MEK/ERK signaling. IFN-γ induces PDL1 transcription in 
HSCC via JAK/STAT signaling, and may also activate the PI3K signaling pathway, which 
regulates PDL1 transcription in other cancers. HIF-1α binds directly to the PDL1 promoter and 
correlates with high PDL1 expression. p53 loss of function is common in HNSCC, and wild type 
p53 blocks PDL1 translation via transcription of miR-34. Also shown are targeted small 
molecule inhibitors and biologics currently being evaluated in active clinical trials open to 
HNSCC patients. Red text indicates inhibitors for which efficacy in combination with PD-
1/PDL1 blockade is being evaluated. Table (lower right) is based upon data generated by the 
TCGA Research Network (http://cancergenome.nih.gov). The middle column denotes the 
percentage of 504 cases with alternations (mutations or copy number variations) in the indicated 
gene. Within this dataset, 35 of 106 cases in which p16 was assessed were designated HPV 
positive. The rightmost column denotes the percentage of HPV positive cases with alterations in 








Table 1-1. Clinical trials, immunotherapy combinations. 
 List of current trials evaluating the use of targeted therapies towards the PD-1/PDL1 pathway in 
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Table 1-2. Clinical trials, PD1/PDL1 inhibitors plus small molecule inhibitors.   
List of current trials evaluating the use of targeted therapies towards the PD-1/PDL1 pathway in 
combination with small molecule inhibitor treatments in HNSCC. 
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Chapter 2 Features of larynx squamous cell carcinomas  
 
Chapter Summary In this chapter we present a retrospective analysis of CD103+, 
CD4+, and CD8+ tumor infiltrating lymphocytes (TILs) in recurrent laryngeal squamous 
cell carcinoma tumor specimens by tissue microarray.  We demonstrate an association 
between specific TIL populations and improved outcomes in this cohort.  To improve 
future modeling of this disease subtype, we also profiled a panel of LSCC cell lines 
derived at the University of Michigan (UM-SCC-) that will serve as a resource for 
contextualizing preclinical studies in terms of the heterogeneous characteristics of 
LSCCs.    
2.1 Analysis of tumor-infiltrating CD103 resident memory T-cell content in 
recurrent laryngeal squamous cell carcinoma.2 
Abstract 
Background: Recurrent laryngeal squamous cell carcinomas (LSCCs) are associated with poor 
outcomes, without reliable biomarkers to identify patients who may benefit from adjuvant 
therapies. Given the emergence of tumor-infiltrating lymphocytes (TIL) as a biomarker in head 
 
2 This section was published in Cancer Immunology, Immunotherapy in collaboration with the following authors: 
Joshua Smith, Andrew Birkeland, Emily Bellile, Paul Swicicki, Michelle Mierzwa, Steven Chinn, Andrew Shuman, 
Kelly Malloy, Keith Casper, Scott McLean, Jeffrey Moyer, Gregory Wolf, Carol Bradford, Mark Prince, Thomas 





and neck squamous cell carcinoma, we generated predictive models to understand the utility of 
CD4+, CD8+ and/or CD103+ TIL status in patients with advanced LSCC. 
Methods: Tissue microarrays were constructed from salvage laryngectomy specimens of 183 
patients with recurrent/persistent LSCC and independently stained for CD4+, CD8+, and 
CD103+ TIL content. Cox proportional hazards regression analysis was employed to assess 
combinations of CD4+, CD8+, and CD103+ TIL levels for prediction of overall survival (OS), 
disease-specific survival (DSS), and disease-free survival (DFS) in patients with 
recurrent/persistent LSCC. 
Results: High tumor CD103+ TIL content was associated with significantly improved OS, DSS, 
and DFS and was a stronger predictor of survival in recurrent/persistent LSCC than either high 
CD8+ or CD4+ TIL content. On multivariate analysis, an “immune-rich” phenotype, in which 
tumors were enriched for both CD103+ and CD4+ TILs, conferred a survival benefit (OS hazard 
ratio: 0.28, p = 0.0014; DSS hazard ratio: 0.09, p = 0.0015; DFS hazard ratio: 0.18, p = 0.0018) in 
recurrent/persistent LSCC. 
Conclusions: An immune profile driven by CD103+ TIL content, alone and in combination with 
CD4+ TIL content, is a prognostic biomarker of survival in patients with recurrent/persistent 
LSCC. Predictive models described herein may thus prove valuable in prognostic stratification 
and lead to personalized treatment paradigms for this patient population. 
Introduction 
Advanced stage laryngeal squamous cell carcinoma (LSCC) remains a clinical challenge, 
with recurrence rates of up to 50% after primary radiation (RT) or chemoradiation (CRT) [1]. 
For patients with recurrent disease after RT/CRT, salvage surgery is often the only established 





salvage laryngectomy are poor [4, 5]. The significant proportion of patients who develop 
recurrence after RT/CRT and the poor prognosis for patients with recurrent LSCC provide the 
rationale for new biomarker studies to improve prognostication and treatment selection in this 
vulnerable cohort. Although a variety of biomarkers ranging from genetic alterations [6], to 
protein expression [7], to tumor-infiltrating cells [8, 9, 10, 11, 12, 13] have been evaluated in this 
population, no prognostic model has demonstrated sufficient sensitivity and specificity to 
warrant further evaluation in prospective cohorts or to dictate clinical decisions. 
Despite the dearth of prognostic data within this population, the role of the adaptive 
immune system in tumor surveillance has emerged as an area of increasing interest for 
development of predictive assays of oncologic outcomes in patients with LSCC [14]. Certain 
immunologic signatures, including number of CD4+ and CD8+ tumor-infiltrating lymphocytes 
(TILs), portend improved survival and response to therapy in head and neck cancer [8, 9]. For 
example, we have recently shown that a higher proportion of CD4+ and CD8+ TILs correlates 
with improved disease-specific and disease-free survival (DFS) in patients with 
recurrent/persistent LSCC [9]. Subsequently, in order to further enhance the sensitivity and 
specificity of our model, we questioned whether prognostication in this cohort could be 
improved by considering immunologic biomarkers of cytotoxic TIL activity and tumor-cell kill, 
in addition to TIL number itself. 
CD103, or αEβ7 integrin, localizes antigen-specific cytotoxic T lymphocytes to epithelial 
tissues and is an indicator of enhanced cytotoxicity and proliferative ability of these cells [14]. In 
recent studies of non-small cell lung cancer [15] and serous ovarian cancer [16, 17], the survival 
benefit conferred by CD8+ TILs was shown to be dependent upon co-expression of CD103. 





subsets of TILs with important prognostic and immunotherapeutic implications in patients with 
recurrent/persistent LSCC. 
Herein, we evaluated the potential of CD103+ TIL density to act as a robust predictor of 
improved survival in patients with recurrent/persistent LSCC. Further, we hypothesize that there 
are patients with distinct immunologic phenotypes of “immune-rich” and “immune-poor” tumors 
that predict survival in recurrent/persistent LSCC. 
Materials and methods 
Patient population 
We performed a single-institution, retrospective analysis of patients with 
recurrent/persistent LSCC using a clinical epidemiology and tissue database. Inclusion criteria 
stipulated: (1) adults with biopsy-proven LSCC; (2) recurrent/persistent disease at the primary 
site after RT or CRT; (3) laryngectomy for surgical salvage; between 1997 and 2014 and (4) 
tumor tissue available for creation of tissue microarray, as previously described [9]. In total, 183 
patients met inclusion criteria, and demographics and clinical characteristics are shown in 
Table 2.1. Patients were staged in accordance with the 7th edition American Joint Committee on 
Cancer (AJCC) Staging System [18]. 
Immunohistology 
Formalin-fixed paraffin-embedded (FFPE) tissue blocks from salvage surgery and 
representative hematoxylin and eosin-stained slides were assessed for ≥ 70% tumor cellularity by 
a head and neck pathologist (Jonathan B. McHugh). A tissue microarray (TMA) was 
subsequently constructed with triplicate 0.7-mm-diameter cores from each patient [19]. 
TMAs were stained for CD4+, CD8+, and CD103+ TILs on arrays constructed as previously 





deparaffinized and rehydrated with stepwise xylene, graded alcohols, and buffer immersion. 
Heat-induced epitope retrieval was then performed, followed by incubation of the slides in a 
preheated pressure cooker with citrate buffer (pH 6) or Tris–EDTA buffer (Ph 9) and horse 
serum. Immunohistochemical staining was done with a DAKO autostainer using liquid 
streptavidin-biotinylated horseradish peroxidase complex and DBA (DAKO labeled avidin-
biotin-peroxidase kits, Thermo Fisher Scientific) as chromogens, as previously described [9]. 
Deparaffinized sections were stained with monoclonal antibodies at the following titrations: 
CD103-1:500 (Abcam Ab129202); CD4-1:250 (Abcam Ab846); CD8-1:40 (Novocastra VP-
C320). TMA slides were digitally imaged, scanned, and retrieved with Aperio ImageScope v.12 
software (Leica Biosystems). 
TIL scoring and statistical analysis 
Cores consisting of < 50% tumor parenchyma, partial cores, and those with significant 
tumor necrosis were excluded from the analysis. The positively stained cells in each included 
core were manually counted at 200× magnification (20× objective lens) by two independent 
blinded reviewers (Jacqueline E. Mann and Joshua D. Smith). Inter-rater reliability was 
determined by calculation of the intraclass correlation coefficient (ICC) using R. Only 
intratumoral TILs were quantified, consistent with the biological function of the CD103 antigen 
and previous studies demonstrating reliability and reproducibility of this measurement parameter 
[14, 16, 17]. Mean TIL counts per core of triplicate samples for each patient were calculated, 
averaged between the two reviewers, and used in subsequent statistical analysis. 
CD4+, CD8+, and CD103+ TIL counts were first input as continuous variables into 
univariate and multivariate models to document that each marker was a significant predictor of 





to maximize survival differences based on Cox proportional hazards regression of DSS using the 
survMisc v0.5.4 package in R [20]. Subsequently, combinations of the markers CD4, CD8 and 
CD103 were explored with multivariable Cox model and ROC analysis. 
Deaths were confirmed through the electronic medical record and the Social Security 
Death Index. Primary outcome measures were overall survival (OS; time from salvage 
laryngectomy to death from any cause), disease-specific survival (DSS; time from salvage 
laryngectomy to death from any disease recurrence/persistence), and disease-free survival (DFS; 
time from salvage laryngectomy to any disease recurrence/persistence). 
Results 
CD103 staining patterns and TIL cutpoints 
For our entire cohort, the mean (range) CD103+ TIL count per tumor was 32.1 (0–298) 
and the median count was 16 (Figure 2.1). Inter-rater reliability for TIL counts between the two 
blinded reviewers was excellent (ICC: 0.919, 95% CI 0.906–0.930). As continuous variables, 
CD4+, CD8+, and CD103+ TIL counts were each predictive of OS, DSS, and DFS (data not 
shown). 
We then determined the optimal cutpoint for CD103+ TIL counts to allow for 
stratification of recurrent/persistent LSCC into CD103+ low (< 11 TILs) and CD103+ high 
groups (≥ 11 TILs) optimized for DSS [20]. Of our entire cohort (n = 183), ten (5.5%) tumors 
were excluded due to partial or absent tumor cores, yielding 69 (40%) CD103+ low tumors and 
104 (60%) CD103+ high tumors. In a similar fashion, we determined optimal cutpoints for 
CD4+ and CD8+ TIL counts to stratify low and high groups with respect to these T-cell markers. 
CD4+ high tumors were defined as having greater than or equal to 3 TILs, yielding 36 (26%) 





absent tumor cores. Finally, the CD8+ cutpoint was determined to be greater than or equal to 12 
TILs, yielding 63 (41%) CD8+ high and 92 (59%) CD8+ low tumors in our cohort after 
excluding 28 due to partial or absent tumor cores. Each of the three dichotomized T-cell markers 
alone was correlated strongly with DSS (Figure 2.2). We had previously noted this for CD4+ 
and CD8+ TILs [9], but identified a new stronger association with CD103 status and DSS 
(p < 0.0001). Importantly, we noted significant correlation between CD8+ and CD103+ TIL 
content, confirming a unique population of cytotoxic T-cells that co-express these markers in 
recurrent/persistent LSCC (Pearson rho = 0.62, p < 0.0001). There was no similar overlap 
between CD4 and CD103 expression (Figure 2.3). 
 
Univariate analysis of CD103+ TILs on survival 
We next performed univariate analysis to assess the prognostic value of CD103+ TILs 
with respect to all three survival outcomes in patients with recurrent/persistent LSCC. Cox 
proportional hazards models found that patients with CD103+ high TILs had a better OS 
(p = 0.003), DSS (p < 0.0001), and DFS (p = 0.001) in comparison to patients with CD103+ low 
TILs (Figure 2.4). In comparing CD103 with CD8 on prognostication of survival, CD103 
status more strongly predicted survival. Thus, we continued forward with CD103 in 
multivariate analysis. 
 
Multivariate analysis of CD103 and other predictors of survival 
Next, we performed multivariate analysis in order to account for additional variables that 
have a prognostic survival value. We included variables previously validated in our cohort to be 





We found an interrelated effect between CD103+ and CD4+ TIL content, such that these 
variables combined were more predictive of survival parameters than either CD103+ or CD4+ 
TILs alone. Using the TIL cutpoint modeling described above, tumors were stratified into three 
groups: CD103+/4+ low (neither CD103+ or CD4+ high), CD103+/4+ mixed (either CD103+ or 
CD4+ high), and CD103+/4+ high staining (both CD103+ and CD4+ high). In univariate and 
multivariate modeling, high and mixed CD103+/4+ status were strong predictors of improved 
OS, DSS, and DFS in a dose-dependent fashion (Figure 2.5; Table 2.2). These models with 
combined CD103+/4+ status had good predictive value with c-indices of 0.75, 0.71, and 0.76, 
respectively, for DSS, OS, and DFS. 
Discussion 
An immunologic statistical profile informed by CD103+ TIL content appears to be a 
valuable predictive marker for survival in recurrent LSCC after RT/CRT. This adds to our 
previous findings that an immune-rich tumor-infiltrating phenotype carries a better prognosis in 
head and neck cancers [8, 9]. Greater TIL content in tumor specimens, whether CD103+, CD4+ 
or CD8+, portends a better prognosis. CD103+ TILs, in particular, were highly correlated with a 
favorable prognosis in our cohort. Moreover, combined high CD103+ and CD4+ TIL status had 
the best prognosis, suggesting an interrelated role of unique adaptive immune cells in controlling 
tumor progression and metastasis. Conversely, patients with “immune depleted” tumors 
relatively devoid of CD103+ and CD4+ TILs had significantly worse observed outcomes. These 
findings support previous studies in suggesting that “immune depleted” tumor status may be a 
key prognostic factor in many malignancies [21, 22, 23]. 
In our cohort, CD103+ and CD8+ TIL content overlapped significantly, supporting the 





malignant cell kill and tumor control. While a similar, albeit moderate, overlap of CD103 and 
CD8 expression was recently reported in TILs of non-small cell lung cancers [15], ours is the 
first study to confirm specialized TIL expression patterns in squamous cell carcinomas of the 
head and neck with translational implications. Further investigations into TIL expression patterns 
of CD4, CD8 and CD103 across a variety of head and neck cancers, both primary and recurrent, 
may lead to the discovery and functional characterization of further T-cell subpopulations vital to 
the adaptive immune response to malignancy. 
Given our findings, it is quite likely that CD103+ TIL content may also prove to be a 
clinically useful biomarker for predicting response to induction chemotherapy, successful larynx 
preservation, and survival in primary laryngeal cancers treated with organ preservation protocols. 
To this aim, we are currently analyzing CD103+, CD8+ and CD4+ TIL content in our extensive 
repository of primary LSCC specimens treated with organ preservation protocols and hope to 
publish these data soon. 
Of note, the pathogenesis of LSCC is not associated with human papillomavirus (HPV), 
and this is reflected in our LSCC cohort [5, 24]. Other HNSCC subsites, specifically 
oropharyngeal tumors, are more commonly associated with HPV, and these cancers are marked 
by a distinct immune phenotype with high levels of CD8+ T-cell infiltration and activation [25, 
26]. HPV infection represents a favorable prognostic factor in HNSCC and it has been postulated 
that the associated immune response may play a role in this relationship. Thus, it is of great 
interest that an immune-rich tumor microenvironment was still associated with an improved 
prognosis in this cancer traditionally not associated with HPV and immune activation. Further 





important in determining the importance of CD103 status and other immune markers in disease 
prognosis for these head and neck cancer subsites. 
While “immune depleted” tumors carry a worse prognosis, it remains to be seen whether 
they may respond differently to immunotherapeutics. Given that the anti-PD-1 antibodies 
pembrolizumab and nivolumab are dependent on T-cell activity, there is theoretical concern that 
these “immune depleted” tumors may also be more resistant to immunotherapies, given their 
relative depletion of TILs [27, 28]. Nevertheless, there remains significant room for further 
characterization of TIL status and “immune depletion” status in head and neck cancers, both in 
vitro and in the clinic. This will be crucial to validate our initial findings and to generate 
algorithms with which to prognosticate patients and potentially stratify treatments. 
The importance of immune signatures in cancer prognosis and the related response of 
immunotherapy in cancer treatment is becoming increasingly apparent. Thus, further elucidation 
of prognostic biomarkers will be a watershed in predicting patient outcomes, and potentially 
selecting patients who may benefit from adjuvant immunotherapy. Accordingly, as future genetic 
studies are completed, it is possible that molecular variables ranging from the status of genomic 
alterations to gene expression may further improve these immune signature-driven predictive 
models. The present study describes for the first time the value of the TIL marker CD103 in 
survival prognostication in head and neck cancer (specifically recurrent LSCC). Our findings 
suggest that CD103 status may be the most significant immune biomarker for disease 
prognostication and thus warrants further investigation in prospective studies and in 












Figure 2-1. CD103 staining patterns and TIL counts. 
Representative stains from CD103+ high (a) and low (b) TIL tumor specimens from our TMA 
(magnification ×20). A box and whisker plot of TIL counts was constructed (c) with mean 










Figure 2-2. Disease specific survival correlation with TIL count.   
We analyzed DSS stratified by CD103+, CD4+, and CD8+ TIL status.  On univariate analysis, 






Figure 2-3. Analysis of co-expression of TIL markers in tumors.  
Comparing CD103+, CD4+, and CD8+ TIL counts for each tumor specimen, we identified a 
strong overlap between CD103+ and CD8+ TIL expression status (Pearson 
rho = 0.62, p < 0.0001). There was no correlation between CD4+ expression status and 










Figure 2-4. Association of CD103 status with survival.  
On univariate analysis, CD103+ high TIL status was strongly predictive of improved OS 
(p = 0.003), DSS (p < 0.0001), and DFS (p = 0.001) 
 
Figure 2-5. CD103/4 status association with survival.  
CD103 and CD4 status stratified into high (both CD103+ and CD4+ high TIL status), mixed 
(either CD103+ or CD4+ high TIL status), or low (both CD103+ and CD4+ low TIL status) 
demonstrated significant association with OS, DSS, and DFS, with high the best prognosis, 








 MALE 153 (83.6) 
 FEMALE 30 (16.4) 
ETHNICITY  
 WHITE 161 (88.0) 
 BLACK/OTHER/UNKNOWN 22 (12.0) 
MEAN AGE AT INITIAL TUMOR 
(YEARS) 
58.63 
INITIAL CLINICAL STAGE  
 I 46 (25.1) 
 II 54 (29.5) 
 III 44 (24.0) 
 IV 25 (13.7) 
 UNKNOWN 14 (7.7) 
INITIAL TREATMENT  
 RT 112 (61.2) 
 CRT 71 (38.8) 
MEAN AGE AT RECURRENCE 
(YEARS) 
60.87 






 I 6 (3.3) 
 II 53 (29.0) 
 III 48 (26.2) 
 IV 76 (41.5) 





Table 2-2. Multivariate analysis of CD103/4 status and survival. 
Multivariable modeling with established variables for survival along with CD103/4 status 
demonstrates a significant survival benefit for CD103/4 mixed status and further greater survival 
for CD103/4 high status. 
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2.2 The molecular landscape of the University of Michigan laryngeal squamous cell 
carcinoma cell line panel.3 
Abstract 
Background: Laryngeal squamous cell carcinomas (LSCCs) have a high risk of recurrence and 
poor prognosis. Patient‐derived cancer cell lines remain important preclinical models for 
advancement of new therapeutic strategies, and comprehensive characterization of these models 
is vital in the precision medicine era. 
Methods: We performed exome and transcriptome sequencing as well as copy number analysis 
of a panel of LSCC‐derived cell lines that were established at the University of Michigan and are 
used in laboratories worldwide. 
Results: We observed a complex array of alterations consistent with those reported in The 
Cancer Genome Atlas head and neck squamous cell carcinoma project, including aberrations in 
PIK3CA, EGFR, CDKN2A, TP53, and NOTCH family and FAT1 genes. A detailed analysis of 
FAT family genes and associated pathways showed disruptions to these genes in most cell lines. 
Conclusions: The molecular profiles we have generated indicate that as a whole, this panel 
recapitulates the molecular diversity observed in patients and will serve as useful guides in 
selecting cell lines for preclinical modeling. 
 
3 This section was published in Head & Neck in collaboration with the following authors: Aditi 
Kulkarni, Andrew Birkeland, Judy Kafelghazal, Julia Eisenberg, Brittany Jewell, Megan 






Head and neck squamous cell carcinoma (HNSCC) is the sixth most common cancer 
worldwide and can arise in the oral cavity, oropharynx, hypopharynx, or larynx (1). The 5‐year 
survival rates for patients with HNSCC range from 40% to 80%, varying by anatomic site, tumor 
stage, and human papillomavirus (HPV) status (2).  Laryngeal squamous cell carcinomas 
(LSCCs), which comprise 20% of all HNSCCs, are typically HPV negative and have a 5‐year 
survival rate of 80% to 90% for stage I/II disease (3), but up to 50% of advanced patients with 
LSCC experience recurrence following frontline therapy, at which point disease progression 
often occurs rapidly with significant regression in quality of life metrics (4). Thus, robust models 
of LSCC are important for identification of biomarkers distinguishing patients most likely to fail 
therapy, as well as to develop novel treatments for aggressive disease. We believe LSCC cell line 
models representing the range of cancer stages and genetic composition in both primary and 
recurrent/metastatic settings will aid in better understanding individual disease processes and 
responses to treatment and in developing therapies that improve outcomes for LSCC. 
From The Cancer Genome Atlas (TCGA) project, a molecular landscape of primary 
untreated LSCC is beginning to emerge (5). Alterations to TP53, NOTCH1, CDKN2A, 
and PIK3CA are common, whereas the presence of HPV is relatively rare. Meanwhile, studies of 
recurrent and/or metastatic LSCC suggest that with progression, the molecular landscape shifts 
to contain more oncogenic lesions (6), although this relationship has not been confirmed in large 
cohorts of matched primary and metastatic tumors. Regardless, it is clear that distribution of 
genetic lesions varies among tumors, and as new questions emerge, it will be important to 





genetic background will likely impact the efficacy of targeted therapies, emphasizing the need 
for improved understanding of the unique complexity of individual cancers (7,8). 
Cell lines serve as valuable tools for assessing the impact of genetic alterations (9-
12). The University of Michigan previously created a repository of HNSCC cell lines (UM‐SCC) 
that were characterized by short tandem repeat typing (13), and although many of these have 
been utilized extensively throughout the world, thorough genetic characterization has not yet 
been performed for cell lines derived specifically from laryngeal carcinomas (8). This limitation 
prevents researchers from interpreting phenotypic and therapeutic results in the context of tumor 
genetics. Thus, we aimed to profile the genetic and transcriptomic landscape of laryngeal UM‐
SCC cell lines in order to provide a molecular basis for future studies that leverage this panel. 
MATERIALS AND METHODS 
UM‐SCC models 
LSCC cell lines were established and characterized in the Head and Neck Oncology laboratory at 
the University of Michigan with written informed consent from patient donors with LSCC, who 
were treated for LSCC between 1980 and 2011. Cell lines were maintained in exponential 
growth phase in Dulbecco's modified eagle medium with 10% fetal bovine serum, 5% 
penicillin/streptomycin, and 5 mM nonessential amino acids in a 5% CO2 incubator. 
In all cases except UM‐SCC‐105, due to the age of the cell lines, donor tissue from either tumor 
or normal tissue was unavailable for further testing. 
 
Exome sequencing 
Exome capture library construction was performed using the NimbleGen V2 (44.1 Mbp) Exome 





41, 46, 76, and 81B, and paired‐end sequencing (2 × 100 bp) was performed on an Illumina 
Genome Analyzer IIx Platform, with an average coverage of ×50. Library construction for UM‐
SCC‐12 and 105 was performed using the Roche NimbleGen V3 and paired‐end sequencing (2 × 
150 bp) was performed on an Illumina HiSeq 4000 platform with average coverage of ×100. All 
sequencing was carried out at the University of Michigan DNA sequencing core according to 
standard protocol. Whole exomes are available through the Sequence Read Archive 
(https://www-ncbi-nlm-nih-gov.proxy.lib.umich.edu/sra) accession # PRJNA525437. 
 
Variant Calling 
Quality control checks were performed on the raw sequencing data using FastQC v.0.11.5 
(14). Reads were aligned to hg19 reference genome using BWA v0.7.8 (15). Duplicates were 
marked using PicardTools v1.79 (Broad Institute, Cambridge, Massachusetts). BAM files were 
created by following the GATK best practices workflow (16). Variants were called on each cell 
line using the HaplotypeCaller producing a VCF file for each sample. These VCFs were then 
combined using the GenotypeGVCFs tool and a single VCF file was obtained for all the samples. 
Variant Quality Score Recalibration was applied to this joint VCF file to filter out low quality 
variants. To annotate and filter the variants of interest, the commercially available tool Goldex 
Helix Varseq v1.4.0 (Golden Helix, Inc., Bozeman, Montana) was used. Filters were set as 
previously described (17). 
 
Variant pathogenicity analysis 
The cancer‐related analysis of variants toolkit (CRAVAT; http://www.cravat.us) was used to 





(VEST) and driver/passenger status via the cancer‐specific high‐throughput annotation of 
somatic mutations (CHASM) tool. Missense mutations were scored with both VEST and 
CHASM; indels were scored with VEST only. The scores are used to generate P values, and a 
cutoff of P < .05 was used to designate highly pathogenic (VEST) or probable driver (CHASM) 
mutations. 
 
Sanger sequencing validation 
Genomic DNA isolation was performed using the Gentra PureGene kit (Qiagen, Hilden, 
Germany). DNA was then polymerase chain reaction (PCR) amplified with Platinum Taq DNA 
Polymerase High Fidelity (Invitrogen, Carlsbad, California) following manufacturer's 
instructions. PCR products were cloned into the pCR8 TOPO vector (Invitrogen) and subjected 
to Sanger sequencing on a 3730XL DNA Sequencer (Applied Biosystems, Foster City, 
California) at the University of Michigan DNA Sequencing Core. Sequence alignment was 
performed using the DNASTAR Lasergene software suite. 
 
 Copy number analysis 
The Affymetrix OncoScan Assay kit was used to analyze copy number alterations in the cell 
lines. The CEL files produced by the kit were merged to produce OSCHP files using the 
OncoScan Console v1.3 software. These OSCHP files were then analyzed by applying the 
TuScan algorithm, which is a part of the Nexus Express for OncoScan software package. From 
our analysis, we found a disparity between the B‐Allele Frequency plot and the copy number 
estimate made by the TuScan algorithm in case of some homozygous deletion calls (copy 





or absence of exome sequencing reads to confirm complete loss of the gene locus. Thus, we 
corrected copy number calls that were assigned a copy number call of zero by the TuScan 
software, but had exome sequencing reads, in Table 2-3 to indicate a single copy of the gene. 
Each of these corrections was annotated with an asterisk to denote the change. Copy number data 
have been deposited in the National Center for Biotechnology Information Gene Expression 
Omnibus (NCBI GEO; http://www-ncbi-nlm-nih-gov.proxy.lib.umich.edu/geo/) and are 
available through GEO Series accession #GSE127231. 
 
Transcriptome analysis 
RNA sequencing was performed for UM‐SCC‐10A, 10B, 12, 17B, 23, 25, 28, 46, 81A, 81B, and 
105 using Illumina stranded transcriptome library preparation kits with 75 nucleotide paired end 
sequencing to >×100 depth on an Illumina HiSEQ4000. Fragments per kilobase of transcript per 
million mapped read were calculated as previously described (16), and values for specific genes 
are listed in Table 2-4. Gene expression data from RNA‐seq experiments have been deposited in 
the NCBI GEO and are available through GEO Series accession # GSE126975. 
RESULTS 
We performed exome sequencing and high‐density arrays on a panel of UM‐SCC cell 
lines generated from patients with LSCC. We analyzed 16 cell lines total, generated from 14 
patients. Our panel represented a range of disease states (stage I through stage IV LSCC) and 
included cell lines from eight primary untreated, three recurrent, and four metastatic LSCCs 
(Table 2-5). Smoking/alcohol use was reported in all except the patient from whom UM‐SCC‐
105 was derived, who was HPV‐18 positive (18). Two matched pairs of cell lines were included 





metastasis, respectively, and UM‐SCC‐81A and 81B, derived from two masses resected in 
separate procedures. 
 Comprehensive capture‐based exome sequencing was performed on 14 cell lines. Our 
analysis showed a large mutational load, with approximately 30‐50 nonsynonymous mutations 
identified per Mb (Figure 2-6). To annotate the cell line panel, we assessed common genetic 
aberrations previously reported by the HNSCC TCGA consortium (5). We identified 
nonsynonymous mutations affecting several of these genes, including TP53 in 11 of 14 (79%) 
and FAT atypical cadherin 1 (FAT1) in 6 of 14 (43%) of cell lines (Figure 2-7A). Table 2-6 lists 
the specific mutations observed. Mutation rates for each gene are provided as compared to 
TCGA HNSCC data (5,19). Importantly, our study lacks matched normal samples and therefore 
cannot account for germline variants, although most genes were mutated with similar frequencies 
in the LSCC cell line panel as in the TCGA tumors. Notable exceptions 
included FAT and NOTCH family genes and BRCA1/2, which are mutated at higher rates in our 
models than in TCGA specimens. 
 The FAT family mutations identified in our LSCC cell line panel are depicted in Figure 
2-7B and were validated by Sanger sequencing (Figure 2-8). For each FAT mutation identified in 
our panel, we used the VEST420-22 to predict pathogenic impact. Variant score P values are 
reported for each mutation in Figure 2-7B and support a pathogenic impact on FAT1 function of 
5 of 7 of the identified alterations (P < .05). Interestingly, FAT4 mutations were also especially 
prevalent, and VEST4 scores predicted a pathogenic impact in 5 of 8 cases. For missense 
mutations, the CHASM‐3.1 tool was used to predict driver mutations (Table 2-7). Similar 
analysis was completed for the NOTCH family genes, and BRCA1/2 alterations identified in our 





pathogenicity scores for BRCA1/2 were not significant, the CHASM predictor of tumorigenic 
impact classified the mutations reported in both genes as likely driver mutations (Table 2-7). 
 
After annotating molecular alterations found in the panel, we assessed copy number 
alterations in 12 LSCC cell lines via high‐density single nucleotide polymorphism (SNP) arrays 
to provide additional molecular detail. We first performed a combined analysis of all 12 lines by 
summing copy number alterations at each probe site (Figure 2-9A). Our analysis revealed 
common copy number alterations in the cell line panel consistent with those reported in previous 
HNSCC studies, including broad amplifications of chromosome 3q, 5p, 7p, 8q, and 20q arms and 
deep deletions in the chromosome 3p, 8p, 9p, 11q, and 18q arms.5, 23-25 Importantly, the 3q 
amplicon includes transcription factors TP63 and SOX2, as well as the oncogene PIK3CA. As 
35% of HNSCCs in the TCGA study harbor an alteration in PIK3CA, it is widely considered a 
potential therapeutic target, with several clinical trials investigating PI3K inhibitors in patients 
with HNSCC (26). Additionally, both broad and focal deletions were observed in the 4q35 
region containing the FAT1 gene. Thus, our analysis suggests that this panel as a whole 
recapitulates the landscape of major chromosomal aberrations found in HNSCC tissues. 
Next, we further interrogated our panel to characterize key genes and pathways. Genes 
chosen for analysis were previously identified as commonly altered in the TCGA HNSCC 
cohort,5 are otherwise implicated in HNSCC pathogenesis (SRC, BCL6, and JAK2), or are 
reportedly linked to FAT1 signaling (SCRIB, STK3, WWTR1, WWC1, MTNR1A, and FAT3). 
Copy number calls are reported in Table 2-3. Median copy numbers are depicted in a heat map 
(Figure 2-9B, upper panel). We refer to median values ≥0.5 as amplifications and values ≤−0.5 





cell lines and amplifications of PIK3CA in 5 of 12. Copy losses at the CDKN2A‐CDKN2B locus 
were especially prevalent (10 of 12 cell lines). We observed broad 9p deletions in 6 of 12 cell 
lines, with an additional 4 cell lines exhibiting focal deletions at the CDKN2A‐CDKN2B locus 
(Figure 2-9C). We also performed RNAseq for a subset of UM‐SCC larynx cell lines (Figure 2-
9B, lower panel). As expected, EGFR was highly expressed in all cell lines. In many cases, copy 
number alterations corresponded with variations in gene expression (Figure 2-10). For example, 
we report deletion and low expression of CDKN2A/B in UM‐SCC‐12 and 81A, as well as 
amplification and high expression of YAP1 in UM‐SCC‐81B. We also asked whether cell lines 
harboring nonsense mutations likely to confer loss of function might exhibit altered gene 
expression, but in this small sample size, we observed no trends with regard to RNA expression 
and mutation status (Figure 2-10). 
FAT1 copy loss was observed in 4 of 12 cell lines in this analysis, with focal deletions in 
UM‐SCC‐10B and 12 (Figure 2-9D). Notably, FAT1 was also a commonly mutated gene in our 
panel (Figure 2-7A). Interestingly, of those cell lines that lacked a point mutation, some (UM‐
SCC 10A, 10B, and 46) did exhibit FAT1 deletions, for a total of nine cell lines with potential 
loss of FAT1 function. Some cell lines exhibited loss of multiple FAT family genes: FAT1 and 
FAT2 losses were both observed in the UM‐SCC‐10A/B pair and losses of all four FAT genes 
were observed in UM‐SCC‐46 (Figure 2-9B). However, RNA‐seq indicated high expression of 
FAT1 in most cell lines, with the exception of UM‐SCC‐10A/B. 
Given the high rate of FAT1 alterations with predicted functional impact in our panel, we 
sought to summarize alterations in FAT family genes. FAT1 alterations occurred in 35% of the 
110 LSCCs in the TCGA cohort and 29% of the overall cohort (Figure 2-11A) (19), and of the 9 





exhibited loss of function alterations in FAT1, consistent with its purported role as a tumor 
suppressor. About 55% of LSCCs and 44% of all HNSCCs in the TCGA study harbored at least 
one FAT family gene alteration. Among these samples, the majority of 110 of 143 (77%) of 
FAT1 mutations are reported as truncating mutations (Figure 2-11A), which was consistent with 
our observation of missense mutations, a frameshift, and a stopgain among UM‐SCC lines 
(Figure 2-7). Figure 2-11B summarizes FAT family alterations observed in the cell line panel. 
Although most FAT1 mutations were truncating or deep deletions, mutations in other FAT 
family members were predominantly missense mutations in TCGA samples and UM‐SCC cell 
lines. 
Our data support a model in which functionally recurrent alterations to multiple genes 
within a pathway contribute to overall pathway disruption. To further understand functional 
recurrence of alterations to FAT signaling, we next examined alterations to genes linked to FAT1 
signaling in both the TCGA dataset and our cell line panel. FAT1 has been shown to inhibit 
Hippo/YAP1 pathway‐induced proliferation and survival through its interactions with Scribble 
(SCRIB) and serine/threonine kinase 3 (STK3) (28-30).  Figure 2-11C summarizes the 
prevalence of genetic alterations in these genes identified in TCGA primary larynx tumors27 and 
all TCGA HNSCC tumors (black). From this summary, it appears that alterations to FAT 
signaling are more common in LSCC than other HNSCC disease sites; in particular, we noted 
that alterations affecting WWTR1, a YAP1 paralog, were especially prevalent in larynx tumors, 
with 31 of 110 (28%) larynx tumors harboring a WWTR1 amplification, compared with 39 of 
394 (10%) at other subsites. Unfortunately, the relatively low number of tumors from each 





In the UM‐SCC panel, we observed broad copy gains to 11q22, which contains the YAP1 
gene, in 2 of 12 cell lines, further implicating Hippo/YAP1 activation in promoting growth and 
survival in these models (Figure 2B). WWTR1 is also frequently amplified, with copy gains 
occurring in 6 of 12 cell lines. This is consistent with frequent WWTR1 amplifications observed 
in the TCGA HNSCC dataset. Figure 2-11D summarizes alterations to Hippo/YAP1 pathway 
genes in UM‐SCC cell lines. Interestingly, contrary to their documented tumor suppressive 
functions, amplifications of both STK3 and SCRIB were observed in 2 of 14 and 6 of 14 cell 
lines, respectively (Figure 2B), with modest copy gains observed in several additional cell lines. 
This is consistent with the broad 8q copy gains observed in the UM‐SCC panel and TCGA data.5 
Also linked to this pathway is the KIBRA protein, encoded by WWC1, which is thought 
to promote the phosphorylation and inhibition of YAP1 and WWTR1 (31). We observed WWC1 
loss in 3 of 12 cell lines, consistent with a role in dampening Hippo/YAP1 signaling, although 
UM‐SCC‐81A exhibits a modest copy gain. Furthermore, NOTCH3, mutated in 5 of 14 cell lines 
in our mutation analysis, was recently shown to act as a tumor suppressor in breast cancer cells 
by inducing KIBRA upregulation (32). Overall, the prevalence of alterations in FAT1‐related 
genes supports a role for Hippo/YAP1 and FAT family signaling in these models, warranting 
further investigation of this network in LSCC. 
DISCUSSION 
As precision medicine protocols are developed, comprehensive genetic stratification of 
tumors becomes increasingly crucial to correlate with disease prognosis and to target known 
driver mutations (33). Large‐scale, integrated analyses have recently provided unparalleled 
molecular detail toward stratification of tumors, paving the way for precision medicine protocols 





combinations, an array of well‐characterized models representative of the diversity of disease 
observed in the clinic must also develop in tandem, as preliminary studies using these tools are 
critical to predict therapeutic response. The UM‐SCC cell line panel is widely used to model 
HNSCC, but genetic characterization of these cell lines has been limited. Furthermore, LSCC is 
a challenging clinical entity, with limited response to current treatment modalities and poor 
survival rates, especially in recurrent disease (34). We therefore sought to create a profile of 
UM‐SCC cell lines derived from patients with LSCC to better understand these models and 
determine how accurately they reflect genetic characteristics of patients. 
Overall, our analysis indicates that many aberrations recurrently identified in the HNSCC 
TCGA study are well represented in the UM‐SCC larynx cell line panel. EGFR, PIK3CA, 
and CCND1 copy gain, CDKN2A copy loss, and TP53 and FAT1 mutation are among the most 
common aberrations observed in our panel, consistent with reports of clinical specimens. Thus, 
this panel appears to adequately represent many well‐studied, targetable alterations in HNSCC 
and should serve as an important tool in advancing combination therapies targeting these 
pathways. Importantly, there were some genes (FBXW7, BRCA1, NOTCH2, and NOTCH3) for 
which our analysis indicated considerably higher mutation rates than those observed in the 
TCGA dataset. Such discrepancies may be attributed to our small sample size, differences in 
variant calling pipelines, or to the fact that the TCGA report includes only somatic mutations, 
whereas our analysis cannot distinguish somatic mutations from germline. It is also possible that 
certain alterations have been selected for during cell line derivation and culture. 
Notably, significant variation in molecular profiles exists within tumor sets and across the UM‐
SCC panel. For example, UM‐SCC‐17B is strikingly devoid of point mutations and copy number 





(35). Likewise, UM‐SCC‐105, an HPV‐18 positive cell line, appears similarly genomically 
stable but harbors a pathogenic nonsense mutation in BRCA2. Identification and stratification of 
such molecular subsets will benefit research applications and could aid in selection of 
appropriate models based on patient characteristics. 
Our data show an unexpectedly high prevalence of FAT1 inactivating mutations or 
genetic deletions and support a deeper analysis of the pathway. Although FAT1 alterations are 
well documented in HNSCC, few reports address FAT2, FAT3, and FAT4, which have lower 
alteration rates than FAT1 in the TCGA dataset (Figure 2-11A). In our cell line panel, we found 
that FAT family alterations were prevalent and UM‐SCC‐10A, 10B, and 46 harbored alterations 
in multiple FAT genes. We observed FAT1 and FAT2 copy loss in the UM‐SCC‐10A/10B pair, 
along with both copy loss and mutation in FAT4 in UM‐SCC‐10A. Furthermore, 
a FAT2 mutation with high predicted pathogenic impact was identified in both cell lines, further 
supporting a prominent pathogenic role for FAT genes in these particular models. 
Although FAT3 is considered paralogous to FAT1 and exhibits similar functions 
(30), fewer FAT3 alterations were discovered in the TCGA cohort, and these appeared less likely 
to confer loss of function, consisting of a mix of amplifications, deletions, missense mutations, 
and truncating mutations (Figure 2-11A). Similarly, in the 12 cell lines subjected to copy number 
analysis, we observed one loss and one gain in FAT3 (in UM‐SCC‐46 and ‐25, respectively; 
Figures 2-9B and 2-11B). Only three FAT3 mutations were observed in our cell line panel and all 
were missense mutations (Figure 2-7). However, UM‐SCC‐11A and 17B both harbored 
mutations classified as pathogenic by the VEST tool, and the mutation in 11A is a predicted 
driver according to the CHASM score. Interestingly, expression of FAT3 was very low in most 





alterations may be required to understand how each type of alteration affects FAT3 pathway 
activity. 
When we expanded our analysis to additional genes linked to FAT signaling, we noted 
frequent copy number alterations consistent with dysregulated Hippo/YAP1 signaling, both in 
our cell lines and in the TCGA dataset, particularly affecting WWTR1. Although amplifications 
of purported tumor suppressors STK3 and SCRIB were also observed, this may be due to the fact 
that both genes are located in a broadly amplified region of 8q. Although a mechanistic role 
for STK3 and SCRIB in promoting tumorigenesis has not been clearly defined, the seemingly 
paradoxical overexpression of these proteins is commonly reported in human cancers (36). 
FAT1 is in the cadherin class of membrane‐bound proteins, with functions that remain to be fully 
characterized. Notably, FAT1 mutations may have context‐dependent effects depending on the 
tissue source. In HNSCC and esophageal squamous cell carcinomas, it appears to act as a tumor 
suppressor gene, inhibiting epithelial‐mesenchymal transition and cell proliferation (37), whereas 
in other tumors, it may have oncogenic function (38,39). There is limited understanding of the 
role of FAT1 in HNSCC in general, apart from the high mutational rate reported in the recent 
TCGA study. Interestingly, FAT1 mutant HNSCCs may have better overall survival (40), 
suggesting that it may portend a better prognosis for which clinical treatment modification may 
be investigated. A prognostic role for FAT1 will need to be investigated in confirmatory cohorts, 
and further characterization of tumors harboring FAT1 alterations will be necessary. Recently, 
Martin et al showed that FAT1 participates in assembly of a Hippo signaling complex 
responsible for negatively regulating YAP1 in HNSCC cell lines, thus its loss may result in 
unrestrained YAP1 activity (27).  Reintroduction of FAT1 intracellular domain into FAT1 





tumorigenesis in vivo. These effects were rescued by YAP1 overexpression. A 2017 study by 
Pan et al assessed YAP1 protein by immunohistochemistry in 121 LSCC tumor samples and 
found positive YAP1 expression to be associated with clinical stage, TNM classification, lymph 
node metastasis, and poor overall survival (41). Taken together, these studies support YAP1 as a 
promising therapeutic target in the context of genetic alterations in FAT1 and the Hippo 
signaling pathway. 
Another recent study identified a potential interaction between FAT1 and CASP8 in oral 
cavity squamous cell carcinomas (42), showing increased growth and migration in cell lines with 
FAT1 loss of function, further corroborating the functional role of FAT1 as a tumor suppressor 
gene. FAT1 may function as a tumor suppressor by binding to β‐catenin and blocking its nuclear 
translocation, thereby inhibiting Wnt signaling pathways fundamental to growth and 
proliferation.38 As discussed above, FAT1 may inhibit the YAP1 pathway, which is critical for 
cell growth and survival. Thus, with FAT1 loss of function in LSCC, there may be unchecked 
tumor cell growth and proliferation through both Wnt/β‐catenin and YAP1 pathways. In 
selecting targeted therapies in LSCC, consideration of FAT1 status may be beneficial, as agents 
inhibiting the Wnt/β‐catenin pathway, many of which are in development, may be particularly 
efficacious. 
The UM‐SCC larynx cell line panel has been in use in laboratories throughout the world 
for the past several decades. We now provide a comprehensive genetic characterization of these 
models that can be used to contextualize past and future studies in terms of the genetic diversity 
seen in patients. However, in utilizing cell lines as model systems, it is important to note the 
likelihood of variations between stocks of the same cell line. In support of the concept that 





performed for UM‐SCC‐17A/B at several different passages by Carey et al in 1989 (43). There 
were no karyotypic differences between UM‐SCC‐17A cells analyzed at passages 8, 23, 28, and 
37 nor between UM‐SCC‐17B cells at passages 13, 17, and 52. However, a UM‐SCC‐17A 
subline was also discovered, differing from the UM‐SCC‐17A stem line both at the cytogenetic 
level and by expression of various surface antigens, including the E7 and A9 antigens. This 
subline was believed to represent a distinct population present in the primary tumor, indicating 
that multiple heterogeneous populations existed initially. Furthermore, Ludwig et al performed 
comprehensive profiling of the UM‐SCC oral cavity cell line panel and provided evidence of 
multiple clones through copy number analysis and fluorescence in situ hybridization (17). 
The concept of cell line evolution in culture was highlighted more recently in a 
comprehensive characterization of 27 MCF7 strains in which the authors observed considerable 
variations in genetics, gene expression programs, morphology, and drug response (44). Many of 
the cell lines discussed here have been distributed to laboratories throughout the world, and 
genetic drift and divergence among lineages cultured in different laboratories is highly likely. As 
the purpose of the present study is to offer a baseline profile of the LSCC cell lines, a direct 
comparison between the genetics of our cell lines and lineages propagated in other laboratories is 
beyond the scope of this report. However, we do describe and reference many of the same 
genetic alterations reported by other laboratories. For example, a 2018 study by Cheng et al 
assessed mutations and copy number variations in a panel of 26 HNSCC cell lines, notably 
including UM‐SCC‐46 and UM‐SC‐105 (45). We recapitulate many of their findings in UM‐
SCC‐46, such as 3q copy gain, YAP1/BIRC2 deletion, a TP53 nonsense mutation, 
and KMT2D frameshift. Cheng et al also report a 3q gain in UM‐SCC‐105, as well 





potential genetic drift between models cultured in different labs over time. Additionally, while 
Cheng et al report FAT1 copy gain in nearly all cell lines, including UM‐SCC‐46 and 105, our 
data show copy loss in UM‐SCC‐46 and no alteration in UM‐SCC‐105. 
Furthermore, Nisa et al analyzed alterations in several UM‐SCC cell line pairs in 2018, 
including the UM‐SCC‐10A/B, 17A/B, and 81A/B pairs (46). They report several differences 
between the 10A (primary tumor) and 10B (lymph node metastasis) lines, including as 
a FAT4 mutation only in 10A, an observation recapitulated in our study. We also reproduce their 
findings of TP53 and FAT2 mutations in both lines, but interestingly, Nisa et al also 
report FAT1, 2, and 4 mutations in UM‐SCC‐17B, as well as a PTEN mutation in UM‐SCC‐81B, 
which we did not observe. 
The present study emphasizes the utility of continuing to expand the available array of 
well‐characterized HNSCC cell lines. Importantly, this report also highlights an 
underappreciated but broad range of molecular alterations to multiple genes associated with FAT 
signaling and supports a need to deeply dissect the function of this pathway in HNSCC 
pathogenesis. As we refine our understanding of molecular complexity and heterogeneity in 
HNSCC, our study provides a foundation for modeling therapeutic responses and advancing 
personalized medicine protocols. 
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10A 10B 12 17B 23 25 28 46 57 81A 81B 105 
TP63 5 3 7 2,2.5 8.67,
5.33 
4 2.33 2.67 6 2.33 6 2 
PIK3CA 5 3 5 2 4.67 4 2.33 2.67 6 2.33 6 2 
PTEN 1 1.67 2 2,1.5 3.33 4 1.67 1.67 2 2 3 3 
PIK3R1 0 1.33 2 2 2.33 3 2 2 2 2 4 3 
CDK6 2 1.67 7 2 4.33 4 2.67 3 3 1.67 4 2 
CDKN2A 0 1.33 1  0,2 0* 4 1 1 0 0* 1.5 3 
CDKN2B 0 1.33  0 2 2.33 4 1 1 0 0* 1.5 3 
TP53 1 1.67 5 2 3.33 3 2.33,
2 
1.67 2 1.67 1.5 2 
NF1 1 2 4 2 4 0 2.67 2 3 2.67 4 2 
CASP8 1 2.33 1.5 2 3.33 4 1.67 1 5 1.67 3 2 
NOTCH1 1.5 2 5 3 4.67 2 3.33,
3.67 
2.33 3 2.33 5 3 
MYC 3 3 15 2 3.33 4 2.67 2 5 3 4 3 
HRAS 1.5 1.67 3 3 2.33 4 1.33 1.67 2 2 3 2 
CCND1 1.5 2 2 3 3.67 6 2 7.33 2 2.33 4 1.5 
SRC 3 2.67 5 2 4 4 1.67 2 3 3 4 3 
BCL6 5 3 4 2 6.33 4 2.33 2.67 6 2.33 6 2 
EGFR 5 3.33 6 3 5, 
2.33 
8 3 2.33 5,2,4 2.67 4 4 
FGFR1 3 2.67 4 2 2 1.
5 
2.67 2 5,2.5 1.67 3,2.
5 
3 
FGFR3 1 2 2.5 1 2 2 1.33 1.67 2 2 2.5 2 
IGF1R 1 1.33 6 2 3.33 2 1.67 2 4 2 4,3 3 
ERBB2 1 2 4 2 3.67 3 2.33,
2.67 
2.33 4 2.67 4 2 





DDR2 2 2.33 3 2 4 4 2 1.67 3 2.67 2.5 2 






2.33 2 3 1.67 4 2 
JAK2 0 1.33 7 2 2 4 1 1.67 2 1.67 1,1.
5 
3 
TRAF3 0 2 4 3 3 1 1 2 4 2.33 4 2 
KEAP1 0 2 3 2 1.67 1 1.33 1.67 2.5 1.67 2.5 1.5 
MYH9 1 2 0 1 3.67 2 1.67 2 2.5 1.67 4 2 
BIRC2 2 2 2 3 3.33 6 1.67 1 3 2.67 21 2 
YAP1 2 2 2 3 3.33 6 1.67 1 3 2.67 21 2 
SCRIB 2.5 2 3 2 3.33 4 2.67 2 4 2.33 4 3 
STK3 3 2.67 4 2 3.33 4 2.67 2 4 3 4 3 
WWTR1 4 3 5 3 6 5 2.33 2.67 2 2.33 6 2 
WWC1 1 1.67 5 2 2 4 2 1.67 2 2 4 2 
FAT4 1 2 2 2 4.33 2 1.67 1 3 1.67 2 2.5 
FAT3 2 2 2 3 2.33 6 1.67 1 3 2.67 1.5 2 
FAT2 1 1.67 4 2 2 4 2 2 2 2.33 4 2 




1 2 1.67 1.5 2 
AJUBA 2.5 2 3 2 3.33 5 1 2 2 2.67 4 2 
Table 2-3. Estimated copy numbers for gene list as noted by the TuScan algorithm for the indicated UM-
SCC-cell lines. 
For entries containing multiple copy numbers separated by a comma, multiple values were reported over the length 
of the gene. Where a copy number of 1* is reported, the TuScan algorithm estimated a complete deletion (CN=0), 
however, we observed those genes had exome sequencing reads. Thus, we determined it more accurate to report a 









 10A 10B 12 17B 23 25 28 46 81A 81B 105 
TP63 7.6623 8.1646 6.7623 8.3993 6.1935 2.5379 6.4389 6.9031 0.3340 6.0780 5.9351 
PIK3CA 4.8020 3.6584 3.4539 2.9023 3.5593 3.1881 2.9400 3.6907 3.5514 4.4735 2.5713 
PTEN 3.4256 4.6801 4.4520 5.0443 4.2966 4.0593 4.0263 4.9740 4.3265 4.2996 4.8531 
PIK3R1 2.1450 2.5989 3.4658 3.4931 2.5063 2.5891 2.4788 2.2305 2.6461 3.2411 2.5006 
CDK6 6.2933 6.4345 5.1640 4.7098 5.3604 4.7772 6.5492 5.6388 5.1648 4.4781 4.9268 
CDKN2A 6.8201 6.3759 0.0393 3.8224 0.0603 5.9065 4.3914 3.9035 0.0000 5.2869 7.0785 
CDKN2B 3.2566 4.5155 0.0000 2.8831 3.3877 4.5271 4.9087 3.8782 0.0070 3.2560 4.8319 
TP53 5.4030 4.8597 2.1541 4.3951 5.6513 1.9003 4.9494 4.7691 4.1666 4.6973 4.9388 
NF1 4.5408 4.5404 5.3128 4.9547 5.1048 3.6482 5.4243 4.9164 4.9959 5.1343 4.1364 
CASP8 3.7236 2.9777 3.3700 3.9183 4.0217 3.7642 3.3313 2.6991 2.4962 2.8335 3.5611 
NOTCH1 3.3731 3.6975 4.2125 5.1377 3.3959 0.9943 2.6231 3.7287 3.6116 4.1226 5.1034 
MYC 4.3881 4.9783 5.4592 5.7721 6.2044 3.3831 4.1588 5.2268 4.7677 5.8586 7.1268 
HRAS 4.5701 3.5060 5.0894 5.2871 4.4427 3.0434 5.3468 4.5178 3.8444 4.0430 4.6768 
CCND1 7.8498 7.1665 5.0656 5.9039 7.2620 5.1855 7.3009 8.1828 6.7250 6.5615 5.6538 
SRC 4.3635 4.5835 4.8736 4.6138 4.0139 4.6236 3.8402 3.1397 4.2211 4.7096 4.8396 
BCL6 3.3161 4.6113 2.5132 2.9562 3.5186 3.0358 3.0722 4.0914 2.4507 4.8402 3.9008 
EGFR 7.8369 7.1857 6.4553 6.9589 5.6047 5.2484 6.4214 6.2852 6.2873 6.2430 6.9608 
FGFR1 1.6183 2.4480 2.3312 3.1269 0.0499 0.7250 2.1736 3.5468 3.9369 0.8622 1.7425 
FGFR3 4.3248 5.6194 2.6482 2.4520 4.5837 1.3600 4.2373 4.6962 2.2620 4.4536 5.3393 





ERBB2 4.9432 4.6229 3.4282 4.7632 4.6750 4.6946 4.6523 4.4665 5.3251 4.1712 4.6199 
EPHA2 6.1029 6.0810 3.9771 4.0648 5.6189 4.6384 5.3724 5.1853 4.8663 5.0718 5.4191 
DDR2 0.0633 0.1773 0.1324 0.1555 2.1455 0.6135 0.3841 0.0989 3.7724 0.3785 0.4390 
MET 6.7031 6.2867 4.5971 3.6581 6.2914 5.8806 6.5183 4.2425 6.0979 6.3115 5.7766 
JAK2 1.2706 1.6025 1.6964 1.6806 1.0809 1.6428 1.1048 1.9090 1.3916 1.1277 2.2140 
TRAF3 2.5141 2.5284 3.6473 3.4388 3.3495 3.0201 2.3404 3.1884 3.2421 4.2148 3.4136 
KEAP1 3.9783 3.8006 5.7343 4.0167 4.0860 3.6292 4.1860 4.7475 4.2453 4.0303 4.4340 
MYH9 7.2056 6.9068 5.8622 5.5756 8.1863 7.3177 6.8321 6.5500 8.4220 7.7824 7.1305 
BIRC2 4.5467 5.2006 3.5243 4.0231 3.2013 4.1267 4.1765 3.3233 4.5288 7.4342 3.4313 
YAP1 6.1855 6.0123 5.3423 6.2335 5.3618 6.2527 5.7629 4.8658 6.0854 9.1912 5.4303 
SCRIB 5.2346 4.2303 3.7906 2.2627 4.3241 3.7329 5.2019 4.1153 5.0544 4.4928 5.4409 
STK3 3.8531 4.7517 3.1143 3.7440 4.5267 4.9563 4.4056 3.5592 6.0992 4.1279 4.2794 
WWTR1 4.0481 3.5084 5.0286 4.8644 5.9052 3.3997 2.9458 3.2259 3.5284 4.7621 2.6416 
WWC1 3.7137 4.5820 3.2929 3.0437 3.4207 5.6651 4.0195 4.5026 5.7884 4.6707 4.1991 
FAT4 2.3774 2.0248 1.3965 2.4367 2.1770 2.4085 0.5321 0.0548 3.2649 0.2501 1.1720 
FAT3 0.2546 2.0054 0.5291 0.2707 0.0082 2.7879 0.0620 0.7411 0.4098 0.8205 0.0000 
FAT2 4.9577 4.7640 5.9967 6.1288 1.1908 2.7020 6.2136 6.1634 0.6397 5.9187 5.5510 
FAT1 0.2184 0.8399 5.8568 7.0253 5.8733 3.7984 6.1790 6.2621 5.9881 6.0268 7.3524 
AJUBA 7.3530 7.1279 5.9213 5.8679 6.0761 6.0936 6.2687 6.2640 6.7508 6.2323 6.6578 






Cell line Age Sex Clinical 
TNM 










UMSCC‐10A 57 M T3N0M0 III True cord P None 
 
20 Heavy 
UMSCC‐10B 58 M rT3N1M0 III Lymph node Met S 
 
20 Heavy 
UMSCC‐11A 65 M T2N2aM0 IV Epiglottis P ICX 
 
35 Heavy 
UMSCC‐12 71 M T2N1M0 III Larynx R S, RT 
 
— — 
UMSCC‐13 60 M T3N0M0 III Stoma R RT,S 
 
90 Heavy 





UMSCC‐23 36 W T2N0M0 II Supraglottis P None 
 
48 Heavy 
UMSCC‐25 50 M rT3N2bM0 III Lymph Node Met RT,S,S 
 
Heavy Heavy 
UMSCC‐28 61 W T1N0M0 I True cord P None 
 
40 — 
UMSCC‐41 78 M T2N1M0 III Arytenoid P None 
 
50 Moderate 
UMSCC‐46 58 W T2N2M0 IV Supraglottis R RT,S 
 
60 Heavy 
UMSCC‐57 69 M — — Supraglottis — — 
 
— — 
UMSCC‐76 66 M T3N2cM0 IV Lymph node Met ICX 
 
40 Heavy 





UMSCC‐81B 58 M T2N0M0 II True cord P None 
 
100 Heavy 




Table 2-5. Clinical characteristics of patients with LSCC from whom UM‐SCC cell lines were derived. 
Note: UM‐SCC‐10A and 10B were derived from samples taken from the same patient at different times and sites. UM‐SCC‐81A and 81B were derived from two 
vocal cord masses resected in separate procedures. HPV‐18 was detected in UM‐SCC‐105 by HPV‐PCR mass array. HPV was not detected in other cell lines. 
Categories for which no data were available are marked with a dash. 
Abbreviations: HPV, human papillomavirus; ICX, induction chemotherapy; LSCC, laryngeal squamous cell carcinomas; M, men; Met, metastasis; P, primary; R, 







10A 10B 11A 12 13 17B 23 25 28 41 46 76 81B 105 
TP53 








  4:187518878     4:187629411*, 
4:187630099 
4:187541379 4:187518255  4:187630240 4:187540040 
 
 
FAT2 5:150943061 5:150943061  5:150945830       5:150942985 5:150924968   
FAT3   11:92086828   11:92533622      11:92533495   
FAT4 
4:126337669     4:126369804, 
4:126412106 
4:126355547 4:126370896 4:126319964, 
4:126372555 
4:126241248    4:12641398** 
RB1     13:48934219          
CDKN2A        9:21971124*   9:21971096    
PIK3CA 
   3:178936094  3:178938934, 
3:178942545 
     3:178916924   
PIK3R1            5:67584513** 5:67584513**  
AJUBA             14:23450548  
NOTCH1 




    9:139411814*, 
9:139411816 






















       1:120572572, 
1:120491153 








  12:49433848, 
12:49426283 
 12:49435240    12:49447384  12:4943187*    
NSD1 
  5:176722417   5:176637471, 
5:176638506, 
5:176710840 
5:176709524        
TGFBR2 




 4:153268228 4:153249384, 
4:153253874, 
4:153253876 
        4:153268228   
TRAF3       14:103342015     14:103342060   
NFE2L2    2:178098810           
CUL3         2:225449767**      
BRCA1 
   17:41243509, 
17:41256877 
17:41243509  17:41246812  17:41244429 17:41244429     
BRCA2           13:32893369  13:32954265 13:32972626 
 
Table 2-6. Locations of all mutations identified in the indicated cell lines by capture based exome sequencing. 
All mutations were missense mutations unless otherwise indicated.  Those listed in italics represent splice donor or acceptor regions.  Red text indicates a stop 





Gene Cell Line Locus CHASM p value VEST p value 
BRCA1 UMSCC13 17:41243509 0.0006 0.1821 
BRCA1 UMSCC28, 41 17:41244429 0 0.4463 
BRCA1 UMSCC23 17:41246812 0.0006 0.2527 
BRCA1 UMSCC12 17:41243509 0.0006 0.1821 
BRCA2 UMSCC46 13:32893369 0.0214 0.1092 
BRCA2 UMSCC81B 13:32954265 0.0206 0.1789 
BRCA2 UMSCC105 13:32972626 stopgain 0.1821 
NOTCH1 UMSCC28 9:139411794 frameshift 0.0217 
NOTCH1 UMSCC25 9:139411814 frameshift 0.0127 
NOTCH1 UMSCC25 9:139411816 0.1854 0.0534 
NOTCH1 UMSCC11A 9:139405111 0.3448 0.2049 
NOTCH1 UMSCC76 9:139417398 stopgain 0.1222 
NOTCH1 UMSCC76 9:139409082 0.061 0.0827 
NOTCH2 UMSCC76 1:120484306 0.5182 0.6263 
NOTCH2 UMSCC25 1:120491153 0.2608 0.2178 
NOTCH2 UMSCC25, 
28,76,23,46,81B 
1:120572572 0.0064 0.8694 




NOTCH3 UM11A 19:15299051 0.157 0.3026 
NOTCH3 UM81B 19:15299051 0.157 0.3026 
NOTCH3 UM25 19:15302584 stopgain 0.0245 
NOTCH3 UM105 19:15289850 0.2398 0.4617 
FAT4 UM10A 4:126337669 0.267 0.0908 
FAT4 UM23 4:126355547 0.088 0.0054 






Table 2-7. Supplemental Table 4. CHASM and VEST p-values for BRCA, NOTCH, and FAT family 
mutations.  
The Cancer-Related Analysis of Variants Toolkit (CRAVAT; http://www.cravat.us) was used to predict 
pathogenicity via the VEST-4 and CHASM-3.1 tools.  Missense mutations were scored with both VEST and 
CHASM; Indels were scored with VEST only.  A p-value was generated for each score and a cutoff of p<0.05 was 






FAT4 UM25 4:126370896 0.094 0.0025 
FAT4 UM28 4:126372555 0.2948 0.6406 
FAT4 UM17B 4:126412106 0.1928 0.1877 
FAT4 UM28 4:126319964 0.0152 0.0035 
FAT4 UM41 4:126241248 0.2948 0.0229 
FAT3 UM11A 11:92086828 0.014 0.0091 
FAT3 UM17B 11:92533622 0.102 0.0136 
FAT3 UM76 11:92533495 0.291 0.1849 
FAT2 UM76 5:150924968 0.0884 0.0201 
FAT2 UM46 5:150942985 0.6368 0.1877 
FAT2 UM10A,B 5:150943061 0.1382 0.0147 
FAT2 UM12 5:150945830 0.6464 0.9886 
FAT1 UM25 187629411 frameshift 0.0954 
FAT1 UM41 187518255 0.0582 0.0025 
FAT1 UM28 187541379 stopgain 0.0225 
FAT1 UM25 187630099 0.2398 0.0417 
FAT1 UM76 187630240 0.1536 0.0298 
FAT1 UM81B 187540040 0.8576 0.2982 


















Figure 2-7Genetic characterization of laryngeal UM‐SCC cell lines by copy number 
analysis.  
 
Genomic DNA was harvested from low passage UM‐SCC cell lines and analyzed using high‐
density SNP arrays (Affymetrix OncoScan Assay) and compared to a commercially available 
pooled control. Affymetrix software was used to call copy number alterations. A, Copy number 
alterations were summed across UM‐SCC‐10A, 10B, 12, 17B, 23, 25, 28, 46, 57, 76, 81A, 81B, 
and 105. Alterations for individual cell lines are shown below with gains indicated in blue and 
losses indicated in red. B, Heat maps displaying median copy numbers (upper panel) and RNA 
expression (lower panel) for selected genes. Key functions and relevant chromosomal regions are 
noted below each column. C, Focal deletions (arrow) at the CDKN2A‐CDKN2B (9p21) locus 
occurring in UM‐SCC 12, 23, 57, and 17B. The CDKN2A gene is indicated by a bracket in the 
row labeled “Genes.” *, CDKN2A;**, CDKN2B. D, Focal deletions (arrow) at the FAT1 locus 
(4q35) occurring in UM‐SCC‐10B and 12. The FAT1 locus is indicated by a bracket and an 







Figure 2-8. Primer sequences and chromatograms for point mutations validated by sanger 
sequencing in the FAT1 gene.   
Cell line and mutation (identified via exome sequencing) are shown in left column. Forward (F) 
and Reverse (R) sequences are shown for each product.  Sections of the chromatogram are 
shown for each PCR product with the product sequence aligned with wild-type FAT1.  Altered 












Figure 2-9. Genetic characterization of laryngeal UM‐SCC cell lines by copy number analysis 
 Genomic DNA was harvested from low passage UM-SCC cell lines and analyzed using high-density SNP arrays (Affymetrix 





alterations. A, Copy number alterations were summed across UM-SCC-10A, 10B, 12, 17B, 23, 25, 28, 46, 57, 76, 81A, 81B, and 105. 
Alterations for individual cell lines are shown below with gains indicated in blue and losses indicated in red. B, Heat maps displaying 
median copy numbers (upper panel) and RNA expression (lower panel) for selected genes. Key functions and relevant chromosomal 
regions are noted below each column. C, Focal deletions (arrow) at the CDKN2A-CDKN2B (9p21) locus occurring in UM-SCC 12, 
23, 57, and 17B. The CDKN2A gene is indicated by a bracket in the row labeled “Genes.” *, CDKN2A;**, CDKN2B. D, Focal 
deletions (arrow) at the FAT1 locus (4q35) occurring in UM-SCC-10B and 12. The FAT1 locus is indicated by a bracket and an 







Figure 2-10.  Relationship between median copy number (x-axis) and RNA expression (y-








Figure 2-11 Summary of aberrations in FAT‐related genes in TCGA tumors and laryngeal 
UM‐SCC cell lines.  
Summary of aberrations in FAT‐related genes in TCGA tumors and laryngeal UM‐SCC cell 
lines. A, Alterations reported in TCGA provisional dataset 
(cbioportal.org; http://cancergenome.nih.gov) for FAT1‐4. Total numbers observed for each 
category of mutation or copy number variation are displayed. For each gene, the percentage of 
510 tumors in the total HNSCC dataset with an alteration is reported to the left in blue (T). The 
percentage of the 110 laryngeal primary tumors in this dataset harboring an alteration in each 
gene is reported in red (L). The percentage of all HNSCC (blue) and LSCC (red) tumors 
harboring one or more mutations in any FAT gene are reported to the far left.27 B, Alterations 
identified in the laryngeal UM‐SCC cell line panel for FAT1‐4. This analysis considers available 
data for all 16 cell lines in this study, although exome sequencing was not performed for UM‐
SCC‐57 or 81A, and copy number data are not available for UM‐SCC‐11A, 13, 41, or 76. C, 
Schematic diagram describing proposed signaling interactions involving the FAT1 protein. 
Percentages of HNSCC tumors bearing alterations (amplifications, deletions, and mutations) in 
each gene are displayed below the gene name for LSCC only27 and the overall cohort (black). D, 
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Chapter 3 Functional Profiling of 17,000 Open Reading Frames for Identification of 




Head and Neck Squamous Cell Carcinoma (HNSCC) is the sixth most common cancer globally 
and is often rapidly lethal, especially in the recurrent and metastatic setting. Recently, inhibition 
of the PD1:PDL1 immune checkpoint has been modestly successful in advanced disease, but the 
proportion of patients that benefit from these strategies remains limited. We therefore sought a 
more comprehensive understanding of the signals modulating the PD1: PDL1 checkpoint in 
HNSCC in order to gain insight into factors that may impact response to therapy.  Here, we used 
a genome-wide open reading frame (ORF) library of 17,000 transcript constructs corresponding 
to 14,000 unique genes, to screen for ORFs capable of driving high cell surface PDL1 
expression. We identify 335 ORFs that were enriched following sorting for PDL1-high 
expressing cells and validated five of these ORFs, including FGF6, IL17A, CD300C, KLR1C and 
NFKBIA. Further, we show that FGF ligand is sufficient to induce PDL1 expression as well as 
glycosylation, even in the absence of induction by interferon gamma. Small molecule inhibition 
of FGFR signaling also blocked interferon-regulated PDL1 expression through a STAT1 







HNSCC is an extremely aggressive disease with poor overall survival that has remained 
unchanged for several decades [1-4]. The disease is molecularly characterized by overexpression 
of several receptor tyrosine kinases, human papilloma virus (HPV) status, and a complex array of 
genomic alterations that comprise a high mutational burden relative to many other cancers [5, 6]. 
Importantly, in the recurrent and metastatic (R/M) setting, HNSCC patients have exceptionally 
poor quality of life and extremely short survival outcomes, and novel treatment strategies that 
improve outcomes are desperately needed. Recently, the PD1:PDL1 immune checkpoint 
inhibitors pembrolizumab and nivolumab have gained FDA approval for use in the R/M HNSCC 
setting with response rates of 13-18% [7-10].   
Despite this advance, and the broad popularity of PD1 blockade across many cancer 
types, the complex molecular mechanisms that regulate PDL1 expression on tumor cells are only 
beginning to be understood. While interferon gamma (IFNγ), which may be released by T-
lymphocytes, has long been known to induce cell surface expression of PDL1, other often cell-
intrinsic signals have more recently been shown to induce PDL1 expression independently of 
IFNγ. For example, treatment of HNSCC cell lines with EGF induced PDL1 expression in a 
JAK2/STAT1 dependent manner, indicating that activation of EGFR, often overexpressed in 
HNSCC, may serve as an IFNγ- independent mechanism for PDL1 upregulation[11]. 
Furthermore, the EGFR effector STAT3 has been shown to be a potent driver of PDL1 
expression in genetically engineered HNSCC mouse models [12]. However, the relationship 
between EGFR expression and PDL1 expression is unclear, as various reports have produced 
conflicting results with regard to this question [13].  Thus, it is likely that multiple different 





Recently, whole-genome screening techniques, such as pooled CRISPR-Cas9 screens, 
have been adapted for a variety of applications to identify mediators of particular phenotypes 
[14].  These strategies often entail lentiviral delivery of pooled shRNA or RNA guided Cas9 
libraries to induce genome-wide disruption of gene expression. The cell population is then 
monitored for dropout of particular constructs, indicating the essentiality of their targets for cell 
viability.  Here, we have modified this scheme to utilize a genome-scale open reading frame 
(ORF) library for overexpression of 17,000 genes in a pooled format, from which we can select 
individual cells in which PDL1 expression has been induced. Through this novel high throughput 
profiling approach, we sought to identify novel regulators of PDL1 expression such that we may 
begin to understand heretofore undiscovered mechanisms that regulate cell surface expression of 
PDL1 in HNSCC.  We hypothesize that inhibition of PDL1 drivers may serve as an effective 
strategy to enhance the effects of immune checkpoint therapy for a subset of HNSCC patients.  
  
Materials and Methods 
Cell Lines and Reagents. All UM-SCC cell lines were derived and characterized in the Head and 
Neck Oncology laboratory at the University of Michigan after consent of the patient donors [15].  
The oral cavity and larynx cell lines studied in this report were selected from models with 
comprehensive integrated SNP array, exome sequencing, and transcriptome sequencing data 
recently completed by our team [16].  All cell lines were grown in exponential growth g in 
DMEM containing 10% FBS, 7µg/mL penicillin/streptomycin and 1% Non-essential amino 
acids in a 5% CO2 incubator. All cell lines were genotyped throughout the study to ensure 





 Small molecule inhibitors were purchased from Selleck Chemicals and maintained in 
DMSO at -80C for a period of no more than 1 year. Interferon gamma (IFN-γ) was purchased 
from R&D and stored in PBS at -20C for no more than 2 months. FGF ligands were purchased 
from Thermo Fisher Scientific and stored in PBS containing 0.5% bovine serum albumin and 
stored at -20C for no more than 2 months. 
ORF Library transduction. The genome-wide ORF library was purchased from Sigma Aldrich as 
transduction-ready pool. We first determined the appropriate multiplicity-of-infection [17] by 
transduction of UM-SCC-49 cells, puromycin selection and cell count assays. Using an MOI of 
0.3-0.5, we then transduced the cell line, selected puromycin resistant clones and expanded the 
population.  UM-SCC-49-ORF library cells were maintained and treated in groups of no less 
than 6 million. After selection, small subsets were cloned out from control and treated 
populations to ensure enrichment of PDL1 expression in individual clones 
Flow Cytometry. Cells were stained for analysis by flow cytometry using the anti-PDL1 antibody 
#14-5983-82 against PDL1 or isotype control #14-4714-82 purchased from Thermo Fisher 
Scientific.  Antibodies were diluted to 0.5ug/mL in PBS containing 1% FBS with 1 million cells 
per mL.  Analysis and sorting were performed at the University of Michigan Flow Cytometry 
Core.  For UM-SCC-49 ORF library selection, cells were sorted on a Moflo Astrios cell sorter to 
select the top 2.0% of PDL1 expressing cells, expanded in culture, and sorted again to collect the 
top 11%.  
Library preparation.  Genomic DNA was harvested from control and sorted populations using 
the Gentra Puregene kit according to manufacturer’s instructions.  PCR amplification was 
performed for each of four primer sets in each sample.  These were pooled and a second round of 






ORF Barcode Quantification. Adapter contamination in the samples was removed using 
Trim_galore (v 0.4.4).  For mapping the reads to the ORF reference library, seqmap(v 1.0.13) 
was used. Since seqmap requires FASTA files as input, all the read FASTQ files were converted 
to FASTA by extracting only the sequence information from the FASTQ files. All the FASTA 
files were also mapped to the reverse complements of the barcodes in the ORF library. The 
barcode counts obtained by mapping the reads to the ORF library were normalized based on the 
total read counts for a sample and the log2 fold change was calculated between the conditions to 
be compared.  Using the log-rank list of genes, we then uploaded the gene set into GSEA (MIT, 
Broad) to identify significant overlap with Hallmark, KEGG and GO biological process 
pathways with false discovery rate (FDR) q-value < 0.05 considered significant. 
Expression of ORF constructs. We purchased cDNA clones for CD300C, KLRC1, FGF6, IL17A, 
and NFKBIA from Geneocopeia, which did not produce usable lentivirus. Therefore, we cloned 
the genes into the PCR8 vector, confirmed the correct orientation and sequence by Sanger 
sequencing, and transferred the expression cassettes to pLenti6.0 using Clonase according to 
manufacturer protocol. Sanger sequencing was again used to confirm the orientation and 
sequence of the inserts, all of which were cloned without a stop codon such that the ORF of each 
construct would contain a c-terminal V5 epitope tag.  Lentivirus made from each of these 
constructs was then used to transduce UM-SCC-49 cells and blasticidin selection was used to 
create stable populations. 
Western Blots. Western blot analysis was performed as described [18]. Briefly, UM-SCC cell 
lines in log-phase growth were treated as indicated, rinsed twice with PBS, and then lysed in 





Glycerol, 1% NP40, 0.1% Triton X-100, 1 mM PIPES, 1 mM MgCl, 50 mM Tris; inhibitors: 
Thermo 186129, 1861277) as previously described [19].   
TCGA transcriptome analysis. Log2(RSEM+1) values from TCGA Head and Neck Cancer 
cohort (n=566) were retrieved from the UCSC cancer genomics browser (xenabrowser.net).  
Correlations were calculated using Pearson r test, and linear regressions and box and whisker 
plots were generated using GraphPad Prism 8 software. 
HNSCC cell line transcriptome analysis. RNA sequencing was performed for 43 HNSCC cell 
lines using Illumina stranded transcriptome library kits as described in (Mann et al.)  Heatmaps 
were generated using MeV software version 4.9 based on log2(FPKM+1) values. 
Quantitative PCR. For qPCR analysis, cells were lysed in QIAzol and RNA was isolated using 
the QIAgen RNeasy Mini Kit (Qiagen, Hilden, Germany) according to manufacturer’s protocol. 
cDNA synthesis was performend using the Superscript™  VILO kit (Thermo Fisher Scientific, 
Waltham, MA, USA).  RT-qPCR was then performed using the Quantitect SYBR Green RT-
qPCR kit (QIAgen) and run using a QuantStudio™ 5 System (Applied Biosystems, Foster, CA, 
US).  Primer sequences are listed in Table 3-2. 
Results.  
 To begin our study, we first analyzed a panel of 6 UM-SCC cell lines to determine the 
relative level of total PDL1 induction driven by interferon gamma (IFNγ) by western blot 
analysis (Figure 3-1A). ImageJ intensity analysis of the bands demonstrated an average PDL1 
induction of 6-fold across the 6 cell lines, with UM-92 exhibiting the smallest induction of PDL1 
expression (2-fold) and UM-SCC-49 and 59 exhibiting the greatest (approximately 14-fold). For 
our screen, we chose to use the UM-SCC-49 cell line due to its ability to upregulate PDL1. 





which IFNγ drives increased PDL1 transcription and expression [11]. Thus, we confirmed that 
IFNγ induces STAT1 phosphorylation on tyrosine 701, indicative of activation (Figure 3-1B). 
Similarly, inhibition of JAK2 activity with TG101348 blocked both IFNγ-mediated STAT1 
phosphorylation and PDL1 expression in the UM-SCC-49, 92, and 14a models, supporting that 
the canonical IFNγ-regulated pathway is active in these models.  
 We next confirmed IFNγ-inducible cell surface expression of PDL1 in UM-SCC-49 cells 
by flow cytometry (Figure 3-2A).  As depicted in Figure 3-2B, we then created stable pools of 
UM-SCC-49 cells transduced with the 17,000 different open reading frame (ORF) constructs, in 
which each ORF contained an in-frame C-terminal V5 epitope tag, by lentiviral transduction and 
puromycin selection. Sorting of the population for the 2% of cells with highest PDL1 expression 
by flow cytometry was followed by expansion in culture.  A subsequent sort for the highest 11% 
was used to further enrich the population for ORFs that drove increased cell surface expression 
of PDL1 (PDL1high) (Figure 3-2C). To confirm that the approach was successful, we expanded 2 
clones from the unsorted population and 7 clones from the serially sorted population. 
Comparison of total and cell surface PDL1 expression between the clones and unsorted pooled 
ORF cells demonstrated a substantial increase in total PDL1 expression in all serially sorted 
clones relative to unsorted pools and clones, confirming that the overall strategy of enriching for 
this phenotype was successful (Figure 3-2D,E). Sanger sequencing of these clones revealed the 
ORF constructs listed in Table 3-3.  We then isolated DNA and created Illumina MiSEQ 
compatible libraries from the unsorted ORF pool and PDL1high population and sequenced 
libraries to a depth of >1.5 million reads per library. Mapping barcodes to the reference 





been shown to regulate PDL1 expression in a murine model of breast cancer [20], supporting that 
our overall strategy was successful.  
 Detailed analysis of the results using gene family annotation of the overrepresented genes 
demonstrated a large increase in cytokines, transcription factors, and kinases in the gene set 
(Table 3-5), suggesting that the enrichment process may have identified ORFs that regulate 
PDL1 expression on multiple levels from transcription to autocrine stimulation.  We next 
performed gene set enrichment analysis on the rank list to identify potential over-represented 
pathways. This demonstrated a strongly significant 34 gene overlap with genes in the GO 
pathway: regulation of immune response (FDR q = 1.55 x 10^-7) demonstrating that the ORFs 
driving increased PDL1 expression in our model were also strongly associated with immune 
response in previously defined gene sets. Similarly, we observed enrichments within gene sets 
associated with “response to external stimulus,” “regulation of response to stress,” and “TNF 
alpha signaling driven by NFκB” (Table 3-6). Collectively, the gene set enrichment analysis 
supported the role of ORFs identified in our screen in the regulation of immune response 
pathways and also suggested that the ORFs drive PDL1 expression through mechanistically 
diverse pathways, some of which may be NFκB-dependent.  
 
Validation of candidate PDL1 drivers. From the top overall hits, we selected a diverse set of 
ORFs for subsequent validation experiments.  We opted to validate IL17A because it had 
recently been shown to modulate PDL1 expression in murine breast and lung tumors, but has not 
been studied in the context of HNSCC [20, 21].  We also interrogated TCGA HNSCC RNAseq 
data to examine expression of genes of interest nominated by the screen in relation to PDL1 





positively correlated with PDL1, including CD300C (Pearson r =0.41, p<0.0001) and KLRC1 
(Pearson r=0.44, p<0.0001).  CD300LB, an uncharacterized gene related to CD300C, also 
weakly correlated with PDL1 expression in TCGA (Pearson r = 0.22, p<0.0001), and was 
enriched in the PDL1-sorted pool to a similar degree to CD300C, but we chose to first focus our 
analysis on CD300C due to its stronger correlation in TCGA.  We also proceeded with validation 
of two additional genes of interest that did not correlate with PDL1 RNA expression in the 
TCGA dataset: NFKBIA and FGF6, although, notably, FGF6 was undetected in the majority of 
the TCGA specimens.  We were intrigued by the finding of FGF6 in our dataset due to the 
known tumorigenic role for FGFR signaling in HNSCC and other cancers [22], and because 
EGFR, which acts through similar downstream mechanisms to FGFRs, was previously shown to 
regulate PDL1 in HNSCC [11].  We were surprised that our screen identified NFKBIA as a 
potential driver of PDL1 expression, as this gene is known to inhibit NFκB activity by blocking 
translocation of p65 to the nucleus, and NFκB is a known transcriptional driver of PDL1. Thus, 
we hypothesized that this gene might represent a false positive result of our screen.  
 The ORFs of interest were each cloned into a lentiviral vector with a c-terminal V5 
epitope tag and expressed in wild type UM-SCC-49 cells following lentiviral transduction. 
Western blot confirmed overexpression of the V5-tagged construct in each case (Figure 3-3B) 
and flow cytometry confirmed that each gene drove an increase in median fluorescence intensity 
of PDL1 cell surface expression in each case, which validated these genes as PDL1 drivers 
(Figure 3-3C). To then determine the effect of these constructs on total PDL1 expression, we 
cultured cells with or without IFNγ and characterized the changes to total PDL1 expression by 
Western blot (Figure 3-3D).  All ORF constructs led to increases in IFNγ-regulated total PDL1 





mechanisms through which each gene regulates PDL1 expression. For example, some of these 
genes may modulate cell surface presentation of PDL1, while others modulate total PDL1 
protein expression.  
 Given that JAK2/STAT1 signaling is implicated in mediating PDL1 induction in similar 
HNSCC models [11], we then assessed the expression and phosphorylation status of STAT1 in 
each of the UM-SCC-49-ORF-V5 cell lines.  As shown in Figure 3-3E, STAT1 phosphorylation 
on Y701 in UM-SCC-49-FGF6-V5 is comparable to that in UM-SCC-49-LacZ-V5 in both 
untreated and IFNγ treated conditions.  Further, JAK2 inhibition using TG101348, a selective 
ATP-competitive inhibitor [23], blocked IFNγ-induced PDL1 expression in both cell lines, and 
reduced baseline PDL1 levels of UM-SCC-49-FGF6-V5, indicating that the JAK2/STAT1 
pathway may modulate FGF6-V5-induced PDL1 expression as well.   
 
Analysis of FGF/FGFR signaling in UM-SCC cell lines.  Given the immediate potential to 
advance FGFR inhibitors clinically, especially with genetic role of FGFR1 and FGFR3 in 
HNSCC pathogenesis [24], we next focused our study on the relationship of FGF/FGFR activity 
with PDL1 expression in HNSCC models.  RNAseq analysis of 40 HNSCC cell lines revealed 
high expression of FGFR2, FGFR3, and FGF11 across nearly all cell lines, with many also 
exhibiting high levels of FGF2, FGFR1, and FGFR4 (Figure 3-4A). UM-SCC-17B showed 
remarkably high expression of nearly all FGF ligands and receptors, with two interesting 
exceptions: UM-SCC17B had the lowest FGF11 expression of all cell lines assessed, and also 
did not have detectable FGFR1 reads.  Notably, FGF6 was not highly expressed in any of the 40 
cell lines; and, to ensure that we studied clinically relevant secreted ligands of the FGF/FGFR 





the expression of FGF ligands and receptors in the RNAseq HNSCC cell line data set was similar 
to the expression pattern observed in the TCGA HNSCC RNAseq data (Figure 3-4B). This 
analysis demonstrated that FGF receptors FGFR1, FGFR2, and FGFR3 were highly expressed in 
HNSCC tumors, which is consistent with previous data [25], and that the FGF ligands FGF2 and 
FGF11 were the most highly expressed FGF family genes in both the HNSCC cell lines and the 
TCGA cohort.  However, while FGF11 is not known to be secreted or interact with any FGFRs 
[26], FGF2 has been reported to promote growth, angiogenesis, survival, motility, and cell 
proliferation in numerous in vitro and in vivo models of HNSCC and other cancers [27, 28].   We 
next asked whether expression of any FGF ligands or receptors correlated with PDL1 expression, 
but found no positive correlations and surprisingly, weak negative correlations for FGFR1 and 2 
(Figure 3-4C).  Thus, it was important to understand the role of activated FGF receptors in our 
models.  Due to its stability in cell culture media and frequent expression in HNSCC tumors and 
cell lines, we focused our subsequent analysis on FGF2.  We treated UM-SCC cells with 
recombinant FGF2 (rFGF2) to assess its effect on PDL1 expression, and to understand whether a 
role for FGFRs in regulating PDL1 could be recapitulated across multiple models.  In UM-SCC-
92 and UM-SCC-14A, rFGF2 induces total PDL1 expression, even in the absence of IFNγ 
stimulation, further supporting the ability of FGF/FGFR signaling to promote PDL1 expression 
in HNSCC (Figure 3-4D).  
 
Modulation of FGFR alters PDL1 expression.  To assess the role of FGFR signaling in UM-
SCC-49-FGF6-V5 cells, we pretreated UM-SCC-49-FGF6-V5 or UM-SCC-49-LacZ-V5 with 
either BGJ398, an inhibitor of FGFR1, 2, and 3 [29], or PD173074, a specific inhibitor of 





(Figure 3-5A).  BGJ398 reduced both baseline and IFNγ-induced expression in both UM-SCC-
49-FGF6-V5 or UM-SCC-49-LacZ-V5.  Likewise, PD173074, also reduced PDL1 expression, 
but had a greater impact on IFNγ-induced total PDL1 protein expression in UM-SCC-49-FGF6-
V5 than UM-SCC-49-LacZ-V5 cells (Figure 3-5B).  The ability of FGFR inhibitors to modulate 
IFNγ induced PDL1 expression was also recapitulated in certain other cell lines, including UM-
SCC-14a (Figure 3-5C).  These data suggested that baseline FGF/FGFR signaling through 
FGFR1 plays an important role in modulating IFNγ-induced total PDL1 protein expression, and 
that situations with accentuated FGF ligand in the microenvironment may further potentiate the 
effects of IFNγ on tumor cells.   
To then better understand the interplay between the FGFR and IFNγ signaling pathways, 
we tested RNA expression of various downstream targets of FGFR and IFNGR activation by 
qPCR in UM-SCC-49 and -14a. At this time point, both IFNγ and rFGF2 induce an increase in 
PDL1 RNA (2-fold and 1.3-fold, respectively). We observed that RNA expression of genes 
regulated by IFNγ in other model systems, such as STAT1, IRF9, SOCS1, and SOCS3 [31], were 
indeed induced 2-4-fold by IFNγ treatment, but not by rFGF2 (Figure 3-5D,E). Instead, rFGF2 
appears to induce a separate transcriptional program that included 1-3-fold upregulation of 
CXCL8 and SPRY.  Jak2 inhibition by TG101348 reduces RNA expression of both the IFNγ- and 
rFGF2-regulated gene sets, while BGJ398 reduced RNA expression of only the rFGF2-regulated 
gene set.  PDL1 RNA expression, however, is induced 2-fold by IFNγ and this induction is 
diminished in cells pre-treated with BGJ398, consistent with protein-level data above.  Also of 
interest, despite the known ability of FGF signaling to activate the Jak/Stat pathway, only IFNγ, 





Finally, because glycosylation of PDL1 is known to prevent its degradation in other 
model systems [32], we asked whether the rFGF2-induced increase in PDL1 may be due to 
glycosylation, and therefore stabilization, of the protein.  When we treated UM-SCC-14a with 
tunicamycin, an inhibitor of N-linked glycosylation [33], we observed a dramatic decrease in the 
ability of rFGF2 to drive PDL1 expression, and an accumulation of 33kD PDL1, which 
represents the non-glycosylated form (Figure 3-5F) [32].  Two recent studies in breast cancer 
cells describe a dual role for EGFR in stabilizing PDL1 protein. EGFR activity and can induce 
upregulation of B3GNT3, an enzyme that catalyzes PDL1 glycosylation, and may promote 
inactivation of GSK3β, a kinase responsible for targeting PDL1 for E3 ligase mediated 
degradation [32, 34]. We therefore speculated that FGFR signaling may act through analogous 
mechanisms to stabilize PDL1.  To understand whether the EGFR-induced mechanisms 
described in breast cancer cells might also be at play in our system, we assessed expression of 
several glycosyltransferases reported to be upregulated by EGFR to determine whether FGFR 
signaling could regulate a similar program in HNSCC.  While we noted very modest increases in 
some of the N-acetylglucosaminyltransferase family genes that we tested, including B3GNT3, 
MGAT5, and GNPTAB following IFNγ or rFGF2 stimulation relative to a vehicle control, it was 
unclear from these data (n=2) whether FGFR inhibition could modulate this effect due to high 
error among technical and biological replicates (Figure 3-5G). 
 We next monitored PDL1 expression and inhibitory phosphorylation of GSK3β on 
serine 9 following either stimulation with EGF or pharmacological inhibition of EGFR with 
gefitinib.  Interestingly, we were able to recapitulate the effects reported by Li et al [32], 
demonstrating that EGF indeed increased PDL1 protein levels and that gefitinib treatment led to 





nor stimulation with rFGF2 affected GSK3β phosphorylation, suggesting a different mechanism 
may mediate the effects of FGFR signaling on PDL1 expression.    
 
Discussion 
HNSCC is a strongly immunosuppressive disease for a majority of patients, and 
understanding the molecular mechanisms that guide immune escape are critical to developing 
therapeutic strategies that create a more favorable tumor niche. Here, we are the first to perform 
a genome-wide ORF screen as an approach to identify novel PDL1 regulatory mechanisms. 
Importantly, our data identified several genes previously known to regulate adaptive PDL1 
expression in other models, including IL17A, which supported the accuracy of the overall 
discovery approach. For example, inhibition of IL17A in ER-negative breast cancer models has 
been shown to inhibit PDL1 expression [20]. HNSCC has previously been associated with high 
TIL infiltrates [35-37], and specifically serval reports have documented significant increases in 
TH17-cells, which express high levels of IL17A, in both pre-malignant oral lesions [38] and 
HNSCC tumor microenvironment [39, 40], supporting a critical role for IL17A-mediated PDL1 
expression in these settings.  
Similar to the known regulators, our experiment also identified several novel genes 
closely linked to pathways known to regulate adaptive PDL1 expression in other cancer settings 
including the NFKB pathway (NFKBIA) and FGF/FGFR signaling pathways (FGF6). In fact, 
while NFKB signaling is one of the most well recognized regulators of adaptive PDL1 
expression discovered thus far [41-46], NFKBIA has not previously been linked with the 
regulation of PDL1. In the HNSCC TCGA project, NFKBIA is amplified in 8/517 (1.5%) cases, 





alterations in HPV+ squamous cell carcinomas with 12/149 (8%) harboring either mutations or 
CNV alterations to the gene [47]. Hence, given our validation of NFKBIA as a driver of IFNγ-
induced PDL1 expression in HNSCC models, the overall data supports a pivotal role for this 
gene in modulation of immune reactivity in HPV+ HNSCC.  
Further, we and others have also previously identified FGFR signaling as a driver 
pathway of some HNSCCs [24, 48-51], and FGFR1 protein has been observed to be 
overexpressed in >80% of HPV+ HNSCCs and 75% of HPV- HNSCCs [51] suggesting an 
important role for the pathway in a large subset of the disease. Similarly, FGFR signaling has 
been shown to be upregulated in HNSCC cancer stem cell (CSC) populations in response to 
platinum-based therapy in vitro [52]. When considering our data showing the strong regulation 
of PDL1 expression by activated FGF/FGFR signaling, the data support the hypothesis that 
cisplatin-mediated adaptive FGFR1 expression may activate the PDL1 checkpoint in the CSC 
population in some tumors, thereby preventing immune-mediated killing of the CSC population. 
Indeed, while we show a strong dependence of PDL1 expression on FGF/FGFR signaling in 
some cell line models, and the CSC data suggest that other common HNSCC therapies such as 
platinum-based regimens, may also induce FGF/FGFR-dependent activation of the PDL1 
immune checkpoint. As such, our finding may have implications for a larger subset of HNSCC 
patients. To understand the link between FGFR and PDL1, a more comprehensive study of these 
pathways will be necessary.  Proteomic and transcriptomic analysis following FGF/FGFR 
modulation, and comparison of these data to IFNγ stimulation, will be valuable, especially in 
clarifying a potential node of crosstalk between IFNγ and FGFR signaling cascades.  Further, it 
will be of interest to examine the posttranslational modification status and stability of PDL1 





Overall, the approach discovered 335 enriched genes that potentially drive PDL1 
expression in HNSCC, of which we validated a few genes as novel drivers including two which 
are genetically linked to subsets of HNSCC patients. The data support the use of ORF profiling 
as discovery technique to complement the previously published functional approach of CRISPR 
profiling that also successfully discovered novel PDL1 regulators. Indeed, we are in an exciting 
time when multiple complementary discovery approaches can be used to help understand to 
combat the immunosuppressive tumor microenvironment of HNSCC and other tumors and 
hopefully develop rational combination approaches to improve survival outcomes.  
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Figure 3-1. Characterization of UM-SCC HNSCC cell line models.  
A) Cell lines were treated with 10ng/mL IFNg for 72 hours and total PDL1 expression was 
assessed by immunoblot (upper).  Densitometry analysis was performed in ImageJ with PDL1 
bands normalized to corresponding beta actin bands.  Relative expression was then calculated by 
dividing IFNγ treatment by untreated (lower).  B) PDL1 and STAT1 were assessed by 








Figure 3-2. Discovery of ORFs that drive PDL1 cell surface presentation in HNSCC.  
A) Cell surface expression of PDL1 in UM-SCC-49.  UM-SCC-49 cells were treated -
/+10ng/mL IFNg for 72h, trypsinized, and stained for cell surface expression of PDL1.  B) 
Schematic of overall project workflow. UM-SCC-49 cells were transduced with the 17,000 gene 
ORF library at an MOI of 0.3 and selected with puromycin. Cells were then serially sorted for 
the top 2% of PDL1 expressing cells in the population. PCR amplified barcodes from the 
genomic DNA of PDL1 enriched or control populations was then sequenced on an Illumina 
MiSEQ for quantification. C) Sorting UM-SCC-49 ORF library for high PDL1 expressing cells.  
The UM-SCC-ORF library cells were stained for cell surface expression of PDL1 and the 2% of 
cells with highest PE positivity were selected and expanded in culture (top).  The select 
population was then subjected to staining and sorting again, this time with the top 11% collected 
for sequencing (bottom right). The initial ORF pool was also analyzed for PDL1 expression for 
comparison (bottom left).  D) Clones from the PDL1 enriched population were expanded and 
used to confirm high total PDL1 expression in each clone by Western blot.  E) A subset of the 
clones from (E) were immunostained for PDL1 and analyzed by flow cytometry.  Dashed line 












Figure 3-3. Validation of FGF6, IL17A, CD300C, KLR1C and NFKBIA as drivers of PDL1 
expression in HNSCC.  
 
A) Linear regression analysis reveals correlations with PDL1 expression in TCGA HNSCC 
RNAseq data.  B) Lentiviral ORF-V5 tagged expression vectors were cloned and used to 
overexpress each of five candidate genes and one control (LacZ) in UM-SCC-49 cells. 
Expression of V5 tag was confirmed in each cell line by anti-V5 immunoblot.  Expected 
molecular weights of protein products are as follows: LacZ. 121kD; KLRC1, 31kD; CD300C, 
29kD; IL17A, 22kD; NFKBIA, 40kD; FGF6, 28kD. C) Quantitative PCR was used to assess 
mRNA expression for target ORFs in each cell line as well as PDL1 transcript levels.  D) Flow 
cytometry was used to determine changes to cell surface presentation of PDL1. Median 
fluorescence intensity was quantified from each histogram. E) Changes to total PDL1 and 
phosphorylated STAT1 were analyzed by western blot in each 49-ORF cell line. E) 49-LacZ and 
49-FGF6 were pretreated with DMSO or JAK1/2 inhibitor TG101348 (2uM) for 6h, followed by 
addition of IFNγ (10ng/mL) as indicated.  Cells were harvested 72h after IFNγ treatment.  PDL1 











Figure 3-4. The FGF/FGFR pathway in HNSCC.  
 A) Log2(FPKM+1) for FGF and FGFR family genes in 40 HNSCC cell lines.   B) 
Log2(RSEM+1) for FGF and FGFR family genes in the TCGA Head and Neck PanCancer Atlas 
dataset accessed via cbioportal.org.   C) Protein isolate from UM-SCC- cell lines in log-phase 
growth was immunoblotted using an antibody directed against FGF2.  D) UM-SCC-14a and 
UM-SCC-92 were treated -/+ 30ng/mL FGF2 or 10ng/mL IFNγ for 72h.  PDL1 expression was 











Figure 3-5.  Effects of FGFR modulation.  
UM-SCC-49-LacZ-V5 and -FG6-V5 were pretreated with DMSO or 3uM BGJ398 (A) or 3uM 
PD173074 (B) for 6h, then 10ng/mL IFNg was added to the cell culture media.  Protein 
expression was assessed after 72h by immunoblot.  C) UM-SCC-14a-WT cells were pretreated 
with 3uM BGJ398 or PD173074 for 6h, then stimulated with IFNg for 72h prior to 
immunoblotting.  D,E) UM-SCC-14a cells were pretreated with DMSO, Fedratinib or BGJ398 
for 3h as indicated, then 10ng/mL IFNg or 30 ng/mL FGF2 was added for an additional 3h.  F) 
UM-SCC-14a cells were pretreated overnight with 50ng/mL tunicamycin or DMSO control for 
6h, then 10ng/mL, 30ng/mL IFNg or rFGF2 was added as indicated.  PDL1 expression was 
assessed by immunoblot.  Arrow points to 33kD band.  G) UM-SCC-14a cells were treated for 
3h with 3uM BGJ398, then IFNg or FGF2 was added.  RNA expression of candidate 
glycosyltransferases was assessed.  H) Cells were pretreated with inhibitors as indicated at 3uM 







































































 AmpFW_  5’-TCGTCGGCAGCGTCAGATGTGTATAAGAGACAGGCTTTATATATC-3’ 









Gene Forward Reverse 
TLR2 AGCAGGATCCAAAGGAGACC ACCAAGGTGGTTTGCTGAGT 
GAPDH AATGGGCAGCCGTTAGGAAA GCCCAATACGACCAAATCAGA 
PDL1 AGTCAATGCCCCATACAACAA CGTCACTGCTTGTCCAGATGA 
MYD88 GACTGCTCGAGCTGCTTACC ACATTCCTTGCTCTGCAGGT 
IRF7 GCCTGGCCACCATAAAAGCG TGTTGAACCAGTGTCCAGGC 
STAT1 AAAATGCTGGCACCAGAACG AGAGGTCGTCTCGAGGTCAA 
B3GNT3 GCAACGCCTGTCCTCCTTTG AAGGTGTCGCCCCTTCCTAT 
GNPTAB CCAGTTCGGAGAGGTGGTTC ATCTGTGCCATTCACCCAGG 
MGAT5 CATGGTATCCTCAGTGGACGG TGGGATGTCAGCTCTCTCAG 









Table 3-3. Open reading frames identified by Sanger sequencing in cell lines derived from 
sorted ORF pool. 
 
 
















ENRICHED ORFS IN PDL1 SORTED POPULATION  
Barcode Gene Control 
# 







1 ACTTCATCAGCAGTGAGAATTCCA ERO1L 7 10889 1208 10.2 
2 CACGACGACATGGGTTATATCGAA NUP85 3 4378 1134 10.1 
3 AGATCAACGCGCCCATACGCACAT OR2L2 15 19065 987 9.9 
4 GCAGGATATTGGTTACATCGACCT TDP2 120 111075 719 9.5 
5 CCGAACACCCTCTAACTCGGCCTC ATF7 352 290057 640 9.3 
6 AAGAATATGTGGTAGTGCTTGATG AMT 48 29441 476 8.9 
7 TGTACACTCGGTGTGATTTGTAGT GSTO1 245 146097 463 8.9 
8 GATCGTATTAACTAGGCTAATGGC SPACA3 5 2513 390 8.6 
9 AATTCCCATTGTGATTGGGCCTGC ZNF101 52 19317 289 8.2 
10 ACCACTAAGGGACAGCAAACCTTC HNF4G 158 53187 261 8.0 
11 TGGCTCATAGCACCATACCCTCCT PPP1R2 99 31497 247 7.9 
12 CTTAGTCTTCATCCTCGTCTTATT FAM209A 1 293 228 7.8 
13 ATGAGCCTTATTGGAGGCTGAAAT LINC00242 129 33748 203 7.7 
14 CCACCTTCCCACCCTCACGAACGA ENOSF1 9 2159 186 7.5 
15 AGAAGGCACGCTTCAGCCGCGCCG ZFHX2 216 48351 174 7.4 
16 ATTATGTTTAGAACTAATATCTAG ZNF581 132 28361 167 7.4 
17 AACCGATGCCTTAAAGGGTAGTCC TALDO1 29 5796 155 7.3 
18 TGTACCCGCGAGTCTCCACACCGT HTR2C 1 178 138 7.1 
19 TTTAAGATTTCTGGGCTTCCCCCT ABHD12B 5 850 132 7.0 
20 ACTAAATTCAGTGATGCCACATAC C8G 93 15030 126 7.0 
21 TAAGCGAATAGTACCAGGGGTTGA DNASE1L1 88 13212 117 6.9 
22 CAGTGACTTATCGTATTTGTCTGA DNM1 2 290 113 6.8 
23 CTGATTCAGACAACGAGCATCAAC CTSL1 125 16125 100 6.6 
24 TCTCTTGGGAGGTGCATTCGATCA PPIAL4G 122 15117 96 6.6 
25 GCCCATCCAGCATGGCGGATTCCC EFNA1 87 10319 92 6.5 
26 ACAGCACTAGCAGGAACCTGGACT TMED4 203 22053 84 6.4 
27 CAACACGAGGCCATACATTGCTTA PRKAA1 23 2471 83 6.4 
28 TCATTGCTGTACATCTAGAGTTCG S100A1 6 618 80 6.3 
29 CTGTATAGACTGGCCGTCGAACTT KRT23 12 1225 79 6.3 
30 ATCGCTCCCTTCACAGTAAGCATA C1ORF49 53 5353 78 6.3 
31 TAGACGGTTTTATACGCTCAGCCA EFHD1 100 9775 76 6.2 
32 TAGAGGAAAGAATACAGGATCTAC DLX6-AS1 397 38327 75 6.2 
33 TAACTTGACGAAAGGACCCTGTGC EIF4B 14 1328 74 6.2 
34 CAAATCGCCTGACCCCAATAAAGA BOD1P 12 1095 71 6.1 
35 AACCCGCAACATGCCCGGTGGTCA CPEB1 5 436 68 6.1 
36 TAGTACCAAAAGCTTAACAGCGTT ATCAY 26 2176 65 6.0 
37 CTAGACATACATGATGCGGCACCT ADORA2B 92 7575 64 6.0 





39 TTAGCTCCGTGCCGCGATATGAAA BDNF 36 2867 62 6.0 
40 AGAGTCCATTCTCCCACTATGCCC REP15 227 17349 59 5.9 
41 ACTTTTCCCGCTTGTCCTGCCCCC GRK6 1 74 57 5.8 
42 CCTGTTTCCCCCGACCCTGAGTCG RASA3 2 138 54 5.7 
43 AATTAACTGTTCATCCGAGTCTTT ZCCHC9 1 68 53 5.7 
44 GTGTTCCCCGCGGTCTGGCGAACG TP73-AS1 81 5274 51 5.7 
45 TTAACTTCAATTCTCTTTTTAATT DIMT1 21 1294 48 5.6 
46 CCTGGTTGCCCCTCTAGGGCTTGA DPY19L2P1 151 8998 46 5.5 
47 GCCACTTTGTAGGCGCCATTCGAC CAPN1 1 59 46 5.5 
48 CACTATATCAATGTTTCCATTCGT FAM78A 8 462 45 5.5 
49 TACCTGATAATGGCACCATGCAAA DEFB129 259 13571 41 5.3 
50 CCAATCAACCGGGCCCCGAAACTC CDK16 10 522 41 5.3 
51 CACCCTATCGTCGAGGTCGACTGC PRAMEF5 63 3288 41 5.3 
52 TCAGCCTACCATCAACTTCGTATT SET 1 51 40 5.3 
53 AAGCTGGGATTACTTCTGTACGGC EEF1G 133 6536 38 5.3 
54 AAGTGGGAGAGTAAGTGCCTGGTC PRB4 371 18019 38 5.2 
55 TTCGTACTCCGGTTCCTGTGCTTC RHOG 213 10224 37 5.2 
56 GGCATATGTCCTGACATCTGGCAG CHIA 111 5244 37 5.2 
57 CCGCATAAGGCCAGATCGGTGCTC CAMLG 43 1997 36 5.2 
58 GATACCATACGACATCCTGTTCAC CCNL1 13 598 36 5.2 
59 ACCTACCTCCTGACACATCAACTT CNBP 216 9539 34 5.1 
60 CCTCACAGTACTTGCCATCCTGAC RBX1 278 11605 32 5.0 
61 AGCAGAACCCTTAAAAGCTCGAGT CST8 227 9049 31 5.0 
62 TGTTGAATCGGTAACGATGACCTG CDX4 24 942 30 4.9 
63 TGCCCGTGTTCTCCATCAGGTTTA TRIM72 1 39 30 4.9 
64 AACTATTAGTGCCCGAGTCATCCC CD82 57 2195 30 4.9 
65 GTTTGTTCTAAACATTGCGACATC ZNF578 9 339 29 4.9 
66 TACACACCCTTCTTAGCCATTCAT NFKBIA 242 9003 29 4.9 
67 TCGGAAACCAGAACTATTAGTATA RHPN1 3 111 29 4.8 
68 CTACAATTTCTGTTCTGCACCTTA ASIC1 18 659 28 4.8 
69 TCCAACACAGCGAGCCTCTTGGCT TNFSF11 79 2841 28 4.8 
70 CACGCCCACCCGTGCCAGGACTAC OR7E91P 45 1617 28 4.8 
71 TCAAGATACCCTTGACCAAATGTT ZNF550 25 883 27 4.8 
72 ATTAACAACCATCCTGTCCTGGCC C1QTNF2 255 8720 27 4.7 
73 TTTAGACTGGTTTTGTAAGAGACC UFSP1 152 5090 26 4.7 
74 ACCGAGTCCGAATAGTTTATTCAG HOOK1 23 764 26 4.7 
75 GTCAACTGGGGCATCTGGCACCTC ARHGEF26 222 7316 26 4.7 
76 AGCTCAATCAACTCAACCTTACAA KLRC1 101 3228 25 4.6 
77 CCCTATGAAGGCCTGAAGCGGGCA METTL21A 464 14778 25 4.6 
78 GCACCGATACCGATCCCCCCAATC GALNT10 147 4385 23 4.5 
79 GTAGGTGCAAACGCGAGACAGACC MAS1 168 4858 22 4.5 
80 TTCAAAGAACAGGAACGGGCTCAT FMN1 33 943 22 4.5 
81 CTGGCATGCTAACCAAGTACACGC CDH26 306 8694 22 4.5 
82 CAAAGGCCTAAGAGGACAGAGAGT ORAI1 185 5160 22 4.4 





84 TGAATTGTCGCCCCCAGATACACC ZCCHC10 208 5745 21 4.4 
85 GCCTAATTCGTGACGTCCCCAAAT DCLRE1B 10 276 21 4.4 
86 TTGCCGAACCGCGCACTCAGAATC PIAS4 15 385 20 4.3 
87 ACGCGCCCGATCCCCACTTCCAAT ANXA11 74 1865 20 4.3 
88 ATAGAACGTGACCAATCGTTGTTT PIPOX 20 491 19 4.3 
89 GCTGTAGTGTGCCCGCTGAGGCCT PRKCZ 9 218 19 4.2 
90 ACCAGAATGATACCTTGATCTCAC GPBAR1 8 191 19 4.2 
91 GTGATACCTCCTTCTCCCGACCCA ASPDH 65 1547 18 4.2 
92 CCATTCCACCTAGAGAATTTATAC P2RX2 1 23 18 4.2 
93 CGTCATTATATTCCTCTCCAGGAT KIAA0284 55 1233 17 4.1 
94 ACTTCCTGGAGAGGGGCTAACAGT WBP2NL 200 4481 17 4.1 
95 CTTAATAAGTCGAAATCCGAGGAC GPR139 13 290 17 4.1 
96 TGGCCCATCAAACGAGCCTTATTT AKR1B1 46 1011 17 4.1 
97 GAGGATGTCACACCACGATATCAT SLC22A11 27 581 17 4.1 
98 CTTGCCCCCATCACCCATATTTCT CMTM2 339 7270 17 4.1 
99 ACACCGGTCTGCTCCCGATCGGGC TNFAIP2 85 1805 16 4.0 
100 TCGACGGACATGGGAAAGATCAAC REEP5 142 2956 16 4.0 
101 AACCTTACTAATAGCTTGGTTGCC CCDC138 9 187 16 4.0 
102 AGCAATCTTACCGGAGCAGTTACA CEACAM8 18 373 16 4.0 
103 TCAGAGCAATATCCCATAATCAGT RUVBL1 109 2242 16 4.0 
104 TTGATTTCCAGTGCGAGAAGACCG HMX2 16 316 15 3.9 
105 ATTGTCAATGGTTTGATCTCAGCA FOS 99 1952 15 3.9 
106 TTCCGCCCTGTATTCCGGTACGTC ENTPD2 8 156 15 3.9 
107 TATATGTCTGAATACTCCGATCAG OR14J1 4 78 15 3.9 
108 AAGCACATCCGTTGTGCGCACAGA BAMBI 19 359 15 3.9 
109 ATCGAGGGTCCACGTACCTGTACT RABL2A 113 2132 15 3.9 
110 CATCACATATAAATGAGGACATGG STRN 10 184 14 3.8 
111 ACCTTAGACGCTCCTTTTCGCTGA TAC1 97 1764 14 3.8 
112 TCTCATCTGTCCCTGGCCCCGTAA TERF2IP 16 285 14 3.8 
113 ACGCCGAGATCCGCATAAGCCGTA GLO1 76 1350 14 3.8 
114 CCATCCTTACCAGAAACAACTCCC UBE2W 102 1800 14 3.8 
115 ATCACAACTATCGTTATTTACCGC KCNAB2 11 194 14 3.8 
116 GGTCGAATGGTCGCATTAGATTCC HIST2H2AA3 91 1592 14 3.8 
117 CATCATTCGCCTCTATCAACAATA ZNRD1 82 1424 13 3.8 
118 ACTTGCATCCTGCCCCAGAGGCTG OR56B1 8 132 13 3.7 
119 TCTGAAAAACTCCGAAATAGCAGA HINFP 47 768 13 3.7 
120 AACTACTATGGGGCCTTGCACCTT RHBDD2 160 2599 13 3.7 
121 TCGACAGCACTCACGGGTTAGCAG LINC00482 48 767 12 3.6 
122 TAATTAACCGTTTGAACTGCAACT SAMD10 44 690 12 3.6 
123 ACTGAGCAAGTCCCCCTTCCTATA C7ORF42 112 1755 12 3.6 
124 GTTCGGAGAGGCTCTATGGTTGGG DUSP10 61 953 12 3.6 
125 CAGCCTTAAACAGACTTCATAAGC HSPA8 56 865 12 3.6 
126 CCGCAGGTCTTCTGTTTTTAGGAT FAM71B 17 262 12 3.6 
127 TTCTAACCCCTTTGTAGACCAATG HIST2H2BA 443 6778 12 3.6 





129 AGCCAATTATCCTGTTGTGTCCCG ANAPC16 222 3188 11 3.5 
130 GTTCGCTAAATCCGTTCTCCCGGC LRRC52 74 1061 11 3.5 
131 ACGCTCAATGAGTGCACGCTCACC PCSK9 94 1324 11 3.5 
132 TTGTCTTCTATTATGAGTTGCGTA CXCL5 43 596 11 3.4 
133 GCTTCTCTAGTGAAAGTAATTTTG FMR1 14 189 10 3.4 
134 ATAACCAAGTTATGGAAACAGGCC CPSF4 97 1305 10 3.4 
135 GGGACCATAATGGCGATCCATTAG AREG 6 80 10 3.4 
136 TCCCGTGTGAATATTTTGGCCTTT DHPS 68 903 10 3.4 
137 AGTTGTGCCCCTCGGAGTGCGCCA GPAA1 2 26 10 3.3 
138 CCTAGACTGTACCTCCCATGGACC COQ4 219 2814 10 3.3 
139 TAGTGTTCCCTCCATCTATCGAAG TMPRSS12 6 77 10 3.3 
140 GTAGTACAATACCCCGAGTCGGAA GJA4 35 443 10 3.3 
141 CATGCGCTACTTAATTGAAGTGCC BCMO1 13 163 10 3.3 
142 TTATATTCCCAGTAGGGCTAGGAG CLDN7 12 148 10 3.3 
143 ACGATCAACCTGCGTTTTCCCGCA APOPT1 175 2091 9 3.2 
144 CGCAGGTTGCACAGAATGCTCGGT EPB41L1 27 319 9 3.2 
145 CGGCATTCCGTCAATTGCCGAACT PMCH 67 777 9 3.2 
146 CGCAAATACTTTCGGATGGCATCC C1ORF64 212 2424 9 3.2 
147 TCAGTACTAGGAAGGTCTCTACGA MAX 73 828 9 3.1 
148 GTCCGTTTAAGAACGTTTCGGCAC C11ORF31 158 1789 9 3.1 
149 TTATCATTCTGGGGATGGCAGGAG PLEKHB2 124 1401 9 3.1 
150 CCCTCCCAGTGTTGACTGTATTCC GCNT3 60 667 9 3.1 
151 GGGCGTGAGATAAAAGTGTAAAAT MTERFD2 85 929 8 3.1 
152 TAGGGTATAATAGATGATCCTGCC ST6GALNAC6 29 315 8 3.1 
153 CTTAGCCAATGGGTGCATCCGTGG OR51G2 18 195 8 3.1 
154 AGCAGACGTTGCATGCGCAATTCA RANBP10 67 718 8 3.1 
155 CCGCAGTCCCCTTCGCCGGAGATC GFOD2 42 446 8 3.0 
156 GCATGGGCCGAGCGCATTTCGCGG FAM27E2 275 2793 8 3.0 
157 ATTCGCGGCTATGCAGGGGCACTA RHBDL2 5 49 8 2.9 
158 CATAGTAGCGCACTACAGTTTAGC REEP6 26 251 7 2.9 
159 ACTTCGACGTCTGGAACCAGTCTC C1ORF158 90 857 7 2.9 
160 TTTGGCATCCCCCCTGTAGTGCGC ZNF689 71 675 7 2.9 
161 ACAGGATACATGATTACATGCCCC SHMT1 11 102 7 2.8 
162 TCTAAACGAACGCATCCCTGCCCT PF4V1 34 313 7 2.8 
163 TATAAGGCACCCAATAACCGAGAT RORB 70 638 7 2.8 
164 CTGCGACGCGGTACTGACGAATAT C11ORF63 74 659 7 2.8 
165 ACTGGGTCACAGTAGTGATTACCC TGIF2 317 2810 7 2.8 
166 CTTCGTGACAATACCTTTCGGAAT CDK2 11 97 7 2.8 
167 GCCCAGCTACACAACCAAGTTGCC PYY 488 4288 7 2.8 
168 GGGTCAGTAGTGGATGTACCAGTA LOC554223 53 457 7 2.7 
169 GCAAAGACACGTAGACGATAAGCC FAM83A 62 515 6 2.7 
170 ACACAAACGCTCATCAGCCCTGGC CD300LB 127 1048 6 2.7 
171 TGACGTCCGTCCCAGACCGTCTGC GRB7 39 314 6 2.6 
172 GAATTTGTCGACGTGCTTTGAGGA TRIM52 65 521 6 2.6 





174 TTGACTTTGATGTATCAGATCTAC CD300C 162 1253 6 2.6 
175 ACAAATTCCGAGATAGACGTCCAA DCTN3 127 981 6 2.6 
176 CCAGAATTACGCACTTGTCGATGT SLC39A7 45 345 6 2.6 
177 TCTCAGTCTCCACTCGTCTTGAGA SUOX 50 376 6 2.5 
178 ACAAGATATTAACGCTCGGCTGGA KIAA1467 19 139 6 2.5 
179 ATGACTGTGTTAGGCGGCTCACGG TIMM17A 128 915 6 2.5 
180 TAGTATGACGCGAGCAGTTCTAAA SH2D2A 123 871 6 2.5 
181 CACTTATCGGGGTCATTCGAGGTC ZCCHC2 44 310 5 2.5 
182 TATCCCCCCTGGAGTCGCAGTCCT LOC541471 399 2808 5 2.5 
183 AATGATGTAGTCCGTCATCCTCAA LINGO1 3 21 5 2.4 
184 TTCCCCGTTCCTAGAAGGGGCAAA CHRM5 2 14 5 2.4 
185 TCCCGAGATTACATTTCAGACAAT ADA 48 335 5 2.4 
186 CGTTCACGTCATAGCGTTCCCGAA AKR1C2 31 215 5 2.4 
187 CAAGAGCTACGATCTACTCCCCCA NR1D2 47 321 5 2.4 
188 GACGGCAACTTCGGGAATCACTAG PNMT 124 839 5 2.4 
189 CACGCCAAAGAAACCTCGAAGCTG CHCHD7 680 4594 5 2.4 
190 AGTAGGTTCAACCGCAAACAGATC NOA1 19 126 5 2.4 
191 GTCAACGACCTAAGGAACTCGTGC LAIR1 21 138 5 2.4 
192 AAAAATGGGCGCTCTGAGACACAC ZNF680 11 72 5 2.3 
193 TGTAGAAGTTTCTGGATAAGCCAC SLC50A1 130 849 5 2.3 
194 GTGCTGACATCTAACCCGTCTAGA HAND1 62 402 5 2.3 
195 TCGTTAGTTGTCAAATGCCAAACC STK32C 5 32 5 2.3 
196 TGTCCCCATCACCATGAGTGCCGT VMAC 146 933 5 2.3 
197 ATGCTGGGAAGCGATAATCGCGTA BCCIP 44 277 5 2.3 
198 CAATCGACGCTAAAGTGACCAGGA RPL14 158 982 5 2.3 
199 TGGCGCATCCTAAAGTGTAAGATT HSBP1 126 779 5 2.3 
200 ATACCCTGTCGGTTGGTCAATCAC ULK4 8 49 5 2.3 
201 CACCTCATGGGGCGTAAGCCCAGG CA6 168 1028 5 2.2 
202 AATGCGTTCGTGACACTTACGCCT PSMC4 5 30 5 2.2 
203 CTTTCAGGTTGCACAGCGGACTTC PRAMEF10 50 297 5 2.2 
204 GTGCCCACCTTTAGACGTAATGGC PPP1R1A 274 1610 5 2.2 
205 TTCATTACCATAACTCGGTGGCCA CCDC114 48 279 5 2.2 
206 TGCTTTCTGCCCCCGTATTAGTAG HSPB6 130 746 4 2.2 
207 CCGTATATTTCTATTTATTTATCG TGS1 25 141 4 2.1 
208 GATTATACTTTCACGTGGACACGA IGHD 60 337 4 2.1 
209 CTGACGTGCCCTAATTCCCTGTGC NDUFA10 75 421 4 2.1 
210 GGACACTACTCCGTAAAGGTACGT MPZL1 51 285 4 2.1 
211 TGACAGTGGCCAGGCGACCCGCCG LOC339535 17 95 4 2.1 
212 GTGCACCCAGGGCCGTGACTGGAG TMEM25 119 660 4 2.1 
213 GTTCCAGTTGCCGCGCCGGGGTGC NAALADL2 101 556 4 2.1 
214 CCTCTGTCACAGGTACTCTCTGTT CTC1 43 235 4 2.1 
215 ATGGGTTCTGTAGGGCCGCCGCAA ZDHHC15 158 859 4 2.1 
216 ATAACCATTGAGGGTAATTTTTAC C7ORF49 83 450 4 2.1 
217 ACCCGAATAACATGTAATCTCCCT EIF5A 68 364 4 2.1 





219 TCTTGAACCTCGAGATTATGACTC SLC25A44 57 299 4 2.0 
220 ACTATAGCACACTGAAGGTTTGAA LIMK2 21 110 4 2.0 
221 TATTTAGCACGCAAGAGCCGGAAC GABRA5 13 68 4 2.0 
222 CAAGTCCCGCTACGTGAGCGCCAA OR2T2 16 83 4 2.0 
223 ACACATTGTTACCGCCACGTTGAG RPL15 83 429 4 2.0 
224 GTGGCGCCAAGTCGCAATGGACTC DNAJC7 12 62 4 2.0 
225 CGCACATCAAGTCCCCAGTTCGTG SYNGR1 141 714 4 2.0 
226 GTCTCCTATTTACTACCTCCCTCC TNFSF18 96 484 4 2.0 
227 AGGTTTAAGGCTCCGCATCTAATC CHCHD2 3 15 4 2.0 
228 GGGGGATCTACGATATGACAGGCG SLC25A22 62 307 4 1.9 
229 CCCCCAATCGTGCTCCTTCACCTG HN1L 52 257 4 1.9 
230 TCTCAGCTTTCATATGACGGCCAC DAP3 34 167 4 1.9 
231 AAAAAAGTCGCCATGCCAGAACAA SEMA4C 29 142 4 1.9 
232 TTAAGGGTAACATGGCTACGCACT UTP23 185 893 4 1.9 
233 GCAGGCCTTACTGTACTCCTCAAG ALG2 137 659 4 1.9 
234 CATCTACGCACTTAACAACACTCT DDX19A 101 483 4 1.9 
235 ATCCGACAGTATGCGCCCTAGTGA ECD 18 86 4 1.9 
236 TTGTTCTAGCATATTTTATTACAA 42990 32 151 4 1.9 
237 GTCATGATTAGTTTTATACGATGT CHRM4 14 66 4 1.9 
238 GTACTCCTACCTTATTCTCGACCG DNAJB1 49 231 4 1.9 
239 GTGCGGCTGTAGGATGTCGGGCCA TSPAN15 9 42 4 1.9 
240 GGTTCACAGTTTTTGAACTCAACC CHI3L2 43 200 4 1.9 
241 AAACTGTACGAACGTCTATCCGGT SNAPC2 14 65 4 1.9 
242 GGCTCATATTGGCAGGAGAAGAAG CBFA2T2 130 603 4 1.8 
243 ATATGCAGTGAATTAAGGCGATCA SIVA1 218 998 4 1.8 
244 TTCCTAAATACAGTTACCTAACCA CATSPER4 35 160 4 1.8 
245 GGACACGGGCGTGCCCGATTCACG CCDC65 16 73 4 1.8 
246 TCCTCGGTTTCTGACTGATCCCCC GPR20 60 273 4 1.8 
247 CTTTCCGCGGCGGTGGCGCCGTTG GPER 5 22 3 1.8 
248 CTGAAATGTTCCCGTACGGGTACG CER1 199 875 3 1.8 
249 CGATACCATTACCGACTTTCAATC WISP2 58 254 3 1.8 
250 TTCCAATAACGCTAAGACGACGGG PARVG 55 240 3 1.8 
251 GACCTACGAGGTCAGACATACTCG RPS2 27 117 3 1.8 
252 AGGACAGAGCCAACGAAAACGGAT AIPL1 42 181 3 1.7 
253 AGTATCTCTCAGCGAAATAGTGAC ZCRB1 25 107 3 1.7 
254 TACACGATACCCCGTGCTGAGACC C1ORF87 44 187 3 1.7 
255 TGGCCGTGCGGCGTCAATTGTCCA RAB28 59 250 3 1.7 
256 CCAACCCCTACGACAGTCGAGTGC SUCNR1 225 946 3 1.7 
257 AGAGGTTTGCTATCCCGTCCTCCG EBAG9 114 475 3 1.7 
258 ACGTTGCATCCCAAGCTTTGAGAG CCDC146 72 298 3 1.7 
259 TCATGTTACCATGCAAAAGTGATG NUDT3 134 550 3 1.7 
260 GCTCGCCCGCTCGGCTTAGGCTCA WHAMMP3 29 119 3 1.7 
261 TGACTTCAAATGTACGGAAGGTAA C10ORF125 143 583 3 1.7 
262 TGGCCCACCCGCCCTTACGGCATA C7ORF34 500 2029 3 1.7 





264 CCCATCTACTAGCATTGGGAGGTT C12ORF4 1 4 3 1.6 
265 CGTGCCTCGTCCCGATTTAGCTAT GPR82 1 4 3 1.6 
266 GCCCTCTAAAAATCTACTTCAGCC TSPYL1 13 51 3 1.6 
267 ATCACATGGAGAGCAATGTTGACC CYCS 574 2244 3 1.6 
268 ACCCCCATCCAACTTCCGGATCTA MFF 11 43 3 1.6 
269 CTAAGGACACAGGCTCCACGAAAT CPA3 111 432 3 1.6 
270 CTCTGAGACGCTGCAATCGACGAT TMEM35 224 869 3 1.6 
271 ACCTAGTCTGGCCTCACGTTAAGG TMOD3 156 605 3 1.6 
272 GCACGGCCCGTAGCCCTATCGCCC FAM27L 71 272 3 1.6 
273 TCTCAATACCCAATGCCCTTTTTG ATG10 181 684 3 1.6 
274 GCACAGTCTCAGAGTGCCACAACC TAS2R3 331 1247 3 1.5 
275 TGTGGTTCTCGGCCTTCACAGGTC RPL14 240 899 3 1.5 
276 CCAAGGACAAAGTCTAGAGAGCCT EIF4E2 69 256 3 1.5 
277 TATTACCGGGCCGTATTAGTTGAA TEX2 31 115 3 1.5 
278 CTTAAAACAACCCATCCTCCGGTG PRAF2 102 375 3 1.5 
279 GTGACGGTAGCCACATGTTCCTGC RPL19 151 554 3 1.5 
280 AGCTTAGCACTATAGGTAGCTATC OSTM1 3 11 3 1.5 
281 GCGGAGATACGACCCTACCACACC COX4I2 232 846 3 1.5 
282 CGCGGTAAGCACCTCATGCGCCGC CEPT1 70 254 3 1.5 
283 ACATCAGTACCCCCGCAGATCGTC DMWD 128 463 3 1.5 
284 TTCGCTAATCATTAAAAAAACGGA NAGS 29 104 3 1.5 
285 CGGACTTCGCGTGCGTAGGTCTTC FGR 7 25 3 1.5 
286 GCAATAACTGAACTTGTACAATAA TYRP1 42 149 3 1.5 
287 GCCGCTTTTGGATGTACCGAGTTG C17ORF53 58 205 3 1.5 
288 TGCCGCCATCCGATTAAGTCCCAT TRIM13 31 109 3 1.4 
289 TCGTAACGCCAGGTATCTCGGGTA PCK1 4 14 3 1.4 
290 CGAACTACTTACCTAATCGTGGGA MST1R 141 493 3 1.4 
291 CTTGTTCGTCGTGTTAGGATCGTT CCDC42 70 244 3 1.4 
292 TAAAGTCTGCATATGCCAAGCTGG SNAP47 188 645 3 1.4 
293 TTTTTAGACCATACGTGGGATTTT GSTA1 14 48 3 1.4 
294 CAACCTGAGAGTGTTGACCGAAGA C14ORF79 319 1074 3 1.4 
295 TGATAGCCGAGTGACCACCTTTTT NRIP3 196 656 3 1.4 
296 TAACCAACTCCCCTGTGCTCTGGG SEC61B 86 287 3 1.4 
297 GGCTTATTAGGACTCATCGCGCCC TXLNA 3 10 3 1.4 
298 TTTCTTGGCTTGCACTGTGACCGC NUDT14 99 330 3 1.4 
299 CCCAGTGGGGTCCGGGTCAACTCG TMEM206 16 53 3 1.4 
300 ATCATTCGCACAACCACGAACTCA CCL4 1293 4240 3 1.3 
301 AAAACGCGAACATGTACCTCGCAC DGUOK 31 101 3 1.3 
302 TGCCTTGCCGTAGTCAAACTCACC ZNF416 8 26 3 1.3 
303 AACGCCAAACCATATGCACCGTCC C3AR1 56 182 3 1.3 
304 AAGTCTATCAAAAGTCCCATCACT ACPP 30 97 3 1.3 
305 GCTGACCAGAAACTCTGACTATTT LACRT 220 708 2 1.3 
306 ATCACAGGCGGCGTAGCCGACCCG BMS1P5 253 813 2 1.3 
307 GATGCGGTGTGACGGATGTTCCCA GOLGA7 183 587 2 1.3 





309 ACAGGTGTTTTGGCCGACTACTAA C15ORF53 102 325 2 1.3 
310 ATCCAAATGCGCGCCAGTTGCCTA MRPS11 170 530 2 1.3 
311 TCAGGGACACTTACAAGCCGGCGT LINC00518 103 321 2 1.3 
312 ATCAGACACGCCTATCCTACGAGG SPATA8 161 501 2 1.3 
313 GCTGCTAGCTATCAAGTTAAAATT C22ORF31 53 162 2 1.2 
314 CCGGCGTACCTCCTACCTAACATT MRPL43 126 383 2 1.2 
315 AAATCCTAGTAACGCCCCAATATA RIMKLA 56 168 2 1.2 
316 TCTCAATATACGGCGGTAAGTGCG NANOG 1 3 2 1.2 
317 CTTGTACGTCAGTAGATCATTTTC WDR18 1 3 2 1.2 
318 TGTCTCGTCCCATTAAAGGTGTCG TREML2 1 3 2 1.2 
319 CCTGGACACAATCTCTGCAAATTA JPH1 25 74 2 1.2 
320 TGCAGCTTTACAACATGCACTCTG PDE6D 136 401 2 1.2 
321 TTCGACGTAGATCTATGGGCGTGC ANKRD49 70 206 2 1.2 
322 CGTGTTGAAGCGCTGCGCAGTTTG NPR3 82 240 2 1.2 
323 GAAAACAGTATACCGCTGCCGACG TRIB2 24 70 2 1.2 
324 GTGTCATGCCCCCCGTTTACCGTT PPIE 24 70 2 1.2 
325 AAATTACCTACGATATTCCTATGA GPR162 71 207 2 1.2 
326 CTTGACCCATCCGACATATTACTC MB21D1 101 294 2 1.2 
327 CAGAGTACTCCGAGACTACAGGTC C2ORF73 138 399 2 1.2 
328 GTTGGCCATCACCTACGCAATTAC CCDC28B 226 638 2 1.1 
329 TCGATGTTAACGCCTCGAGCACTT SLC25A10 106 299 2 1.1 
330 GGACCCGAACGTCACTGCTATACC DAD1 9 25 2 1.1 
331 GAGACGCCGTACGACATTTTTAAA PPIL1 28 76 2 1.1 
332 GGCGAACTGTGAGTTTGTTGCACC IL28A 258 684 2 1.0 
333 TAGCGCTCCGCATCATCGACTTGC TXNDC11 74 195 2 1.0 
334 AAATTTGTATGCCACCGTCGCCTA FGF6 352 921 2 1.0 
335 TACTAAATTCACTGAAACCATTAC IL17A 504 1309 2 1.0 
 
Table 3-4. Enriched ORFs in PDL1 sorted population. 
 
 



















Tumor suppressors 0 0 0 0 0 0 0 0
Oncogenes 0 1 0 0 0 3 3  
Translocated cancer genes 0 1 0 0 0 3   
Protein kinases 0 0 0 1 12    
Cell differentiation markers 1 0 0 7     
Homeodomain proteins 0 5 5      
Transcription factors 0 20       

























Enriched Gene Set Name # Genes in Gene Set (K)
# Genes in 
Overlap (k) p-value
FDR          
q-value
GO_RESPONSE_TO_EXTERNAL_STIMULUS 1821 43 2.99E-12 6.63E-09
GO_CELL_CELL_SIGNALING 767 26 4.44E-11 4.93E-08
GO_REGULATION_OF_RESPONSE_TO_STRESS 1468 36 7.36E-11 5.44E-08
GO_REGULATION_OF_IMMUNE_SYSTEM_PROCESS 1403 34 3.50E-10 1.55E-07
HALLMARK_MYC_TARGETS_V1 200 7 5.31E-04 1.33E-02
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Chapter 4 Validation of a genome-scale CRISPR knockout screening protocol for 
identification of regulators of PDL1  
 
Abstract 
The immunosuppressive molecule PDL1 is expressed in HNSCC tumors and is a target for 
immunotherapy.  Recent reports show that activity of known oncogenes can influence PDL1.  
Thus, we aimed to better understand the molecular underpinnings of PDL1 expression in 
HNSCC.  We utilized a genome-scale CRISPR library and selected cells with diminished or 
enhance PDL1 expression to identify genetic knockouts conferring PDL1 up- or down-
regulation.  We successfully selected cells with altered PDL1 expression phenotypes, and 
validated that one of the candidate genes nominated by the screen, TLR2, can modulate PDL1.   
Introduction 
The ligation of PD-1 expressed on T-lymphocytes with PDL1, expressed on the surface 
of tumor cells, leads to repression of anti-tumor immunity and represents an essential target for 
immunotherapy.  Previous studies have shown that PDL1 expression on the surface of tumors is 
induced in response to interferon gamma (IFNγ) released by T-lymphocytes, and that this 
induction relies on Jak2/Stat1 mediated transcription in HNSCC[1, 2].  More recently, other 
signals modulating the expression of PDL1 have been identified.  Notably, in head and neck 
squamous cell carcinoma (HNSCC) cell lines, epidermal growth factor receptor (EGFR) 
activation was shown to positively regulate PDL1 expression on the cell surface [1].  





that of EGFR in 23 tumor specimens [1].  Such observations led us to question whether 
additional pathways, including other oncogenic and pro-inflammatory signals, may contribute to 
immune escape via PDL1 upregulation, and whether these signals could be targeted to enhance 
response rates to immunotherapy. 
Historically, large scale screening techniques such as those employing RNAi have 
yielded disappointing results due in part to technical challenges including lack of specificity [3].  
Upon the discovery and advancement of CRISPR technology, however, new methods and 
applications for genome-scale functional screening have rapidly arisen [4].  In 2014, Shalem et al 
and Wang et al simultaneously published two of the first genome-scale screens utilizing a library 
of CRISPR constructs to generate pools of genetic knockouts in cultured cells [5, 6].  Since then, 
the field has rapidly expanded with diverse applications of this technology, from identifying 
genes essential for cell proliferation to nominating pathways conferring for resistance to 
therapies.  Thus, CRISPR library screening represents a valuable tool to expand our 
understanding of various pathways.  In the present study, we sought a more detailed 
understanding of the mechanisms regulating the expression of PDL1 in an effort to improve 
responses to therapies and identify new biomarkers for response.   The Genome-scale CRISPR 
Knock-Out (GeCKO) v2 library consists of ~60,000 gRNAs designed to target Cas9 to over 
19,000 different genes [7].  Using this library to generate a pool of genetic knockouts in HNSCC 







Materials and methods: 
Cell culture: Cell lines were maintained in logarithmic growth phase in Dulbecco’s Modified 
Eagle’s Medium (DMEM) (Gibco #11965) containing 10% fetal bovine serum (FBS, Sigma), 
1% NEAA (Gibco #15140122) and 7 μL/mL penicillin-streptomycin (Gibco #15140122) in a 
humidified atmosphere of 5% CO2 at 37°C. Cells were tested for mycoplasma contamination 
using the MycoAlert detection kit (Lonza). 
 
Transduction of UM-SCC cell lines with Genome-scale CRISPR knock-out library: UM-SCC 
lines were transduced with the Human GeCKO CRISPR knockout pooled library version 2 
(Addgene plasmid #52961). Conditions for transduction were established for a multiplicity of 
infection (MOI) of 0.3. Cells were subjected to 7 days of puromycin selection, then expanded 
and seeded for treatment and flow cytometry.  To preserve at least 300x coverage, 30 million 
cells were seeded per treatment.  Upon selection of the final populations of cells for sequencing, 
genomic DNA was extracted from the remaining cells using Gentra Puregene Cell Kit (Qiagen). 
Treatment and staining of GeCKO library cell line for cell sorting: UM-SCC-49 GeCKO cells 
were seeded at 30 million per condition.  18h after seeding, media was replaced with plain media 
(Control) or media containing 10ng/mL IFNg.  After 72h incubation, cells were trypsinized and 
counted, and 30 million cells were incubated with a monoclonal antibody directed against PDL1 
(ThermoFisher #14-5983-82) diluted to 1ug/mL in HBSS (Gibco) for 15 min in a suspension of 
1 million cells per mL.  500,000 cells were also incubated without primary antibody as a control.  
Control and PDL1 stained cells were pelleted and resuspended in PE-conjugated rat anti-mouse 





incubation, cells were pelleted, resuspended at 2 million cells per mL in HBSS plus 0.5% FBS, 
and transported on ice for flow cytometry. 
Serial cell sorting: Flow cytometry analysis and sorting was performed using an iCyt Synergy 
cell sorter (Sony Biotechnology) at the University of Michigan Flow Cytometry Core facility. A 
secondary antibody- only control was first analyzed to delineate positive vs. negative PDL1 
immunostaining. For the first sort of the UM-SCC-49 GeCKO pool, gates were drawn to select 
the 10% of cells with lowest PE fluorescence (PDL1low) and 10% with highest (PDL1high).  These 
populations were expanded separately in culture to 30 million cells each, then immunostained as 
above and subjected to cell sorting again, selecting the lowest 10% of cells from PDL1low and 
highest 10% of cells from PDL1high.  Again, these cells were expanded to 30 million in culture, 
immunostained for PDL1, and analyzed by flow cytometry a third time to ensure divergent 
phenotypes.  “Positive” and “Negative” gates were drawn based on 0.1% and 99% of the control, 
respectively.  At this point, all PDL1-negative (PDL1low) and all PDL1-positive (PDL1high) cells 
were selected.  Following expansion in culture, genomic DNA was harvested from these final 
populations, as well as the initial unsorted UM-SCC-49 GeCKO pool.   
GeCKO library preparation: Genomic DNA was extracted from the UM-SCC-49 GeCKO pools 
cells using the Gentra Puregene Cell Kit (Qiagen).  130ug genomic DNA per sample was divided 
into 13 reactions with 10ug input each and used to PCR amplify gRNA sequences using 
Herculase II Fusion DNA Polymerase (Agilent #600675).  `The following primer sequences 
were used: Forward = AATGGACTATCATATGCTTACCGTAACTTGAAAGTATTTCG; 





The 13 reactions were combined, and 5 μL were used as input for the second round PCR 
reactions (4 reactions per sample) with the following primers to add sequencing adapters and 
barcodes to the PCR products:  Forward= 
AATGATACGGCGACCACCGAGATCTACACTCTTTCCCTACACGACGCTCTTCCGATC 
T(1-9bp stagger)AAGTAGAGtcttgtggaaaggacgaaacaccg.  Reverse= 
CAAGCAGAAGACGGCATACGAGATTCGCCTTAGTGACTGGAGTTCAGACGTGTGCT 
CTTCCGATCTataacggactagccttattttaac.  The underlined sequence in the Forward primer 
indicates a representative 8 base pair barcode, which was different for each sample (control, 
PDL1high, PDL1low).  Uppercase sequence indicates Illumina adapters.  The forward primer 
contains the TruSeq Universal adapter, and the reverse primer consists of Illumina P7, 8 base 
pair index, and multiplexing PCR primer 2.0.  Lowercase sequence indicates the priming sites 
for the lentiviral construct. 
The PCR products were extracted and purified using Gel Extraction PCR Purification Kit 
(Qiagen) before submission to the University of Michigan DNA Sequencing Core for sequencing 
with Illumina MiSeq V3 Kit.Analysis of CRISPR libraries: Reads were demultiplexed by 
barcode and then mapped to the corresponding reference library using an in-house python script.  
We did not consider gRNAs represented by fewer than ten reads for further analysis.  Read 
counts were normalized to the total number of reads for a given sample and the read count for 
each gRNA was then computed relative to the read count in the control to determine relative 
abundance in the sorted populations vs control. 
SiRNA transfection: ON-TARGETplus siRNA SMARTpools were purchased from Horizon 





Non-targeting siRNA was purchased from Horizon Discovery (D-001810-02-05).  Cells were 
seeded in six-well dishes at 100,000 cells per well. 18h post seeding, cells were serum starved 
for 3h, followed by transfection with 5uM siRNA per well with oligofectamine (Invitrogen 
#12252011) in a total of 1mL of OptiMEM (Gibco).  After 6h, an additional 1mL standard media 
was added.  For qPCR analysis, cells were harvested in 700uL QiaZOL (Qiagen) 24h after initial 
transfection.  For analysis of PDL1 protein, cells were treated as indicated for an additional 48h, 
then total protein lysate was collected. 
Cell line transcriptome analysis: RNA sequencing was performed for 43 HNSCC cell lines using 
Illumina stranded transcriptome library preparation kits as described in [8].  Heatmaps were 
generated using MeV software version 4.9 based on log2(FPKM+1) values. 
TCGA transcriptome analysis. Log2(RSEM+1) values from TCGA Head and Neck Cancer 
cohort (n=566) were retrieved from the UCSC cancer genomics browser (xenabrowser.net).  
Correlations were calculated using Pearson r test, and linear regressions and box and whisker 
plots were generated using GraphPad Prism 8 software. 
Western blotting: Cells were rinsed twice with ice cold PBS and lysed in a modified RIPA lysis 
buffer (150mM NaCl, 50mM Tris pH 8.0, 1mM PIPES, 1mM MgCl, 10% Glycerol, 1%NP40, 
0.1% Triton X100) with HALT protease and phosphatase inhibitor cocktails (Thermo 186129, 
1861277).  Cells were spun at 14,000 rpm for 15 min and protein was quantified by BCA assay 
(Pierce).  Separation by SDS-PAGE was performed and the antibodies were used for 
visualization of target proteins were purchased from Cell Signaling Technology as follows: 





qPCR: RNA extraction from cell lysates preserved in QiaZOL was performed using RNeasy 
Spin Kit (Qiagen) according to manufacturer recommendations. cDNA templates were then 
synthesized using random primers and SuperScript III Reverse Transcriptase VILO kit 
(Invitrogen) according to manufacturer recommendations. Primers used for qPCR analysis are 
listed in Table 4-1. Amplification by qPCR was performed with Quantitect Sybr Green (Qiagen) 
on QuantStudio5 (Applied Biosystems) under the cycling conditions recommended by 
manufacturer. 
Results 
Selection of PDL1high and PDL1low cells 
We elected to use a positive selection screening model to enrich for deficient or enhanced 
PDL1 expression (Figure 4-1A).  UM-SCC-49 cells were transduced with the GeCKO v2A 
CRISPR library and subjected to puromycin selection.  To identify genetic knockouts conferring 
altered PDL1 expression on the cell surface, we stained an IFNg treated UM-SCC-49 GeCKO 
pool using a PE-tagged antibody directed against PDL1 and used flow cytometry to select cells 
with the highest (PDL1high) and lowest (PDL1low) PE fluorescence (Figure 4-1B).  The selected 
populations were then expanded separately in culture.  To enrich each population for the desired 
phenotype, we subjected each to further sorting by flow cytometry, selecting the 10% of cells 
with highest and lowest PE fluorescence for PDL1high and PDL1low populations, respectively.  
After expanding the final population in culture, sorting was repeated a second time for a total of 
three sorts.  We validated successful enrichment for PDL1high and PDL1low phenotypes by 
comparing PE fluorescence in each of the final populations to each other and to an unsorted 





exhibited a median fluorescence intensity (MFI) equal to 100, with 16% of cells expressing 
PDL1 based on comparison to a control stained with secondary antibody only.  PDL1low cells 
exhibited a similar phenotype, with 17% expressing PDL1 (MFI=90.8) in response to IFNg.  In 
contrast, 99% of PDL1high cells expressed PDL1 (MFI=813).  These data are summarized in 
Figure 4-2B.  Because it was not apparent from this analysis that PDL1low had diverged 
phenotypically from the control population, we generated clonal cell lines from single cells 
isolated from the PDL1low pool (Figure 4-2C).  We found that these cell lines had dramatically 
diminished ability to upregulate PDL1 expression in response to IFNγ, indicating that we had 
indeed selected individual cells with dysregulated PDL1. 
  Next, barcodes from the initial UM-SCC-49 GeCKO library pool (control), PDL1high 
pool, and PDL1low pool were analyzed to determine enrichment of specific knockouts in sorted 
populations over the control.  In the control pool, 44,892 gRNAs were identified (70% library 
coverage).  Sequencing of barcodes from PDL1high and PDL1low pools identified 9922 (16% 
library coverage) and 7162 gRNAs (11% library coverage), respectively (Figure 4-3A). 
Distributions of reads across the detected gRNAs for each pool is shown in Figure 4-3B-D, and 
indicate that in the sorted populations, the majority of reads represent only a small proportion of 
gRNAs.  
 We set an arbitrary cutoff and only included gRNAs for which normalized read counts 
were greater than or equal to 10, and found that of these, 34% overlapped between PDL1high and 
PDL1low. We were surprised to find a large number of hits overlapping between the PDL1high and 
PDL1low pools.  Because of this high degree of overlap, we next attempted to identify hits for 
which representation was enriched over the control pool in only one of the selected populations.  





(PDL1Low) and Table 4-3 (PDL1high).  In our final gRNA lists, we observed an interesting 
reciprocal relationship between some of the top hits in the PDL1high and PDL1low pools.  A 
gRNA targeting Toll Like Receptor 2 (TLR2) was among the most abundant in the PDL1high 
pool, while gRNAs targeting mir-105-1 and mir-105-2, thought to negatively regulate toll like 
receptors [9], were enriched in PDL1low.  Thus, we hypothesized that TLR2 may positively 
regulate PDL1 expression.   
 We therefore asked whether PDL1 and TLR2 were co-expressed in HNSCC tumors.  We 
interrogated the TCGA HNSC dataset (n=566, https://www.cancer.gov/tcga) to assess RNA 
expression in human tumor samples.  As expected, we found that expression of JAK2, a known 
driver of PDL1 downstream of IFNg, correlates strongly with PDL1 expression in HNSCC 
(Pearson r = 0.58, p < 0.0001; Figure 4-4A).  We also discovered a positive, albeit weaker, 
correlation between TLR2 and PDL1 (Pearson r = 0.32, p < 0.0001; Figure 4-4B).  
Hypothesizing that TLR2 may represent one of multiple signals converging on a downstream 
regulator of PDL1, we also noted that expression of other TLRs, including TLR7 and TLR8 
(Figure 4-4C,D), correlated positively with that of PDL1. Because several TLRs, including those 
mentioned above, signal through Myd88, we also assessed whether PDL1 expression correlated 
with Myd88 expression and again identified a positive correlation (Pearson r = 0.42, p < 0.0001; 
Figure 4-4E).  A correlation between Myd88 and PDL1 RNA expression was also observed in 
HNSCC cell lines (n=43; Pearson r = 0.50, p = 0.0006; Figure 4-4F), although no correlation 
between TLRs and PDL1 expression was evident in this dataset (not shown).   
While these observations suggest a potential relationship between TLR activity and 
expression of PDL1, it is also possible that TLR upregulation and PDL1 expression are simply 





PDL1 expression is often increased in inflamed tissues [10].  Thus, we sought to establish a 
causal link between TLR2 and PDL1 in cell lines.  To validate that modulation of TLR2 can 
influence PDL1 expression, we knocked down TLR2 expression via siRNA (Figure 4-5A) and 
assessed PDL1 expression by immunoblot following treatment with IFNg.  We noted a decrease 
in the ability of IFNg to induce PDL1 expression when TLR2 expression was diminished, 
indicating that our screening protocol successfully identified a gene capable of modulating PDL1 
expression in UM-SCC-49 (Figure 4-5B).  This decrease is quantified in Figure 4-5C. 
We next sought to understand whether TLR2 could be activated to induce PDL1 
expression.  Pam3CSK4 is a synthetic lipopeptide that acts as a specific TLR1/2 agonist [11].  
We treated wild-type UM-SCC-49 cells with Pam3CSK4, for 72h and observed no significant 
increase in total PDL1 expression evaluated by immunoblot (Figure 4-6A).  However, when 
Pam3CSK4 was given simultaneously with IFNg, the ability of IFNg to induce PDL1 expression 
was enhanced (Figure 4-6A, quantified in 4-6B).  Because activation of TLR2 is known to 
induce phosphorylation and activation of the p65 subunit of NFkB (also called RelA) [12], we 
also assessed phosphorylation of p65 on Serine 536 by immunoblot.  We observed small 
increases in phosphorylated p65 in response to Pam3CSK4 or IFNg alone, but a greater induction 
was observed with the combination.  A modest increase in total p65 protein was also observed 
only in response to the combination.   
Next, we considered the role of TLR2 in initiating an immune response.  TLRs recognize 
pathogen associated molecular patterns (PAMPs) and initiate signaling cascades to drive various 
aspects of immune response, including production of pro-inflammatory cytokines.  Previously, 
Wang et al showed that TLR2 is activated and PDL1 expression is increased following 





[13].  Given that HNSCC often arises in tissues with high exposure to pathogens, such as the oral 
cavity, we postulated that TLR2 may modulate PDL1 expression following activation by 
bacterial ligands.  We therefore assessed total PDL1 protein in UM-SCC-49 cells treated with S. 
aureus, and found that indeed, S. aureus can induce expression of PDL1 (Figure 4-6C). 
Furthermore, S. aureus induced phosphorylation of p65, which has previously been described as 
an effector of TLR2 and as a driver of PDL1 in other models [14].  We therefore analyzed a 
small panel of IFNγ regulated and p65-regulated effectors, and showed that cells treated with 
Pam3CSK4 and S. aureus showed induction of p65 target IL6, but interestingly, there was 
minimal induction of PDL1 transcript expression in the absence of IFNγ.  IFNγ appears to induce 
a distinct transcriptional profile at this time point, including HLAB and SOCS1 (Figure 4-6D, E).   
 We next examined the ability of TLR2 to regulate PDL1 in other HNSCC models. First, 
we assessed RNA expression of all TLRs in 43 HNSCC cell lines by RNAseq.  TLR1, 2, 3, 4, 
and 6 were the most highly expressed (Figure 4-7A).  We then tested several UM-SCC cell lines 
for PDL1 upregulation in response to either Pam3CSK4 or S. aureus, and discovered varying 
responses to these stimuli.  UM-SCC-58, 59, and 97 are shown to represent the spectrum of 
responses (Figure 4-7B-D).  UM-SCC-58, which exhibited lower expression of most TLRs, 
showed no increase in PDL1 expression in response to S. aureus or Pam3CSK4, although we 
observed similar results in UM-SCC-14a, which does express TLR2 mRNA.  UM-SCC-59 
appears to upregulate PDL1 in response to S. aureus but not the TLR2 specific agonist 
Pam3CSK4, suggesting that a different receptor might mediate this response.  UM-SCC-97 
modestly upregulates PDL1 in response to both S. aureus and Pam3CSK4. Both, UM-SCC-59 





 Due to the ability of UM-SCC-97 to upregulate PDL1 in response to TLR2 agonists, we 
used this model to further interrogate the role of TLR activation in modulating PDL1.  As we 
showed that S. aureus can induce expression of PDL1 in HNSCC cell lines, we also asked 
whether other common infectious bacteria might induce a similar response.  PDL1 is generally 
thought to be upregulated in response to cytokine release by T-cells, but we found that even in 
the absence of T-cells, various bacterial strains known to activate TLR2 were able to induce 
PDL1 expression (Figure 4-7C).  Additionally, siRNA knockdown of TLR2 in UM-SCC-97 
blocked the upregulation of PDL1 in response to Pam3CSK4, indicating that the ligand indeed 
acts as a TLR2 agonist in this system (Figure 4-7D).  We saw similar results with knockdown of 
the p65 (RELA) subunit of NFkB, indicating that the NFkB pathway may be an essential 
mediator of PDL1 induction following TLR2 activation. 
 
Discussion 
Here, we present validation of a genome-scale CRISPR knockout-screen to identify genes 
regulating the expression of PDL1 on the surface of UM-SCC-49 cells.  Our study highlights 
both the promise and challenges of positive selection based screening of CRISPR libraries.  
While we were able to validate a PDL1 regulating signal from among the top hits of our screen, 
certain technical issues obscure our ability to interpret our screening results as a whole. Because 
the library was constructed with three gRNAs targeting each gene, we expected that for our 
strongest candidate PDL1 regulators, multiple gRNAs for the same gene would be identified.  
This was not the case, however, and limited our ability to statistically nominate candidate genes.  
We postulate that 1) highly variable initial representation of gRNAs in the initial library, and 2) 





precision and accuracy may have contributed to the unexpected distribution of gRNAs in our 
sorted samples. Additionally, heterogeneity of the UM-SCC-49-WT cell line, including 
variability in the epigenome, could cause altered regulation of PDL1 in subpopulations 
regardless of genetic knockout status.  We also may have been selecting for a survival and/or 
proliferative advantage as our cells were propagated in culture between sorts.  For example, the 
PDL1high and PDL1low screens each nominated a unique gRNA targeting KLHL30, suggesting 
that knockout of this gene conferred an advantage under our growth conditions.  Further 
validation of targets from this screen, and repetition of our screening protocol in this and other 
models, will be necessary to truly define the robustness of our method. 
Another puzzling finding was that the GeCKO screen did not nominate the gene 
encoding PDL1 (CD274), despite the presence of CD274 targeted gRNAs in the unsorted control 
library.  Further investigation will be necessary to understand the cause of this observation.  It is 
possible, despite the purported optimization of the GeCKO library for efficient and specific 
knockout, that CD274 was not efficiently or specifically disrupted. Otherwise, this observation 
may necessitate further optimization of our sorting protocol.   
We also provide evidence that activation of innate immune response genes, not only in 
immune cells but also intrinsically to HNSCC cells, can induce PDL1 expression.  This finding 
suggests that tumor cells may be able to intrinsically upregulate PDL1 by overexpressing or 
activating TLRs.  It is also possible that tumors arising in the context of inflammation may be 
more likely to utilize TLRs as a mechanism for PDL1 upregulation.  Lyford-Pike et al showed 
that PDL1 is highly expressed in tonsillar crypts, a common site of infection, and postulate that 
this may represent and “immune privileged” environment hospitable to oncogenic virus infection 





directly promote upregulation of PDL1 in tumor cells brings an additional facet to this 
hypothesis.   
This observation is of particular interest due to recent clinical trials using TLR agonists to 
treat cancer.  Toll-like receptors reportedly exhibit both tumorigenic and anti-tumor effects, 
which are not fully understood and may be highly context-dependent.  Stimulation of TLRs to 
treat bladder cancer dates back to the 1880s, and the TLR2/4 agonist Monophosphoryl lipid A is 
used in as a prophylactic vaccine adjuvant for HPV associated cervical cancer [15].  However, 
studies in other cancer types have reported an association between TLR expression and invasion 
and metastasis.  Furthermore, knockdown or knockout of TLRs has led to tumor regression and 
reduced metastasis in in liver, breast and lung cancer models [15, 16].  Thus, elucidating the 
precise, likely multifactorial, impact of TLR modulation across the spectrum of HNSCC 
subtypes will be important in understanding the clinical implications of this work. 
The present study is limited in that it does not address functional effects of TLR2 
modulation of PDL1 expression in more complex systems.  T-cell co-cultures and in vivo models 
will be necessary to determine the functional significance of our observation.  Specifically, we 
will need to assess whether direct modulation of TLR2 on cancer cells impacts T-cell killing, and 
whether PDL1 mediates this effect.  Due to the many established roles of TLRs in controlling 
immune responses, it is very likely that modulation of TLRs will have broader effects in vivo 
beyond simply PDL1 protein regulation, and understanding these will be crucial if our findings 
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Figure 4-1 Establishing phenotypically distinct populations from UM-SCC-49-GeCKO 
pool.  










Figure 4-2 Sorting of UM-SCC-49-GeCKO pool for PDL1 enhanced or deficient cells.  
 
A) UM-SCC-49 cells infected with the GeCKO library were treated with 10ng/mL IFNg for 72h, 
trypsinized, and stained using a PE-conjugated antibody directed against PDL1.  Cells were then 
subjected to cell sorting by flow cytometry (upper panels) to select the 10% of cells with the 
lowest PDL1 expression (green gate) and 10% with the highest (blue gate). PDL1low cells were 
expanded in culture and sorted again for the 10% of cells with lowest PDL1 expression, while 
PDL1high cells were expanded and sorted for the 10% with highest PDL1 expression (middle).  
The two populations were expanded again in culture and PDL1 surface expression analyzed a 
third time (lower panels).  Green and red gates indicate populations of cells collected for 
PDL1low and PDL1high respectively. (B) Median fluorescence intensities (MFIs) are reported for 
indicated populations.  (C) Individual cells were isolated and propagated from PDL1-low final 
sort, arbitrarily designated Clone #1 and #2.  These and UM-SCC-49-wt were treated +/- IFNg 








Figure 4-3. Sequencing of UM-SCC-49-GeCKO populations.  
A) Mapping statistics from UM-SCC-49-GeCKO sequencing results.  B-C) Distribution of 



























Figure 4-4. RNA expression in TCGA HNSC cohort. 
 A-E) TCGA Head and Neck Cancer samples were analyzed (n=566) for correlation between 
genes of interest (y-axis) and PDL1 (CD274; x-axis).  Linear regression analysis was performed 
using (log2(RSEM+1) and Pearson’s r values are reported. F) Log2(FPKM+1) values for PDL1 














Figure 4-5. Knockdown of TLR2 in UM-SCC-49 reduces IFNg mediated upregulation of 
PDL1. 
 
  A) Knockdown of TLR2 and GAPDH was confirmed by qPCR.  B) Cells were transfected with 
non-targeting (NT), GAPDH, or TLR2 siRNA for 24h were then treated -/+ IFNγ for 48h.  PDL1 
expression was assessed by immunoblot. C) Bands in (B) for IFNγ treated samples were 
quantified by densitometry.  Densitometry units for PDL1 bands were normalized to respective 

















Figure 4-6. Effects of TLR2 activators in UM-SCC-49.   
 
A) UMSCC49 cells were treated -/+300ng/mL Pam3CSK4 -/+ 10ng/mL IFNg for 72h.  Protein 
lysates were analyzed by immunoblot and bands were quantified by densitometry in (B).  C) 
UM-SCC-49 cells were treated for indicated timepoints with 0.075% S. aureus (Millipore) and 
lysates were analyzed by immunoblot.  D) qPCR analysis of IFNg and TLR effectors and PDL1 
























Figure 4-7. TLR2 signaling in HNSCC cell lines. 
A) RNA expression (log2(FPKM+1)) of indicated genes in HNSCC cell lines. Cell lines are 
arranged from left to right in order of increasing expression of PDL1 (CD274).  B-D) HNSCC 
cells were treated with vehicle control, 10ng/mL IFNγ, 0.075% S. aureus (Millipore), or 
300ng/mL Pam3CSK4 for 72h.  PDL1 expression was analyzed by immunoblot. E) UM-SCC-97 
was incubated with heat-killed commercially available bacterial strains as indicated for 72h.  F) 
Indicated siRNAs were transfected into UM-SCC-97 cells.  24h post transfection, cells were 
treated with Pam3CSK4 for an additional 48h.  PDL1 was analyzed by immunoblot (left) and 





























Gene Forward Reverse 
TLR2 AGCAGGATCCAAAGGAGACC ACCAAGGTGGTTTGCTGAGT 
GAPDH AATGGGCAGCCGTTAGGAAA GCCCAATACGACCAAATCAGA 
PDL1 AGTCAATGCCCCATACAACAA CGTCACTGCTTGTCCAGATGA 
MYD88 GACTGCTCGAGCTGCTTACC ACATTCCTTGCTCTGCAGGT 






















Rank gRNA target PDL1low/Control  PDL1high/Control 
1 RNF130 130.4702 0.61437 
2 UIMC1 97.62247 0.533461 
3 KLHL30 97.47681 0 
4 C1orf116 93.29673 0.604938 
5 SLC2A6 93.00492 0.467358 
6 TLR2 80.91354 0.363622 
7 KIDINS220 74.24762 0.376101 
8 COMP 73.34039 0.374752 
9 STAB1 48.71035 0.181629 
10 NFYB 45.65152 0.163268 
11 DISP2 38.79179 0.872197* 
12 SLC25A25 36.74726 0.14868 
13 C7orf55 36.6708 0.194452 
14 SSMEM1 34.35596 0.153269 
15 TSPAN31 30.65758 0.121086 
16 UNKL 27.33073 0.127668 
17 ITSN1 14.07346 0.076536 
18 HIRA 13.86975 0.066925 
19 ZDHHC24 11.48397 5.910346 
20 NODAL 11.19729 0.06114 







22 C1orf35 7.269804 0.038215 
23 ULBP2 6.721698 0.028772 
24 AXDND1 6.5365 0.040082 
25 ZFP64 6.110201 0.042713 
26 MAGEA6 5.625484 0.045438 
27 PCDHGB6 5.256831 0.039738 
28 FAM168B 4.806231 0.031167 
29 FABP6 4.648937 0.03478 
30 USP16 4.350071 0.028961 
31 VPS25 4.180224 0.033329 
32 SPATA31A2 4.175848 0.035267 
33 NPR1 3.975242 0.033517 
34 CKMT1A 3.801816 0.020674 
35 CCDC117 3.520316 0.02719 
36 KIF13B 3.131082 0.022894 
37 FZR1 2.847764 0.022893 
38 ZNRF3 2.696549 0.02445 
39 STRN3 2.642702 0.026301 
40 BLCAP 2.598926 0.020274 
41 GMNC 2.586674 0.020701 
42 KDM6A 2.56034 0.026508 
43 OR5T2 2.554679 0.028434 





45 RAD50 2.088789 0.0218049 
46 NARR 2.070283 0.020284 
47 NARR 2.070283 0.020284* 
48 HINT1 2.068037 0.018824 
49 IRG1 2.043546 0.0089151 
50 SLC9A6 2.043088 0 
51 TTC34 1.554888 0.022822 
 






Table 4-3. gRNAs enriched in PDL1high over control.  
Rank gRNA target Chapter 1 PDL1high/Control  Chapter 2 PDL1low/Control  
1 IZUMO3 223.6348 1.0669 
2 hsa-mir-105-1 167.3409 1.178067 
3 GLS 111.713 0.854239 
4 FAT2 104.4253 0.590414 
5 SCGB3A1 50.81308 0.337907 
6 RAPGEF3 37.84282 0.242991 
7 AP2A1 31.35016 0.214096 
8 TRIM49 29.33133 0.181142 
9 hsa-mir-105-2 9.937754 0.060283 
10 FIGLA 6.562241 0.021861 
11 POGLUT1 6.558918 0.06121 
12 ZDHHC24 5.910346 11.48397 
13 KCNIP2 5.604062 0.0485690 
14 ZNF37A 4.446165 0.038013 
15 TTC5 3.348804 0 
16 SLC35F3 2.39854 0 
17 FAM71C 2.325857 0 
18 CXorf21 2.179963 0.014468 
19 RBBP8 2.111634 0.04188 
20 CCDC129 1.992549 0 
21 SLC5A8 1.902974 0 
22 CHST2 1.864696 0.068597 
23 P2RY2 1.836203 0 
24 SEMA6C 1.834026 0.015726 
25 SPHK1 1.797793 0 
26 KLHL30 1.794423 0.007607 
27 hsa-mir-212 1.77299 0 
28 CARNS1 1.744393 0 
29 BRF2 1.744393 0 
30 LMNB2 1.744393 0 
31 MCL1 1.744393 0 
32 GNA13 1.744393 0 
33 NF2 1.722029 0.714116 
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 Here, we have profiled various genetic, transcriptomic, and immunologic features of 
HNSCC, provided evidence for CD103+ TIL content as a potential prognostic biomarker, and 
validated multiple drivers of PDL1 expression.  Because PDL1 expression is believed to play a 
role in HNSCC immune evasion but immunotherapies targeting this pathway are minimally 
effective, we sought to better understand the mechanisms contributing to this pathway in the 
hopes that we may eventually identify features of HNSCC that predict immunogenicity.  We 
utilized cutting-edge genome wide screening techniques to select HNSCC cells with altered 
PDL1 expression and validated multiple hits nominated by these screens.  Moving forward, we 
hope to further elucidate the precise mechanisms underpinning our observations and ultimately 
to advance the signals we discuss here as prognostic/predictive biomarkers or therapeutic targets 
to improve outcomes in HNSCC.  The detailed landscape of the UM-SCC cell line panel we 
describe here will serve as a useful tool for integrating our findings with the heterogeneous 
characteristics of HNSCCs.  In the future, we envision the development of a more 
comprehensive profile of tumor- intrinsic and extrinsic features influencing immunogenicity to 






Section 1: Challenges and opportunities in immune modulation 
 It has been previously established that immune infiltration portends more favorable 
outcomes in HNSCC and other cancer types, suggesting that particular tumors may be better 
primed for immune-mediated clearance [1, 2].  This is especially true of HPV-associated tumors, 
which are known to carry a better prognosis than HPV negative tumors, bear a distinct 
immunologic phenotype marked by high levels of CD8+ T-lymphocytes, and respond better to 
anti-PD1 immunotherapy [3].  Here, we sought to better understand the prognostic value of 
specific subsets of tumor infiltrating lymphocytes (TILs) in recurrent laryngeal squamous cell 
carcinoma, which is typically HPV-negative [4].  While CD103 status was previously assessed in 
lung and ovarian cancers [5, 6], we were the first to investigate its significance in HNSCC.  Our 
findings build upon previous reports by specifically identifying a CD103+/CD4+ TIL phenotype 
as an especially strong predictor of survival in this setting, supporting further investigation into 
the role of the CD103+ TIL population in HNSCC.  Since the publication of our report, a large 
(464 participant) prospective evaluation of TILs in previously untreated HNSCC patients has 
been described [7], showing that TILs were independently associated with improved overall 
survival in each disease site, albeit to varying degrees.  Furthermore, high CD4+ TIL counts 
were associated with decreased risk of death after primary chemoradiation, but not after surgery, 
further bolstering the concept that specific TIL populations may serve as predictive biomarkers 
and guide patient stratification.  As the predictive/prognostic potential of TILs in HNSCC 
becomes clear, it will be useful to continue to more intricately characterize T-cell subsets to 
generate improved models for predicting outcomes.  It will be of particular interest to investigate 





as a predictive marker in patients treated with immunotherapy, as it is possible that tumors rich 
in specific T-cell subsets will derive greater benefit. 
 Considering the potential prognostic significance of immune infiltration in HNSCC and 
the idea that certain tumors may be better primed for immune response, we chose to investigate 
mechanisms modulating tumor immune checkpoints, with the ultimate goal of predicting or 
improving response to immunotherapy.  Since the 2016 FDA approval of anti-PD1 therapies for 
R/M HNSCC, Pembrolizumab as a monotherapy has also been approved as first line treatment 
for HNSCC patients whose tumors express PDL1 [8].  However, while the approval of anti-PD1 
therapy represents a landmark development in the management of a disease that has been, for 
several decades, strikingly devoid of therapeutic advances, the overall proportion of HNSCC 
patients who benefit from immunotherapy is small, and clinicians’ capacity to prospectively 
select these patients is limited [9].  Some characteristics of HNSCC and other cancers have been 
shown to correlate with response to immunotherapy, including PDL1 expression, T-lymphocyte 
infiltration, HPV status, and tumor mutational burden [10-19].  Each is a rational approach to 
stratifying patients, but in practice falls short of reliably defining responsive populations.  While 
PDL1 expression levels are currently used to guide clinical decisions surrounding anti-PD1 
therapy, numerous studies on this topic have yet to reach a consensus as to how strongly this 
metric correlates with response [9, 20].  Interpretation of these results as a whole has likely been 
complicated by discordance in study design, as thresholds for PDL1 positivity vary widely, 
detection antibodies differ in specificity, and different methods of tissue sampling (tumor only vs 
tumor plus peritumoral sampling, for example) are used across studies.  Additionally, PDL1 
expression is intratumorally heterogeneous, further convoluting the results of these 





and establishing its role in predicting survival and therapeutic response highlight a need for 
improved biomarkers.  
 Our work suggests that common features of HNSCCs, such as FGFR activity, could 
potentially function in tumor cells to modulate immune checkpoints in addition to their 
documented roles in tumorigenesis.  As we have identified novel PDL1 drivers that are also 
known to be dysregulated in cancer, we would next ask whether aberrant activity of these genes 
could mark highly immunosuppressive tumors and potentially serve as more reliable biomarkers 
for response to anti-PD1 therapy.  TCGA reported FGFR1 and FGFR3 alterations among the 
most common genetic aberrations in HNSCC tumors [21].  Based on our findings, we next 
hypothesize that a subset of tumors with FGFR pathway dysregulation may also express more 
PDL1.  Thus, we would next investigate a correlation between PDL1 expression and FGF/FGFR 
family alterations, including fusions, amplifications, mutations, and overexpression.  It will be 
especially crucial to assess FGFR activity in this setting (e.g. phosphorylated FGF receptors) to 
bolster the claim that FGFRs induce high PDL1 levels.  It would therefore be pertinent to 
analyze phosphorylated (activated) FGFRs in relation to PDL1 levels in human tumors by 
immunohistochemistry. 
This work also aims to eventually inform rational combination immunotherapy 
approaches.  We specifically pursued candidate pathways (FGFR and TLR) that have already 
been established as drug targets and for which clinical trials are underway, which could allow for 
more efficient translation of our findings to the clinic.  The concept that immune checkpoints 
may be targeted indirectly via known drivers of cancer invites exciting new avenues for immune 
modulation and implies heretofore unexplored anti-tumor effects of current therapeutics. In 





the use of FGFR inhibitors in combination with anti-PD1 therapy.  Li et al showed in cell line 
and murine models of colorectal cancer that FGFR2 activity induces PDL1 expression [22].  In 
September 2019, Palakurthi et al demonstrated that FGFR inhibition reduces PDL1 expression in 
murine models of non-small cell lung cancer (NSCLC) and that FGFR inhibition in combination 
with anti-PD1 yielded a survival benefit over either treatment alone [23]. Thus, we speculate that 
targeting of FGFR activity may also serve to improve the efficacy of immunotherapy regimens 
for HNSCC.   Also yet to be investigated is the influence of genetic aberrations in the FGFR 
pathway in mediating the phenotypes described above.  FGFR mutations and fusions are not 
especially common in HNSCC (4.2% of tumors) and most affect FGFR3 [21], but it is possible 
that these features may denote a specific subset of patients more or less likely to respond to 
immunotherapy alone or to combination FGFR/anti-PD1 therapy.  Further exploration of the 
FGFR mutant population would therefore be of particular interest and could lead to development 
of a biomarker more perspicuous than those that are currently in use, which are challenging to 
reliably quantify.  
 Our observation that TLR2 may directly modulate PDL1 is also of interest given recent 
trials of TLR agonists in HNSCC.  Multiple trials currently underway are investigating TLR8 
and TLR9 agonists in combination with the biologic cetuximab, which targets EGFR [24, 25].  
Rationalizing this approach is the observation that cetuximab can induce antibody-dependent 
cellular cytotoxicity in addition to inhibiting EGFR activity, and that this effect could be 
enhanced by activation of TLRs [25].  The results of our study, however, suggest that the 
potential for PDL1 upregulation under these conditions could be an important consideration, and 
may support either more scrupulous patient selection for TLR agonist therapy or even the 





 Another point for future inquiry would be the role of the microbiome in modulating 
response to immunotherapy, and whether this could be influenced by tumor-intrinsic aberrant 
expression or activity of TLRs.  Myriad roles for specific bacterial taxa in modulating anti-tumor 
immune responses have been described in melanoma, and the abundance of certain bacteria has 
been associated with such metrics as survival, response to immunotherapy or chemotherapy, and 
risk of treatment toxicities in several human cancers and in murine models [26-28].  Generally, it 
appears that components of the normal gut microbiota confer therapeutic response and survival 
benefits, while imbalances may lead to detrimental immune inhibitory effects [26, 29].  These 
studies exclusively consider the gut microbiome, and center around the ability of microbes to 
modulate local and systemic immune responses.  The impact of the oral microbiome in HNSCC 
is unclear, and the concept that bacteria may act directly on tumor cells to modulate 
immunogenicity has not been thoroughly explored.  Recently, periodontal bacteria 
Porphyromonas gingivalis and Fusobacterium nucleatum have been implicated in carcinogenesis 
[30].  Both are also known to activate TLR2 [31, 32], leading us to speculate that these species 
might directly contribute to immune evasion in tumor cells expressing TLR2 during oral 
carcinogenesis.  Modeling this in vivo will be vital to understanding the complexity of 
interactions between oral bacteria, the local and systemic immune system, and the tumor itself.   
 
Section 2: Positive-selection based genome-wide screening  
 We describe here the application of two different genome-scale screening techniques 
toward the identification of genes and pathways regulating PDL1 expression in cell lines.  
Functional screening at this scale has historically relied on sh- or si-RNA libraries, which are 





offered by CRISPR technology has revolutionized library screening and presents a plethora of 
opportunities to apply this concept towards improving our understanding of critical biological 
processes.  Our report adds to the array of studies demonstrating the utility of these libraries in 
elucidating drivers of particular phenotypes.  The open reading frame screen we present here is 
also among the first applications of whole-genome overexpression screening in mammalian cells.  
However, our results also highlight some important technical challenges that will need to be 
addressed as we expand our usage of these systems. 
 The overexpression screen discussed in Chapter 3 revealed multiple intriguing genes 
potentially driving PDL1 expression, five of which we were able to validate.  Future experiments 
will define the mechanisms through which these genes modulate PDL1 and expand our analysis 
of the enriched gene list to validate and advance other hits.  Shortly after we completed our 
screen, an interesting report was published involving the most enriched gene we identified: 
ERO1L.  Tanaka et al demonstrated that in breast cancer cell lines, ERO1L promotes PDL1 
expression both through a HIF1alpha dependent transcriptional mechanism and through 
facilitation of oxidative protein folding [34].  This finding lends support to the idea that our 
screening protocol was able to select positive PDL1 regulators.  It will be of interest to our group 
to explore a similar relationship between ERO1L and PDL1 in HNSCC, and to understand 
whether this could be assessed as a biomarker or could represent a novel therapeutic target. 
 Of particular relevance to our work was the 2017 discovery of CMTM6 as a critical 
regulator of PDL1 in pancreatic cancer cells using genome-wide CRISPR screening with FACS 
based selection [35, 36].  This finding was recapitulated in breast cancer, melanoma, and lung 
cancer models.  Burr et al and Mezzadra et al reported that CMTM6 specifically regulated cell 





the similarity of our experimental design to that described by Burr et al, we expected 
concordance between our findings.  Surprisingly, CMTM6 was not represented in the list of 
enriched gRNAs nominated by our CRISPR screen.  While this finding could be the result of 
biological differences between these two systems, we postulate that it could be due to poor 
representation of CMTM6 gRNAs in the control pool.  Only one of three CMTM6 gRNAs was 
detected at all in the control pool (60 reads ; Appendix 1), and this gRNA was not detected in 
either PDL1 sorted population.  Similar issues were evident with regard to other genes we 
expected to be nominated by our screen, such as the interferon gamma receptor (IFNGR) and 
STAT1.  We found that IFNGR gRNAs were poorly represented in the unsorted control pool (0, 
3, and 6 reads), and only one STAT1 gRNA was detected (7 reads).  It is possible that these 
knockouts confer such an insurmountable survival disadvantage that cells harboring these 
gRNAs are rapidly lost from the population. 
Another point of interest is the lack of overlap among genes nominated by the two 
screening mechanisms, despite use of the same cell line model and selection conditions.  We 
expected, for example, to identify some of the same targets in the PDL1low pool as in the selected 
ORF pool. We will need to better understand the efficiency of functional ORF overexpression 
and of genetic knockout in our systems in order to interpret this finding.  It is possible that, with 
poor efficiency, many of the cells we selected were random false positives with either no 
alteration functionally expressed, or exhibiting an off target effect conferring a survival 
advantage.  These cells may have overgrown many of the true positive cells over the course of 
serial sorting and expansion.  We will need to repeat these screens multiple times in UM-SCC-49 
to clarify false discovery rates.  It will then be useful to screen additional cell lines to identify 






Section 4: Future directions 
 Our immediate next step will be to elucidate the mechanisms of candidate PDL1 drivers 
nominated by our screens.  To understand how the FGFR pathway, for example, influences 
PDL1 expression, we will perform proteome and transcriptome analyses following stimulation of 
cells with FGF ligands and following FGFR inhibition.  It will be of particular interest to 
examine proteome and transcriptome changes in IFNg stimulated cells while FGFRs are 
inhibited, as this may reveal novel crosstalk mechanisms between these pathways.  It will also be 
important to replicate these experiments in multiple genetic backgrounds to determine whether 
these mechanisms are widely utilized and whether further advancement of this work could be 
broadly clinically applicable.  It is possible that by examining the mechanism(s) through which 
candidate drivers modulate PDL1, we will identify a novel signaling node for PDL1 regulation 
utilized by multiple signaling pathways.    
 To fully understand the functional significance of FGFR and TLR signaling in anti-tumor 
immunity, it will be crucial to study these pathways in more complex systems. The logical next 
step will be to knock out or knock down our candidate drivers of PDL1 expression and assess T 
cell activation and T cell mediated killing in a co-culture assay using Jurkat T cells, or 
potentially HLA-matched patient-derived T-cells.  Eventually, we can assess the impact of 
modulating these pathways in vivo.  Several questions could be addressed with an in vivo model 
deficient in, for example, TLR.  We would first ask whether modulation of TLR2 specifically in 
tumor cells impacts tumor growth and survival.  We would also investigate the impact of altered 
TLR2 activity in the contexts of traditional HNSCC therapy (radiation, cisplatin) and in the 





prognostic or predictive biomarker.  It would then follow to ask whether TLR inhibitors or 
agonists can impact outcomes.  To follow up on our TLR2 observation specifically, it would be 
interesting to examine the role of the microbiome.  It is possible that the presence of particular 
bacteria could influence tumor immunogenicity by activating TLRs.   
 An important limitation of our studies that must be addressed in vivo is the systemic 
impact of modulating candidate PDL1 drivers, as our current model exclusively examines these 
pathways in cancer cell lines.  For example, while it may be possible to combat 
immunosuppression using FGFR or TLR inhibitors, it is likely that these will also affect other 
cell types in the microenvironment, which could lead to unforeseen pro- or anti-tumorigenic 
effects.  FGFR inhibition, for example, also induces stromal fibroblast senescence and reduces 
MDSC recruitment [37].   It is also likely that our candidate PDL1 drivers support tumorigenesis 
in numerous ways beyond PDL1 mediated immune evasion, as is certainly the case for the FGFR 
signaling pathway.  Thus, it may be that our PDL1 regulation data indicate just one of many 
factors rationalizing the modulation of these genes in HNSCC, and could indicate a feasible 
alternative or ancillary method of immune checkpoint targeting to improve outcomes.   
 Taken together, we hope the work presented here will serve as a starting point for new 
inquiries into the pathways modulating immunogenicity in HNSCC and that we can eventually 
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